



US012389889B2

(12) **United States Patent**
Gurer et al.

(10) **Patent No.:** US 12,389,889 B2
(45) **Date of Patent:** *Aug. 19, 2025

(54) **MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE**

(71) Applicant: **Regeneron Pharmaceuticals, Inc.,**
Tarrytown, NY (US)

(72) Inventors: **Cagan Gurer**, Chappaqua, NY (US);
Ella Ioffe, Bronx, NY (US); **Alexander Mujica**, Elmsford, NY (US); **Gavin Thurston**, Briarcliff Manor, NY (US)

(73) Assignee: **Regeneron Pharmaceuticals, Inc.,**
Tarrytown, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **18/413,219**

(22) Filed: **Jan. 16, 2024**

(65) **Prior Publication Data**

US 2024/0138384 A1 May 2, 2024

Related U.S. Application Data

(63) Continuation of application No. 17/161,801, filed on Jan. 29, 2021, now Pat. No. 11,910,788, which is a continuation of application No. 15/982,174, filed on May 17, 2018, now Pat. No. 10,939,673, which is a continuation of application No. 14/951,825, filed on Nov. 25, 2015, now abandoned.

(60) Provisional application No. 62/087,992, filed on Dec. 5, 2014.

(51) **Int. Cl.**

A01K 67/027 (2024.01)
A01K 67/0278 (2024.01)
C07K 14/47 (2006.01)
C07K 14/705 (2006.01)
C07K 16/28 (2006.01)
C12N 15/63 (2006.01)
C12N 15/85 (2006.01)
G01N 33/50 (2006.01)

(52) **U.S. Cl.**

CPC **A01K 67/0278** (2013.01); **C07K 14/4703** (2013.01); **C07K 14/705** (2013.01); **C07K 14/70503** (2013.01); **C07K 14/70596** (2013.01); **C07K 16/2803** (2013.01); **C12N 15/63** (2013.01); **C12N 15/8509** (2013.01); **G01N 33/5011** (2013.01); **G01N 33/5014** (2013.01); **G01N 33/5055** (2013.01); **G01N 33/5088** (2013.01); **A01K 2207/12** (2013.01); **A01K 2207/15** (2013.01); **A01K 2217/052** (2013.01); **A01K 2217/072** (2013.01); **A01K 2217/15** (2013.01); **A01K 2227/105** (2013.01); **A01K 2267/0331** (2013.01); **A01K 2267/0381** (2013.01); **C07K 2319/00** (2013.01); **C07K 2319/02** (2013.01); **G01N 2333/70596** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,586,251 B2	7/2003	Economides et al.
7,294,754 B2	11/2007	Poueymirou et al.
8,354,389 B2	1/2013	Frendewey et al.
8,518,392 B2	8/2013	Frendewey et al.
8,697,851 B2	4/2014	Frendewey et al.
10,939,673 B2	3/2021	Gurer et al.
2007/0113297 A1*	5/2007	Yang A61K 35/12 435/325
2013/0111616 A1	5/2013	Macdonald et al.
2013/0111617 A1	5/2013	Macdonald et al.
2013/0117873 A1	5/2013	Wang et al.
2014/0134662 A1	5/2014	Flavell et al.
2014/0245466 A1	8/2014	Macdonald et al.
2014/0245467 A1	8/2014	Macdonald et al.
2014/0369924 A1	12/2014	Weissman et al.
2015/0089678 A1	3/2015	Murphy et al.
2015/0106961 A1	4/2015	Rojas et al.
2015/0143558 A1	5/2015	McWhirter et al.
2015/0143559 A1	5/2015	McWhirter et al.
2015/0282463 A1	10/2015	Murphy et al.
2015/0320021 A1	11/2015	Wang et al.
2015/0327524 A1	11/2015	Murphy et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	101133083 A	2/2008
CN	101506235 A	8/2009

(Continued)

OTHER PUBLICATIONS

Schickel Biochemistry and Cell Biology, 169-176 (Year: 2002).*
Rebres et al The Journal of Bio. Chem., 34607-34616 (Year: 2001).*
Willinger et al Trends in Immunology vol. 32, No. 7, 321-327 (Year: 2011).*

Tena A. et al., "Miniature Swine Expressing Human CD47 to Enhance Bone Marrow Engraftment in Non-Human Primates", Supplement to Transplantation 94(10S):776 (Nov. 27, 2012).

(Continued)

Primary Examiner — Anoop K Singh

(74) **Attorney, Agent, or Firm — Scully, Scott, Murphy & Presser, P.C.; Casey Donahoe**

(57)

ABSTRACT

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).

9 Claims, 9 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**U.S. PATENT DOCUMENTS**

- 2015/0342163 A1 12/2015 Voronina et al.
 2015/0366174 A1 12/2015 Burova et al.
 2016/0345549 A1 12/2016 Gurer et al.
 2017/0164588 A1 6/2017 Olson et al.
 2018/0249689 A1 9/2018 Gurer et al.

FOREIGN PATENT DOCUMENTS

- | | | | |
|----|---------------|------|---------------|
| RU | 2 425 880 | C2 | 8/2011 |
| WO | 2007/033221 | A2 | 3/2007 |
| WO | 2009/039244 | A2 | 3/2009 |
| WO | 2011/044050 | A2 | 4/2011 |
| WO | WO-2012112544 | A2 * | 8/2012 |
| WO | 2013/056352 | A1 | 4/2013 |
| WO | WO-2013063556 | A1 * | 5/2013 |
| WO | WO-2013144165 | A1 * | 10/2013 |
| WO | 2013/192030 | A2 | 12/2013 |
| WO | 2014/039782 | A2 | 3/2014 |
| WO | 2014/071397 | A2 | 5/2014 |
| WO | 2014/093678 | A2 | 6/2014 |
| WO | 2015/042557 | A1 | 3/2015 |
| WO | 2015/057758 | A1 | 4/2015 |
| WO | 2015/077071 | A1 | 5/2015 |
| WO | 2015/077072 | A1 | 5/2015 |
| WO | 2015/171861 | A1 | 11/2015 |
| WO | 2015/196051 | A1 | 12/2015 |
| WO | 2016/085889 | A1 | 6/2016 |

OTHER PUBLICATIONS

- Teraoka Y. et al., "Expression of Recipient CD47 on Rat Insulinoma Cell Xenografts Prevents Macrophage-Mediated Rejection Through SIRPa Inhibitory Signaling in Mice", *PLOS One* 8(3):e58359 (Mar. 2013).
- Traggiai E. et al., "Development of a Human Adaptive Immune System in Cord Blood Cell- Transplanted Mice", *Science* 304:104-107 (Apr. 2, 2004).
- Tseng D. et al., "Anti-CD47 Antibody-Mediated Phagocytosis of Cancer by Macrophages Primes an Effective Antitumor T-Cell Response", *PNAS* 110(27):11103-11108 (Jul. 2, 2013).
- Tulasne D. et al., "C-Terminal Peptide of Thrombospondin-1 Induces Platelet Aggregation Through the Fc Receptor γ -Chain-Associated Signaling Pathway and by Agglutination", *Blood* 98(12):3346-3352 (Dec. 1, 2001).
- Valenzuela D.M. et al., "High-Throughput Engineering of the Mouse Genome Coupled with High-Resolution Expression Analysis", *Nature Biotechnology* 21(6):652-659 (Jun. 2003).
- Verdrengh M. et al., "Integrin-Associated Protein (IAP)-Deficient Mice are Less Susceptible to Development *Staphylococcus aureus*-Induced Arthritis", *Microbes and Infection* 1:745-751 (1999).
- Waern J.M. et al., "Ectopic Expression of Murine CD47 Minimizes Macrophage Rejection of Human Hepatocyte Xenografts in Immunodeficient Mice", *Hepatology* 56:1479-1488 (Oct. 2012).
- Wang C. et al., "Human CD47 Expression Permits Survival of Porcine Cells in Immunodeficient Mice that Express SIRPa Capable of Binding to Human CD47", *Cell Transplantation* 20:1915-1920 (2011).
- Wang H. et al., "Lack of CD47 on Nonhematopoietic Cells Induces Split Macrophage Tolerance to CD47null Cells", *PNAS* 104(34):13744-13749 (Aug. 21, 2007).
- Wang X-Q et al., "Integrin-Associated Protein Stimulates α 2 β 1-Dependent Chemotaxis Via Gi-Mediated Inhibition of Adenylate Cyclase and Extracellular-Regulated Kinases", *The Journal of Cell Biology* 147(2):389-399 (Oct. 18, 1999).
- Wheeler M.B. et al., "Transgenic Technology and Applications in Swine", *Theriogenology* 56:1345-1369 (2001).
- Willinger T. et al., "Human IL-3/GM-CSF Knock-In Mice Support Human Alveolar Macrophage Development and Human Immune Responses in the Lung", *PNAS* 108(6):2390-2395 (Feb. 8, 2011).
- Willinger T. et al., "Improving Human Hemato-Lymphoid-System Mice by Cytokine Knock-in Gene Replacement", *Trends in Immunology* 32(7):321-327 (Jul. 2011).
- Zhou H. et al., "Developing tTA Transgenic Rats for Inducible and Reversible Gene Expression", *International Journal of Biological Sciences* 5(2):171-181 (2009).
- Database Accession No. HQ585874, XP-002753825 (2 pages) (Nov. 19, 2010).
- Database Accession No. Q08722, XP-002753826 (7 pages) (Nov. 1995).
- Database Accession No. E5Q371, XP-002753827 (2 pages) (Feb. 8, 2011).
- Chinese Office Action dated Mar. 3, 2020 received in Chinese Patent Application No. 201580066047.0, together with an English-language translation.
- Russian Office Action and Search Report dated Jun. 3, 2019 received in Russian Patent Application No. 2017123357, together with an English-language translation.
- International Search Report and Written Opinion dated Feb. 26, 2016 received in International Application No. PCT/US2015/062614.
- Anderson P., "Post-Transcriptional Control of Cytokine Production", *Nature Immunology* 9(4):353-359 (Apr. 2008).
- Barclay A.N. et al., "The SIRP Family of Receptors and Immune Regulation", *Nature Reviews-Immunology* 6:457-464 (Jun. 2006).
- Brevini T.A.L. et al., "No Shortcuts to Pig Embryonic Stem Cells", *Theriogenology* 74:544-550 (2010).
- Brooke G. et al., "Human Lymphocytes Interact Directly With CD47 Through a Novel Member of the Signal Regulatory Protein (SIRP) Family", *The Journal of Immunology* 173:2562-2570 (2004).
- Bruce L.J. et al., "A Band 3-Based Macrocomplex of Integral and Peripheral Proteins in the RBC Membrane", *Blood* 101(10):4180-4188 (May 15, 2003).
- Capecci M.R., "Generating Mice With Targeted Mutations", *Nature Medicine* 7(10):1086-1090 (Oct. 2001).
- Chao M P et al., "The CD47-SIRPa Pathway in Cancer Immune Evasion and Potential Therapeutic Implications", *Current Opinion in Immunology* 24:225-232 (2012).
- Cao S. et al., "Isolation and Culture of Primary Bovine Embryonic Stem Cell Colonies by a Novel Method", *Journal of Experimental Zoology* 311A:368-376 (2009).
- Chang H.P. et al., "Impaired Memory Retention and Decreased Long-Term Potentiation in Integrin-Associated Protein-Deficient Mice", *Learning & Memory* 6:448-457 (1999).
- Clark J. et al., "A Future for Transgenic Livestock", *Nature Reviews-Genetics* 4:825-833 (Oct. 2003).
- Dennis Jr. M.B., "Welfare Issues of Genetically Modified Animals", *ILAR Journal* 43(2):100-109 (2002).
- Devoy A. et al., "Genomically Humanized Mice: Technologies and Promises", *Nature Reviews-Genetics* 13:14-20 (Jan. 2012).
- Frankel A.E. et al., "Characterization of Diphtheria Fusion Proteins Targeted to the Human Interleukin-3 Receptor", *Protein Engineering* 13(8):575-581 (2000).
- Gama Sosa M.A. et al., "Animal Transgenesis: An Overview", *Brain Struct Funct* 214:91-109 (2010).
- Gimeno R. et al., "Monitoring the Effect of Gene Silencing by RNA Interference in Human CD34+ Cells Injected into Newborn RAG2/- γ c/- Mice: Functional Inactivation of p53 in Development T Cells", *Blood* 104(13):3886-3893 (Dec. 15, 2004).
- Glick B. et al., *Moleculjarnaya Biotehnologija. Printsipy i primeneniye*. Moscow: Mir, 2002, together with an English-language translation.
- Harari D. et al., "Bridging the Species Divide: Transgenic Mice Humanized for Type-I Interferon Response", *PLoS One* 9(1):e84259, XP055553720, DOI:10.1371/journal.pone.0084259 (Jan. 9, 2014).
- Hofker M.H. et al., "Transgenic Mouse Methods and Protocols", *Methods in Molecular Biology* 209:51-67 (2002-2003).
- Houdebine L-M, "Methods to Generate Transgenic Animals", *Genetic Engineering in Livestock, New Applications and Interdisciplinary Perspectives*, Engelhard M. et al., XVI, 1 46, p. 8, illu. pp. 31-47 (2009).
- Johansen M.L. et al., "Dual Regulation of SIRPa Phosphorylation by Integrins and CD47", *The Journal of Biological Chemistry* 282(33):24219-24230 (Aug. 17, 2007).
- Koshimizu H. et al., "Comprehensive Behavioral Analysis of Cluster of Differentiation 47 Knockout Mice", *PLOS One* 9(2):e89584 (Feb. 2014).


(56)

References Cited**OTHER PUBLICATIONS**

- Lavender K.J. et al., "Production of Bone Marrow, Liver, Thymus (BLT) Humanized Mice on the C57BL/6 Rag2^{-/-} γc^{-/-}CD47^{-/-} Background", *Journal of Immunological Methods* 407:127-134 (2014).
- Lavender K.J. et al., "BLT-Humanized C57BL/6 Rag2^{-/-} γc^{-/-}CD47^{-/-} Mice are Resistant to GVHD and Develop B- and T-Cell Immunity to HIV Infection", *Blood* 122(25):4013-4020 (Dec. 12, 2013).
- Legrand N. et al., "Transient Accumulation of Human Mature Thymocytes and Regulatory T Cells with CD28 Superagonist in "Human Immune System" Rag2^{-/-} γc^{-/-} Mice", *Blood* 108(1):238-245 (Jul. 1, 2006).
- Lindberg F.P. et al., "Decreased Resistance to Bacterial Infection and Granulocyte Defects in IAP-Deficient Mice", *Science* 274:795-798 (Nov. 1, 1996).
- Muñoz M. et al., "Constraints to Progress in Embryonic Stem Cells from Domestic Species", *Stem Cell Rev and Resp* 5:6-9 (2009).
- Mouro-Chanteloup I. et al., "Normal Red Cell Membrane Expression of Rh and Rhag Polypeptides in CD47-Deficient Mice", *Vox Sanguinis* 78:P030 (Jul. 2000).
- Mouro-Chanteloup I. et al., "Evidence that the Red Cell Skeleton Protein 4.2 Interacts with the Rh Membrane Complex Member CD47", *Blood* 101(1):338-344 (Jan. 1, 2003).
- Navarro-Alvarez N. et al., "CD47: A New Player in Phagocytosis and Xenograft Rejection", *Cellular & Molecular Immunology* 8:285-288 (2011).
- Niemann H. et al., "Transgenic Farm Animals: Present and Future", *Rev Sci. Techn. Off. Int. Epiz.* 24(1):285-298 (2005).
- Oldenborg P-A et al., "Role of CD47 as a Marker of Self on Red Blood Cells", *Science* 288:2051-2054 (Jun. 16, 2000).
- Pakula A.A., "Genetic Analysis of Protein Stability and Function", *Annu. Rev. Genet.* 23:289-310 (1989).
- Pan Y. et al., "Studying the Mechanism of CD47-SIRPa Interactions on Red Blood Cells by Single Molecule Force Spectroscopy", *Nanoscale* 6:9951-9964 (2014).
- Paris D.B.B.P. et al., "Equine Embryos and Embryonic Stem Cells: Defining Reliable Markers of Pluripotency", *Theriogenology* 74:516-524 (2010).
- Prelle K. et al., "Pluripotent Stem Cells—Model of Embryonic Development, Tool for Gene Targeting, and Basis of Cell Therapy", *Anat Histo Embryol.* 31(3):169-186 (Jun. 2002).
- Poueymirou W.T. et al., "FO Generation Mice Fully Derived from Gene-Targeted Embryonic Stem Cells Allowing Immediate Phenotypic Analyses", *Nature Biotechnology* 25(1):91-99 (Jan. 2007).
- Rebres R.A. et al., "Normal Ligand Binding and Signaling by CD47 (Integrin-Associated Protein) Requires a Long Range Disulfide Bond Between the Extracellular and Membrane-Spanning Domains", *The Journal of Biological Chemistry* 276(37):34607-34616 (Sep. 14, 2001).
- Reinhold M.I. et al., "In Vivo Expression of Alternatively Spliced Forms of Integrin-Associated Protein (CD47)", *Journal of Cell Sciences* 108:3419-3425 (1995).
- Rendtlew J.M. et al., "Dysregulation of CD47 and the Ligands Thrombospondin 1 and 2 in Multiple Myeloma", *British Journal of Haematology* 138:756-760 (2007).
- Ristevski S., "Making Better Transgenic Models", *Molecular Biotechnology* 29:153-163 (2005).
- Rongvaux A. et al., "Human Thrombopoietin Knockin Mice Efficiently Support Human Hematopoiesis In Vivo", *PNAS* 108(6):2378-2383 (Feb. 8, 2011).
- Rybchin V.N., "Fundamentals of Genetic Engineering", *Textbook for High Schools*, Saint-Petersburg, Publishing House SPbSTU 522:411-413 (2002).
- Sano S-I et al., "Gene Structure of Mouse BIT/SHPS-1", *Biochem. J.* 344:667-675 (1999).
- Schickel J. et al., "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle", *Biochem. Cell Biol.* 80: 169-176 (2002).
- Shultz L.D. et al., "Humanized Mice for Immune System Investigation: Progress, Promise and Challenges", *Nature Reviews-Immunology* 12:786-798 (Nov. 2012).
- Sick E. et al., "CD47 Updated: A Multifaceted Actor in the Tumour Microenvironment of Potential Therapeutic Interest", *British Journal of Pharmacology* 167:1415-1430 (2012).
- Sigmund C.D., "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?", *Arterioscler Thromb Vasc Biol.* 20:1425-1429 (2000).
- Smith K.R., "Gene Transfer in Higher Animals: Theoretical Considerations and Key Concepts", *Journal of Biotechnology* 99:1-22 (2002).
- Takenaka K. et al., "Polymorphism in Sirpa Modulates Engraftment of Human Hematopoietic Stem Cells", *Nature Immunology* 8(12):1313-1323 (Dec. 2007).
- Tena A. et al., "Transgenic Expression of Human CD47 Markedly Increases Engraftment in a Murine Model of Pig-to-Human Hematopoietic Cell Transplantation", *American Journal of Transplantation* 14:2713-2722 (2014).

* cited by examiner

Mouse CD47



Human CD47





Figure 1


Endogenous CD47 gene with human CD47 exons 2-7 inserted, neomycin cassette intact (~4995 bp)



Mouse 5' arm
39 Kb from RP23-
230L20

Human KI 23.9 Kb
from RP11-69A17

Endogenous CD47 gene with human CD47 exons 2-7 inserted, neomycin cassette deleted (76 bp remain)



Mouse 5' arm
39 Kb from RP23-
230L20

Human KI 23.9 Kb
from RP11-69A17

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

1**MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE****CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a continuation of U.S. patent application Ser. No. 17/161,801, filed Jan. 29, 2021, which is a continuation of U.S. patent application Ser. No. 15/982,174, filed May 17, 2018, now U.S. Pat. No. 10,939,673, which is a continuation of U.S. patent application Ser. No. 14/951,825, filed Nov. 25, 2015, now abandoned, which claims the benefit of U.S. Provisional Patent Application Ser. No. 62/087,992, filed Dec. 5, 2014, which is incorporated herein by reference in its entirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

The Sequence Listing in XML file, named as 32584YXW_10108US05_SequenceListing.xml of 86 KB, created on Jan. 15, 2024, and submitted to the United States Patent and Trademark Office via Patent Center, is incorporated herein by reference.

BACKGROUND

Cancer therapy can be separated into four main categories: chemo/radio therapy, hormone therapy, targeted therapy, and immunotherapy. An intense focus of medical research and development has focused on targeted therapy and significant improvements have been made, yet cancer remains a major challenge to patients and to the healthcare industry worldwide. This major challenge is due, in part, to the ability of cancer cells to evade the monitoring mechanisms of the innate and adaptive immune systems, which is partly the result of inhibition of phagocytic clearance. Currently, no *in vivo* system exists to optimally determine the therapeutic potential of new cancer therapies that are designed to activate phagocytic clearance of cancer cells and determine the molecular aspects of how cancer cells provide inhibitory signals to macrophages and phagocytic cells. Such a system provides a source for assays in phagocytosis and macrophage functions *in vivo*, and identification of new cancer therapies that are targeted at providing an anti-tumor environment by promoting pro-phagocytic signals to the immune system.

SUMMARY

The present invention encompasses the recognition that it is desirable to engineer non-human animals to permit improved systems for identifying and developing new cancer therapeutics. The present invention also encompasses the recognition that it is desirable to engineer non-human animals to permit improved engraftment of human hematopoietic stem cells. Further, the present invention also encompasses the recognition that non-human animals having a humanized CD47 gene and/or otherwise expressing, containing, or producing a human or humanized CD47 polypeptide are desirable, for example for use in identifying and developing cancer therapeutics that overcome systemic toxicity associated with blockade of CD47 and overcome CD47-mediated inhibition of phagocytosis of tumor cells, and provide a more efficient *in vivo* system for engraftment of human hematopoietic stem cells that provides an increase in homeostasis of a broader number of human cell types.

2

In some embodiments, the present invention provides a non-human animal having a genome comprising a CD47 gene that includes genetic material from two different species (e.g., a human and a non-human). In some embodiments, the CD47 gene of the non-human animals as described herein encodes a CD47 polypeptide that contains human and non-human portions, wherein the human and non-human portions are linked together and form a functional CD47 polypeptide.

10 In some embodiments, a non-human animal of the present invention comprises a CD47 gene that comprises an endogenous portion and a human portion, wherein the endogenous and human portions are operably linked to an endogenous promoter.

15 In some embodiments, an endogenous portion comprises exon 1 and the exons downstream of exon 7 of an endogenous CD47 gene. In some certain embodiments, exon 1 and the exons downstream of exon 7 of an endogenous CD47 gene are at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the corresponding exon 1 and the exons downstream of exon 7 of a mouse CD47 gene that appears in Table 3. In some embodiments, exon 1 and the exons downstream of exon 7 20 of an endogenous CD47 gene are identical to the corresponding exon 1 and the exons downstream of exon 7 of a mouse CD47 gene that appears in Table 3.

25 In some embodiments, a human portion encodes amino acids 16-292 of a human CD47 polypeptide. In some 30 embodiments, a human portion encodes amino acids 19-292 of a human CD47 polypeptide. In some embodiments, a human portion encodes amino acids 19-141 of a human CD47 polypeptide. In some embodiments, a human portion encodes amino acids 19-127 of a human CD47 polypeptide. 35 In some embodiments, a human portion comprises exons 2-7 of a human CD47 gene.

30 In some embodiments, exons 2-7 of a human CD47 gene are at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the corresponding exons 2-7 of a human CD47 gene that appears in Table 3. In some embodiments, exons 2-7 of a human CD47 gene are identical to the corresponding exons 2-7 of a human CD47 gene that appears in Table 3.

40 In some embodiments, a non-human animal of the present invention expresses a CD47 polypeptide comprising an extracellular portion of a human CD47 polypeptide and an intracellular portion of an endogenous CD47 polypeptide. In some embodiments, a CD47 polypeptide comprises a transmembrane portion of a human CD47 polypeptide. In other embodiments, a CD47 polypeptide comprises a transmembrane portion of a non-human CD47 polypeptide. In some embodiments, a CD47 polypeptide is translated in a cell of a non-human animal with a non-human signal peptide. In 45 some certain embodiments, a non-human signal peptide is a rodent (e.g., a mouse or a rat) signal peptide.

In some embodiments, a CD47 polypeptide of the present invention is expressed from an endogenous non-human CD47 gene.

50 In some embodiments, an intracellular portion of an endogenous CD47 polypeptide comprises an intracytoplasmic tail that has an amino acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to an intracytoplasmic tail of a mouse CD47 polypeptide that appears in Table 3. In some 55 embodiments, an intracellular portion of the endogenous

CD47 polypeptide comprises an intracytoplasmic tail that has an amino acid sequence that is identical to an intracytoplasmic tail of a mouse CD47 polypeptide that appears in Table 3.

In some embodiments, an extracellular portion of a human CD47 polypeptide comprises amino acids corresponding to residues 19-141 of a human CD47 polypeptide. In some embodiments, an extracellular portion of a human CD47 polypeptide comprises amino acids corresponding to residues 19-127 of a human CD47 polypeptide. In some embodiments, the extracellular portion of a human CD47 polypeptide comprises an amino acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to a corresponding amino acid sequence of an extracellular portion of a human CD47 polypeptide that appears in Table 3. In some embodiments, an extracellular portion of a human CD47 polypeptide comprises an amino acid sequence that is identical to a corresponding amino acid sequence of an extracellular portion of a human CD47 polypeptide that appears in Table 3.

In some embodiments, the present invention provides a CD47 polypeptide encoded by the CD47 gene of a non-human animal as described herein. In some certain embodiments, an encoded CD47 polypeptide comprises an amino acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 or SEQ ID NO: 20. In some certain embodiments, an encoded CD47 polypeptide comprises an amino acid sequence that is identical to SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 or SEQ ID NO: 20.

In some embodiments, the present invention provides a humanized CD47 gene comprising one or more exons of a non-human CD47 gene operably linked to one or more exons of a human CD47 gene. In some certain embodiments, a humanized CD47 gene of the present invention comprises non-human exons that encode an intracellular portion of a CD47 polypeptide and human exons that encode an extracellular portion of a human CD47 polypeptide. In some embodiments, a humanized CD47 gene also comprises human exons that encode a transmembrane portion of a human CD47 polypeptide. In some certain embodiments, a humanized CD47 gene of the present invention comprises non-human exons that encode a signal peptide, in whole or in part, and an intracellular portion of a CD47 polypeptide, and human exons that encode an extracellular portion and optionally a transmembrane portion of a CD47 polypeptide.

In some embodiments, the present invention provides an isolated cell or tissue from a non-human animal as described herein. In some embodiments, the present invention provides an isolated cell or tissue comprising a CD47 gene as described herein. In some embodiments, a cell is selected from a dendritic cell, lymphocyte (e.g., a B or T cell), macrophage and a monocyte. In some embodiments, a tissue is selected from adipose, bladder, brain, breast, bone marrow, eye, heart, intestine, kidney, liver, lung, lymph node, muscle, pancreas, plasma, serum, skin, spleen, stomach, thymus, testis, ovum, and a combination thereof.

In some embodiments, the present invention provides a non-human embryonic stem cell whose genome comprises a CD47 gene as described herein. In some embodiments, a non-human embryonic stem cell is a mouse embryonic stem cell and is from a 129 strain, C57BL/6 strain or a BALB/c

strain. In some embodiments, a non-human embryonic stem cell is a mouse embryonic stem cell and is from a mixture of 129 and C57BL/6 strains.

In some embodiments, the present invention provides the use of a non-human embryonic stem cell as described herein to make a non-human animal. In some certain embodiments, a non-human embryonic stem cell is a mouse embryonic stem cell and is used to make a mouse comprising a CD47 gene as described herein. In some certain embodiments, a non-human embryonic stem cell is a rat embryonic stem cell and is used to make a rat comprising a CD47 gene as described herein.

In some embodiments, the present invention provides a non-human embryo comprising, made from, obtained from, or generated from a non-human embryonic stem cell comprising a CD47 gene as described herein. In some certain embodiments, a non-human embryo is a rodent embryo. In some embodiments, a rodent embryo is a mouse embryo. In some embodiments, a rodent embryo is a rat embryo.

In some embodiments, the present invention provides a method of making a non-human animal that expresses a CD47 polypeptide from an endogenous CD47 gene, wherein the CD47 polypeptide comprises a human sequence, the method comprising inserting a genomic fragment into an endogenous CD47 gene in a non-human embryonic stem cell, said genomic fragment comprising a nucleotide sequence that encodes a human CD47 polypeptide in whole or in part; obtaining a non-human embryonic stem cell comprising an endogenous CD47 gene that comprises the nucleotide sequence that encodes a human CD47 polypeptide in whole or in part; and creating a non-human animal using the non-human embryonic stem cell comprising said nucleotide sequence that encodes a human CD47 polypeptide in whole or in part.

In some embodiments, a human sequence comprises amino acids corresponding to residues 19-141 (or 19-292) of a human CD47 polypeptide. In some embodiments, a human sequence comprises amino acids corresponding to residues 19-127 of a human CD47 polypeptide.

In some embodiments, a nucleotide sequence comprises exons 2-7 of a human CD47 gene. In some embodiments, a nucleotide sequence comprises one or more selection markers. In some embodiments, a nucleotide sequence comprises one or more site-specific recombination sites.

In some embodiments, the method further comprises a step of inserting a genomic fragment into an endogenous SIRP α gene of a non-human embryonic stem cell, said genomic fragment comprising a nucleotide sequence that encodes a human SIRP α polypeptide in whole or in part (e.g., encodes an extracellular portion of a human SIRP α polypeptide). In some certain embodiments, a genomic fragment comprising a nucleotide sequence that encodes a human SIRP α polypeptide in whole or in part (e.g., encodes an extracellular portion of a human SIRP α polypeptide) is inserted into an endogenous SIRP α gene of the non-human embryonic stem cell prior to an insertion into an endogenous CD47 gene.

In some embodiments, the method further comprises breeding a non-human animal comprising an endogenous CD47 gene that includes a nucleotide sequence that encodes a human CD47 polypeptide, in whole or in part, with a second non-human animal, said second non-human animal having a genome comprising a SIRP α gene that encodes a SIRP α polypeptide comprising an extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) and an intracellular portion of an endogenous SIRP α polypeptide.

In some embodiments, the present invention provides a method of providing a non-human animal whose genome comprises a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide, the method comprising modifying the genome of a non-human animal so that it comprises a CD47 gene that encodes the extracellular portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide thereby providing said non-human animal. In some embodiments, a CD47 gene encodes a CD47 polypeptide that comprises an extracellular portion and a transmembrane portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous non-human CD47 polypeptide. In other embodiments, a CD47 gene encodes a CD47 polypeptide that comprises an extracellular portion of a human CD47 polypeptide linked to a transmembrane portion and an intracellular portion of an endogenous non-human CD47 polypeptide.

In some embodiments, the modifying the genome of a non-human animal is performed in a non-human embryonic stem cell. In some certain embodiments, the non-human embryonic stem cell is a rodent embryonic stem cell; in some embodiments, a mouse embryonic stem cell; in some embodiments, a rat embryonic stem cell.

In some embodiments, the method further comprises modifying the genome of the non-human animal so that it comprises a SIRP α gene that encodes the extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) linked to the intracellular portion of an endogenous SIRP α polypeptide. In some certain embodiments, the modifying the genome of the non-human animal so that it comprises a SIRP α gene that encodes the extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) linked to the intracellular portion of an endogenous SIRP α polypeptide is performed prior to modifying the genome of the non-human animal so that it comprises a CD47 gene that encodes the extracellular portion and optionally a transmembrane portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide.

In some embodiments, the method further comprises breeding a non-human animal whose genome comprises a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide with a second non-human animal, said second non-human animal having a genome comprising a SIRP α gene that encodes a SIRP α polypeptide comprising an extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) and an intracellular portion of an endogenous SIRP α polypeptide.

In some embodiments, the present invention provides a non-human animal obtainable by methods as described herein.

In some embodiments, the present invention provides a method of engrafting human cells into a non-human animal, the method comprising steps of providing a non-human animal whose genome comprises a CD47 gene that encodes the extracellular portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide; and transplanting one or more human cells into said non-human animal. In some certain embodiments, the method further comprises a step of assaying engraftment of the one or more human cells in said non-human animal. In

some certain embodiments, a step of assaying comprises comparing the engraftment of the one or more human cells to the engraftment in one or more wild-type non-human animals or in one or more non-human animals whose genome does not comprise a CD47 gene that encodes the extracellular portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide.

In some embodiments, human cells are hematopoietic stem cells. In some embodiments, human cells are transplanted intravenously. In some embodiments, human cells are transplanted intraperitoneally. In some embodiments, human cells are transplanted subcutaneously.

In some embodiments, the present invention provides a method of assessing the therapeutic efficacy of a drug targeting human cells, the method comprising providing a non-human animal whose genome comprises a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; transplanting one or more human cells into said non-human animal; administering a drug candidate to said non-human animal; and monitoring the human cells in the non-human animal to determine the therapeutic efficacy of the drug candidate.

In some embodiments, human cells are cancer cells and the drug candidate is an anti-cancer drug candidate. In some certain embodiments, a drug candidate is an antibody.

In some embodiments, a non-human animal further comprises human immune cells. In some certain embodiments, a drug candidate is a bi-specific antibody that binds human CD47 and an antigen on transplanted human cancer cells.

In some embodiments, the present invention provides a method comprising providing one or more cells whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; incubating the one or more cells with a labeled substrate; and measuring phagocytosis of the labeled substrate by the one or more cells. In some embodiments, the substrate is fluorescently labeled. In some embodiments, the substrate is labeled with an antibody. In some embodiments, the substrate is one or more red blood cells. In some embodiments, the substrate is one or more bacterial cells. In some embodiments, the substrate is one or more tumor cells.

In some embodiments, the present invention provides a method comprising providing a non-human animal whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; exposing the non-human animal to an antigen; and measuring phagocytosis of the antigen by one or more cells of the non-human animal. In some embodiments, the step of exposing comprises exposing the non-human animal to an antigen that is fluorescently labeled. In some embodiments, the step of exposing comprises exposing the non-human animal to one or more cells that comprise the antigen. In some embodiments, the step of exposing comprises exposing the non-human animal to one or more cells that comprise the antigen. In some embodiments, the step of exposing comprises exposing the non-human animal to one or more cells that comprise the antigen. In some embodiments, the step of exposing comprises exposing the non-human animal to one or more cells that have been transformed with the antigen so that the antigen is expressed on the surface of the one or more transformed cells. In some embodiments, the step of exposing comprises exposing the non-human animal to one or more tumor cells that comprise the antigen.

In some embodiments, the present invention provides methods for identification or validation of a drug or vaccine, the method comprising the steps of delivering a drug or vaccine to a non-human animal whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide, and monitoring one or more of the immune response to the drug or vaccine, the safety profile of the drug or vaccine, or the effect on a disease or condition. In some embodiments, monitoring the safety profile includes determining if the non-human animal exhibits a side effect or adverse reaction as a result of delivering the drug or vaccine. In some embodiments, a side effect or adverse reaction is selected from morbidity, mortality, alteration in body weight, alteration of the level of one or more enzymes (e.g., liver), alteration in the weight of one or more organs, loss of function (e.g., sensory, motor, organ, etc.), increased susceptibility to one or more diseases, alterations to the genome of the non-human animal, increase or decrease in food consumption and complications of one or more diseases.

In some embodiments, the present invention provides use of a non-human animal as described herein in the development of a drug or vaccine for use in medicine, such as use as a medicament.

In some embodiments, the present invention provides use of a non-human animal as described herein in the manufacture of a medicament for the treatment of cancer or a neoplasm.

In some embodiments, the present invention provides use of a non-human animal as described herein to assess the efficacy of a therapeutic drug targeting human cells. In various embodiments, a non-human animal of the present invention is transplanted with human cells and a drug candidate targeting said human cells is administered to the animal. In some embodiments, efficacy of the drug is determined by monitoring the human cells in the non-human animal after the administration of the drug.

In some embodiments, the present invention provides a non-human animal or cell as described herein for use in the development and/or identification of a drug (e.g., an antibody) for therapy or diagnosis.

In some embodiments, the present invention provides a non-human animal or cell as described herein for use in the development and/or identification of a drug (e.g., an antibody) for the treatment, prevention or amelioration of cancer or a neoplasm.

In some embodiments, the present invention provides a method of assessing the pharmacokinetics of a drug targeting human CD47, the method comprising the steps of administering the drug to a non-human animal as described herein, and performing an assay to determine one or more pharmacokinetic properties of the drug targeting human CD47.

In some embodiments, the present invention provides a method of assessing the on-target toxicity of a drug targeting human CD47, the method comprising the steps of administering the drug to a non-human animal as described herein, and performing an assay for one or more parameters associated with on-target toxicity of a drug.

In some embodiments, the present invention provides a method of assessing the off-target toxicity of a drug targeting human CD47, the method comprising the steps of administering the drug to a non-human animal as described herein, and performing an assay for one or more parameters associated with off-target toxicity of a drug.

In many embodiments, a non-human animal as described herein is a rodent whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; in some embodiments, a rodent is a mouse; in some embodiments, a rodent is a rat.

In some embodiments, a drug targeting human CD47 is a CD47 antagonist. In some certain embodiments, a CD47 antagonist is an anti-CD47 antibody. In some embodiments, a drug targeting human CD47 is a CD47 agonist.

In various embodiments, a CD47 gene of the present invention includes a CD47 gene as described herein. In various embodiments, a CD47 polypeptide of the present invention includes a CD47 polypeptide as described herein.

In various embodiments, a non-human animal of the present invention does not detectably express a full-length endogenous non-human CD47 polypeptide. In various embodiments, a non-human animal of the present invention does not detectably express an extracellular portion of an endogenous CD47 polypeptide. In various embodiments, a non-human animal of the present invention does not detectably express an extracellular portion of both an endogenous CD47 polypeptide and an endogenous SIRP α polypeptide.

In various embodiments, an extracellular portion of a human CD47 polypeptide comprises amino acids corresponding to residues 19-141 of a human CD47 polypeptide as described herein.

In various embodiments, an N-terminal immunoglobulin V domain of a human CD47 polypeptide comprises amino acids corresponding to residues 19-127 of a human CD47 polypeptide as described herein.

In various embodiments, non-human animals, cells, tissues, embryonic stem cells and/or embryos of the present invention have a genome that further comprises a SIRP α gene that encodes a SIRP α polypeptide comprising an extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) and an intracellular portion of an endogenous SIRP α polypeptide.

In various embodiments, a non-human animal of the present invention is a rodent; in some embodiments, a mouse; in some embodiments, a rat.

As used in this application, the terms "about" and "approximately" are used as equivalents. Any numerals used in this application with or without about/approximately are meant to cover any normal fluctuations appreciated by one of ordinary skill in the relevant art.

Other features, objects, and advantages of the present invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments of the present invention, is given by way of illustration only, not limitation.

Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The Drawings included herein, which are composed of the following Figures, are for illustration purposes only and not for limitation.

FIG. 1 shows a diagram, not to scale, of the genomic organization of a non-human (e.g., mouse) and human Cluster of Differentiation 47 (CD47) genes. Exons are numbered beneath each exon.

FIG. 2 shows a diagram, not to scale, of an exemplary method for humanization of a non-human Cluster of Differentiation 47 (CD47) gene.

FIG. 3 shows a diagram, not to scale, of the genomic organization of a mouse and human Cluster of Differentiation 47 (CD47) genes. Locations of probes used in an assay described in Example 1 are indicated.

FIG. 4 shows an exemplary histogram of CD47 expression in red blood cells from humanized CD47 mice detected by anti-CD47 antibodies. Ab A, Ab B, Ab C, Ab D and Ab E: anti-CD47 antibodies; hIgG4s: human IgG4 of irrelevant specificity with modified Fc region that has reduced effector function; hIgG4: human IgG4 antibody of irrelevant specificity. All five anti-CD47 antibodies bound to red blood cells from humanized CD47 mice RBCs, as shown by the curves closely clustered together on the right portion of the histogram, separate from the curves for hIgG4s and hIgG4 on the left portion of the histogram.

FIG. 5 shows exemplary hemagglutination of mouse red blood cells from wild-type (n=2) and humanized CD47 (n=2) mice by anti-CD47 antibodies. WT: wild-type; HuCD47: humanized CD47; Ab A, Ab B, Ab C, Ab D and Ab E: anti-CD47 antibodies; hIgG4s: human IgG4 of irrelevant specificity with modified Fc region that has reduced effector function; hIgG4: human IgG4 antibody of irrelevant specificity.

FIG. 6 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in humanized CD47 mice represented as antibody concentration (in $\mu\text{g/mL}$, y-axis) over time (in days, x-axis); Ab F, Ab G, Ab H and Ab I: anti-CD47 antibodies; hIgG4s: human IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function.

FIG. 7 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in humanized CD47/SIRP α mice ($\text{CD47}^{\text{hu/hu}}\text{SIRP}\alpha^{\text{hu/hu}}$) represented as antibody concentration (in mcg/mL, y-axis) over time (in days, x-axis). Ab J, Ab F, Ab G and Ab I: anti-CD47 antibodies; hIgG4s: human IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function.

FIG. 8 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in humanized CD47/SIRP α mice ($\text{CD47}^{\text{hu/hu}}\text{SIRP}\alpha^{\text{hu/hu}}$) represented as antibody concentration (in mcg/mL, y-axis) over time (in days, x-axis). Ab J, Ab F: anti-CD47 antibodies; Ab Fs: Ab F with modified Fc region that has reduced effector function; Ab Fmono: monovalent version of Ab F; hIgG4s: human IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function.

FIG. 9 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in wild type mice represented as antibody concentration (in mcg/mL, y-axis) over time (in days, x-axis). Mice demonstrating mouse anti-human antibody response (MAHA) were excluded. Ab J, Ab F, Ab I and Ab G: anti-CD47 antibodies; hIgG4s: human IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function (star: all points after 15 days were excluded from hIgG4s treatment group due to MAHA); Ab J F(ab') $_2$; F(ab') $_2$ fragment of Ab J.

DEFINITIONS

This invention is not limited to particular methods and experimental conditions described herein, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing

particular embodiments only, and is not intended to be limiting, since the scope of the present invention is defined by the claims.

Unless defined otherwise, all terms and phrases used herein include the meanings that the terms and phrases have attained in the art, unless the contrary is clearly indicated or clearly apparent from the context in which the term or phrase is used. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, particular methods and materials are now described. All publications mentioned herein are hereby incorporated by reference.

The term "approximately", as applied herein to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

The term "biologically active", as used herein, refers to a characteristic of any agent that has activity in a biological system, in vitro or in vivo (e.g., in an organism). For instance, an agent that, when present in an organism, has a biological effect within that organism, is considered to be biologically active. In particular embodiments, where a protein or polypeptide is biologically active, a portion of that protein or polypeptide that shares at least one biological activity of the protein or polypeptide is typically referred to as a "biologically active" portion.

The term "comparable", as used herein, refers to two or more agents, entities, situations, sets of conditions, etc. that may not be identical to one another but that are sufficiently similar to permit comparison there between so that conclusions may reasonably be drawn based on differences or similarities observed. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable.

The term "conservative", as used herein to describe a conservative amino acid substitution, refers to substitution of an amino acid residue by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of interest of a protein, for example, the ability of a receptor to bind to a ligand. Examples of groups of amino acids that have side chains with similar chemical properties include: aliphatic side chains such as glycine, alanine, valine, leucine, and isoleucine; aliphatic-hydroxyl side chains such as serine and threonine; amide-containing side chains such as asparagine and glutamine; aromatic side chains such as phenylalanine, tyrosine, and tryptophan; basic side chains such as lysine, arginine, and histidine; acidic side chains such as aspartic acid and glutamic acid; and, sulfur-containing side chains such as cysteine and methionine. Conservative amino acids substitution groups include, for example, valine/leucine/isoleucine, phenylalanine/tyrosine, lysine/arginine, alanine/valine, glutamate/aspartate, and asparagine/glutamine. In some embodiments, a conservative amino acid substitution can be a substitution of any native residue in a protein with alanine, as used in, for example, alanine scanning mutagenesis. In some embodiments, a conservative substitution is made that

11

has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Exhaustive Matching of the Entire Protein Sequence Database, *Science* 256:1443-45, hereby incorporated by reference. In some embodiments, the substitution is a moderately conservative substitution wherein the substitution has a nonnegative value in the PAM250 log-likelihood matrix.

The term “control”, as used herein, refers to the art-understood meaning of a “control” being a standard against which results are compared. Typically, controls are used to augment integrity in experiments by isolating variables in order to make a conclusion about such variables. In some embodiments, a control is a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparator. As used herein, a “control” may refer to a “control animal”. A “control animal” may have a modification as described herein, a modification that is different as described herein, or no modification (i.e., a wild-type animal). In one experiment, the “test” (i.e., the variable being tested) is applied. In the second experiment, the “control,” the variable being tested is not applied. In some embodiments, a control is a historical control (i.e., of a test or assay performed previously, or an amount or result that is previously known). In some embodiments, a control is or comprises a printed or otherwise saved record. A control may be a positive control or a negative control.

The term “disruption”, as used herein, refers to the result of a homologous recombination event with a DNA molecule (e.g., with an endogenous homologous sequence such as a gene or gene locus. In some embodiments, a disruption may achieve or represent an insertion, deletion, substitution, replacement, missense mutation, or a frame-shift of a DNA sequence(s), or any combination thereof. Insertions may include the insertion of entire genes or fragments of genes, e.g., exons, which may be of an origin other than the endogenous sequence (e.g., a heterologous sequence). In some embodiments, a disruption may increase expression and/or activity of a gene or gene product (e.g., of a protein encoded by a gene). In some embodiments, a disruption may decrease expression and/or activity of a gene or gene product. In some embodiments, a disruption may alter sequence of a gene or an encoded gene product (e.g., an encoded protein). In some embodiments, a disruption may truncate or fragment a gene or an encoded gene product (e.g., an encoded protein). In some embodiments, a disruption may extend a gene or an encoded gene product; in some such embodiments, a disruption may achieve assembly of a fusion protein. In some embodiments, a disruption may affect level but not activity of a gene or gene product. In some embodiments, a disruption may affect activity but not level of a gene or gene product. In some embodiments, a disruption may have no significant effect on level of a gene or gene product. In some embodiments, a disruption may have no significant effect on activity of a gene or gene product. In some embodiments, a disruption may have no significant effect on either level or activity of a gene or gene product.

The terms “determining”, “measuring”, “evaluating”, “assessing”, “assaying” and “analyzing” are used interchangeably herein to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assaying may be relative or absolute. “Assaying for the presence of” can be determining the amount of something present and/or determining whether or not it is present or absent.

12

The phrase “endogenous locus” or “endogenous gene”, as used herein, refers to a genetic locus found in a parent or reference organism prior to introduction of a disruption, deletion, replacement, alteration, or modification as described herein. In some embodiments, the endogenous locus has a sequence found in nature. In some embodiments, the endogenous locus is a wild type locus. In some embodiments, the reference organism is a wild-type organism. In some embodiments, the reference organism is an engineered organism. In some embodiments, the reference organism is a laboratory-bred organism (whether wild-type or engineered).

The phrase “endogenous promoter” refers to a promoter that is naturally associated, e.g., in a wild-type organism, with an endogenous gene.

The term “heterologous”, as used herein, refers to an agent or entity from a different source. For example, when used in reference to a polypeptide, gene, or gene product or present in a particular cell or organism, the term clarifies that the relevant polypeptide, gene, or gene product: 1) was engineered by the hand of man; 2) was introduced into the cell or organism (or a precursor thereof) through the hand of man (e.g., via genetic engineering); and/or 3) is not naturally produced by or present in the relevant cell or organism (e.g., the relevant cell type or organism type).

The term “host cell”, as used herein, refers to a cell into which a heterologous (e.g., exogenous) nucleic acid or protein has been introduced. Persons of skill upon reading this disclosure will understand that such terms refer not only to the particular subject cell, but also is used to refer to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein. In some embodiments, a host cell is or comprises a prokaryotic or eukaryotic cell. In general, a host cell is any cell that is suitable for receiving and/or producing a heterologous nucleic acid or protein, regardless of the Kingdom of life to which the cell is designated. Exemplary cells include those of prokaryotes and eukaryotes (single-cell or multiple-cell), bacterial cells (e.g., strains of *E. coli*, *Bacillus* spp., *Streptomyces* spp., etc.), mycobacteria cells, fungal cells, yeast cells (e.g., *S. cerevisiae*, *S. pombe*, *P. pastoris*, *P. methanolica*, etc.), plant cells, insect cells (e.g., SF-9, SF-21, baculovirus-infected insect cells, *Trichoplusia ni*, etc.), non-human animal cells, human cells, or cell fusions such as, for example, hybridomas or quadromas. In some embodiments, the cell is a human, monkey, ape, hamster, rat, or mouse cell. In some embodiments, the cell is eukaryotic and is selected from the following cells: CHO (e.g., CHO K1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cell, Vero, CV1, kidney (e.g., HEK293, 293 EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, WI38, MRC 5, Colo205, HB 8065, HL-60, (e.g., BHK21), Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cell, C127 cell, SP2/0, NS-0, MMT 060562, Sertoli cell, BRL 3A cell, HT1080 cell, myeloma cell, tumor cell, and a cell line derived from an aforementioned cell. In some embodiments, the cell comprises one or more viral genes, e.g., a retinal cell that expresses a viral gene (e.g., a PER.C6™ cell). In some embodiments, a host cell is or comprises an isolated cell. In some embodiments, a host cell is part of a tissue. In some embodiments, a host cell is part of an organism.

The term “humanized”, is used herein in accordance with its art-understood meaning to refer to nucleic acids or proteins whose structures (i.e., nucleotide or amino acid

sequences) include portions that correspond substantially or identically with structures of a particular gene or protein found in nature in a non-human animal, and also include portions that differ from that found in the relevant particular non-human gene or protein and instead correspond more closely with comparable structures found in a corresponding human gene or protein. In some embodiments, a “humanized” gene is one that encodes a polypeptide having substantially the amino acid sequence as that of a human polypeptide (e.g., a human protein or portion thereof—e.g., characteristic portion thereof). To give but one example, in the case of a membrane receptor, a “humanized” gene may encode a polypeptide having an extracellular portion having an amino acid sequence as that of a human extracellular portion and the remaining sequence as that of a non-human (e.g., mouse) polypeptide. In some embodiments, a humanized gene comprises at least a portion of a DNA sequence of a human gene. In some embodiment, a humanized gene comprises an entire DNA sequence of a human gene. In some embodiments, a humanized protein comprises a sequence having a portion that appears in a human protein. In some embodiments, a humanized protein comprises an entire sequence of a human protein and is expressed from an endogenous locus of a non-human animal that corresponds to the homolog or ortholog of the human gene.

The term “identity”, as used herein in connection with a comparison of sequences, refers to identity as determined by a number of different algorithms known in the art that can be used to measure nucleotide and/or amino acid sequence identity. In some embodiments, identities as described herein are determined using a ClustalW v. 1.83 (slow) alignment employing an open gap penalty of 10.0, an extend gap penalty of 0.1, and using a Gonnet similarity matrix (MACVECTOR™ 10.0.2, MacVector Inc., 2008).

The term “isolated”, as used herein, refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated. In some embodiments, isolated agents are about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is “pure” if it is substantially free of other components. In some embodiments, as will be understood by those skilled in the art, a substance may still be considered “isolated” or even “pure”, after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, percent isolation or purity of the substance is calculated without including such carriers or excipients. To give but one example, in some embodiments, a biological polymer such as a polypeptide or polynucleotide that occurs in nature is considered to be “isolated” when: a) by virtue of its origin or source of derivation is not associated with some or all of the components that accompany it in its native state in nature; b) it is substantially free of other polypeptides or nucleic acids of the same species from the species that produces it in nature; or c) is expressed by or is otherwise in association with components from a cell or

other expression system that is not of the species that produces it in nature. Thus, for instance, in some embodiments, a polypeptide that is chemically synthesized or is synthesized in a cellular system different from that which produces it in nature is considered to be an “isolated” polypeptide. Alternatively or additionally, in some embodiments, a polypeptide that has been subjected to one or more purification techniques may be considered to be an “isolated” polypeptide to the extent that it has been separated from other components: a) with which it is associated in nature; and/or b) with which it was associated when initially produced.

The phrase “non-human animal”, as used herein, refers to any vertebrate organism that is not a human. In some embodiments, a non-human animal is acyclostome, a bony fish, a cartilaginous fish (e.g., a shark or a ray), an amphibian, a reptile, a mammal, or a bird. In some embodiments, a non-human mammal is a primate, a goat, a sheep, a pig, a dog, a cow, or a rodent. In some embodiments, a non-human animal is a rodent such as a rat or a mouse.

The phrase “nucleic acid”, as used herein, in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a “nucleic acid” is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, in some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g., nucleotides and/or nucleosides); in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, a “nucleic acid” is or comprises RNA; in some embodiments, a “nucleic acid” is or comprises DNA. In some embodiments, a “nucleic acid” is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a “nucleic acid” is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid analog differs from a “nucleic acid” in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a “nucleic acid” is, comprises, or consists of one or more “peptide nucleic acids”, which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. Alternatively or additionally, in some embodiments, a “nucleic acid” has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a “nucleic acid” is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine). In some embodiments, a “nucleic acid” is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a “nucleic acid” comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. In some embodiments, a “nucleic acid” has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a “nucleic acid” includes one

15

or more introns. In some embodiments, a “nucleic acid” is prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a “nucleic acid” is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long. In some embodiments, a “nucleic acid” is single stranded; in some embodiments, a “nucleic acid” is double stranded. In some embodiments, a “nucleic acid” has a nucleotide sequence comprising at least one element that encodes, or is the complement of a sequence that encodes, a polypeptide. In some embodiments, a “nucleic acid” has enzymatic activity.

The phrase “operably linked”, as used herein, refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. “Operably linked” sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. The term “expression control sequence”, as used herein, refers to polynucleotide sequences, which are necessary to effect the expression and processing of coding sequences to which they are ligated. “Expression control sequences” include: appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism. For example, in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence, while in eukaryotes, typically, such control sequences include promoters and transcription termination sequence. The term “control sequences” is intended to include components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

The term “polypeptide”, as used herein, refers to any polymeric chain of amino acids. In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that contains portions that occur in nature separately from one another (i.e., from two or more different organisms, for example, human and non-human portions). In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man.

The term “recombinant”, as used herein, is intended to refer to polypeptides (e.g., CD47polypeptides as described herein) that are designed, engineered, prepared, expressed, created or isolated by recombinant means, such as polypeptides expressed using a recombinant expression vector transfected into a host cell, polypeptides isolated from a recom-

16

binant, combinatorial human polypeptide library (Hoogenboom H. R., (1997) *TIB Tech.* 15:62-70; Azzazy H., and Highsmith W. E., (2002) *Clin. Biochem.* 35:425-445; Gavilondo J. V., and Lerrick J. W. (2002) *BioTechniques* 29:128-145; Hoogenboom H., and Chames P. (2000) *Immunology Today* 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) *Nucl. Acids Res.* 20:6287-6295; Kellermann S-A., and Green L. L. (2002) *Current Opinion in Biotechnology* 13:593-597; Little M. et al. (2000) *Immunology Today* 21:364-370; Murphy, A. J., et al. (2014) *Proc. Natl. Acad. Sci. U.S.A.* 111(14):5153-5158) or polypeptides prepared, expressed, created or isolated by any other means that involves splicing selected sequence elements to one another. In some embodiments, one or more of such selected sequence elements is found in nature. In some embodiments, one or more of such selected sequence elements is designed in silico. In some embodiments, one or more such selected sequence elements result from mutagenesis (e.g., in vivo or in vitro) of a known sequence element, e.g., from a natural or synthetic source. For example, in some embodiments, a recombinant polypeptide is comprised of sequences found in the genome of a source organism of interest (e.g., human, mouse, etc.). In some embodiments, a recombinant polypeptide has an amino acid sequence that resulted from mutagenesis (e.g., in vitro or in vivo, for example in a non-human animal), so that the amino acid sequences of the recombinant polypeptides are sequences that, while originating from and related to polypeptides sequences, may not naturally exist within the genome of a non-human animal in vivo.

The term “replacement” is used herein to refer to a process through which a “replaced” nucleic acid sequence (e.g., a gene) found in a host locus (e.g., in a genome) is removed from that locus, and a different, “replacement” nucleic acid is located in its place. In some embodiments, the replaced nucleic acid sequence and the replacement nucleic acid sequences are comparable to one another in that, for example, they are homologous to one another and/or contain corresponding elements (e.g., protein-coding elements, regulatory elements, etc.). In some embodiments, a replaced nucleic acid sequence includes one or more of a promoter, an enhancer, a splice donor site, a splice receiver site, an intron, an exon, an untranslated region (UTR); in some embodiments, a replacement nucleic acid sequence includes one or more coding sequences. In some embodiments, a replacement nucleic acid sequence is a homolog of the replaced nucleic acid sequence. In some embodiments, a replacement nucleic acid sequence is an ortholog of the replaced sequence. In some embodiments, a replacement nucleic acid sequence is or comprises a human nucleic acid sequence. In some embodiments, including where the replacement nucleic acid sequence is or comprises a human nucleic acid sequence, the replaced nucleic acid sequence is or comprises a rodent sequence (e.g., a mouse or rat sequence). The nucleic acid sequence so placed may include one or more regulatory sequences that are part of source nucleic acid sequence used to obtain the sequence so placed (e.g., promoters, enhancers, 5'- or 3'-untranslated regions, etc.). For example, in various embodiments, the replacement is a substitution of an endogenous sequence with a heterologous sequence that results in the production of a gene product from the nucleic acid sequence so placed (comprising the heterologous sequence), but not expression of the endogenous sequence; the replacement is of an endogenous genomic sequence with a nucleic acid sequence that encodes a protein that has a similar function as a protein encoded by

the endogenous sequence (e.g., the endogenous genomic sequence encodes a CD47 protein, and the DNA fragment encodes one or more human CD47 proteins). In various embodiments, an endogenous gene or fragment thereof is replaced with a corresponding human gene or fragment thereof. A corresponding human gene or fragment thereof is a human gene or fragment that is an ortholog of, or is substantially similar or the same in structure and/or function, as the endogenous gene or fragment thereof that is replaced.

The phrase “cluster of differentiation 47protein” or “CD47protein”, as used herein, refers to a multi-pass transmembrane protein that belongs to the immunoglobulin superfamily and has an extracellular amino-terminal immunoglobulin V domain, five transmembrane domains and a short carboxyl-terminal intracellular tail. CD47 is expressed on the cell surface and is involved in interactions between membrane surface proteins such as, for example, integrins, SIRP α and thrombospondin-1 (TSP-1). CD47 is expressed in normal tissues and up-regulated in many human cancers. CD47 has been shown to be involved in several cellular processes such as, for example, apoptosis, proliferation, adhesion and migration. Several alternatively spliced CD47 isoforms have been identified between mouse and man. By way of illustration, nucleotide and amino acid sequences of mouse and human CD47 genes are provided in Table 3. Persons of skill upon reading this disclosure will recognize that one or more endogenous CD47 genes in a genome (or all) can be replaced by one or more heterologous CD47 genes (e.g., polymorphic variants, subtypes or mutants, genes from another species, humanized forms, etc.).

A “CD47-expressing cell”, as used herein, refers to a cell that expresses a CD47 transmembrane protein. In some embodiments, a CD47-expressing cell expresses a CD47 transmembrane protein on its surface. In some embodiments, a CD47 protein expressed on the surface of the cell in an amount sufficient to mediate cell-to-cell interactions via the CD47 transmembrane protein expressed on the surface of the cell. Exemplary CD47-expressing cells include neurons, immune cells, keratinocytes, and circulating cells. CD47-expressing cells regulate the interaction of immune cells and circulating cells to regulate various cellular processes such as adhesion, cell proliferation and/or apoptosis, angiogenesis and inflammation. In some embodiments, non-human animals of the present invention demonstrate regulation of various cellular processes (as described herein) via humanized CD47 proteins expressed on the surface of one or more cells of the non-human animal.

The term “reference” is used herein to describe a standard or control agent, cohort, individual, population, sample, sequence or value against which an agent, animal, cohort, individual, population, sample, sequence or value of interest is compared. In some embodiments, a reference agent, cohort, individual, population, sample, sequence or value is tested and/or determined substantially simultaneously with the testing or determination of the agent, cohort, individual, population, sample, sequence or value of interest. In some embodiments, a reference agent, cohort, individual, population, sample, sequence or value is a historical reference, optionally embodied in a tangible medium. In some embodiments, a reference may refer to a control. As used herein, a “reference” may refer to a “reference animal”. A “reference animal” may have a modification as described herein, a modification that is different as described herein or no modification (i.e., a wild-type animal). Typically, as would be understood by those skilled in the art, a reference agent, animal, cohort, individual, population, sample, sequence or value is determined or characterized under conditions com-

parable to those utilized to determine or characterize the agent, animal (e.g., a mammal), cohort, individual, population, sample, sequence or value of interest.

The term “substantially”, as used herein, refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

The phrase “substantial homology”, as used herein, refers to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be “substantially homologous” if they contain homologous residues in corresponding positions. Homologous residues may be identical residues. Alternatively, homologous residues may be non-identical residues will appropriately similar structural and/or functional characteristics. For example, as is well known by those of ordinary skill in the art, certain amino acids are typically classified as “hydrophobic” or “hydrophilic” amino acids, and/or as having “polar” or “non-polar” side chains. Substitution of one amino acid for another of the same type may often be considered a “homologous” substitution. Typical amino acid categorizations are summarized in Table 1 and 2.

TABLE 1

Alanine	Ala	A	Nonpolar	Neutral	1.8
Arginine	Arg	R	Polar	Positive	-4.5
Asparagine	Asn	N	Polar	Neutral	-3.5
Aspartic acid	Asp	D	Polar	Negative	-3.5
Cysteine	Cys	C	Nonpolar	Neutral	2.5
Glutamic acid	Glu	E	Polar	Negative	-3.5
Glutamine	Gln	Q	Polar	Neutral	-3.5
Glycine	Gly	G	Nonpolar	Neutral	-0.4
Histidine	His	H	Polar	Positive	-3.2
Isoleucine	Ille	I	Nonpolar	Neutral	4.5
Leucine	Leu	L	Nonpolar	Neutral	3.8
Lysine	Lys	K	Polar	Positive	-3.9
Methionine	Met	M	Nonpolar	Neutral	1.9
Phenylalanine	Phe	F	Nonpolar	Neutral	2.8
Proline	Pro	P	Nonpolar	Neutral	-1.6
Serine	Ser	S	Polar	Neutral	-0.8
Threonine	Thr	T	Polar	Neutral	-0.7
Tryptophan	Trp	W	Nonpolar	Neutral	-0.9
Tyrosine	Tyr	Y	Polar	Neutral	-1.3
Valine	Val	V	Nonpolar	Neutral	4.7

TABLE 2

Ambiguous Amino Acids	3-Letter	1-Letter
Asparagine or aspartic acid	Asx	B
Glutamine or glutamic acid	Glx	Z
Leucine or Isoleucine	Xle	J
Unspecified or unknown amino acid	Xaa	X

As is well known in this art, amino acid or nucleic acid sequences may be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul et al. (1990) Basic local alignment search tool, *J. Mol. Biol.*, 215(3): 403-410; Altschul et al. (1997) Methods in Enzymology; Altschul et al., “Gapped BLAST and PSI-

BLAST: a new generation of protein database search programs”, *Nucleic Acids Res.* 25:3389-3402; Baxevanis et al. (1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley; and Misener et al. (eds.) (1999) Bioinformatics Methods and Protocols (*Methods in Molecular Biology*, Vol. 132), Humana Press. In addition to identifying homologous sequences, the programs mentioned above typically provide an indication of the degree of homology. In some embodiments, two sequences are considered to be substantially homologous if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are homologous over a relevant stretch of residues. In some embodiments, the relevant stretch is a complete sequence. In some embodiments, the relevant stretch is at least 9, 10, 11, 12, 13, 14, 15, 16, 17 or more residues. In some embodiments, the relevant stretch includes contiguous residues along a complete sequence. In some embodiments, the relevant stretch includes discontinuous residues along a complete sequence. In some embodiments, the relevant stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, or more residues.

The phrase “substantial identity”, as used herein, refers to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be “substantially identical” if they contain identical residues in corresponding positions. As is well known in this art, amino acid or nucleic acid sequences may be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul et al. (1990) Basic local alignment search tool, *J. Mol. Biol.*, 215(3): 403-410; Altschul et al., *Methods in Enzymology*; Altschul et al. (1997) *Nucleic Acids Res.* 25:3389-3402; Baxevanis et al. (1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley; and Misener et al., (eds.) (1999) Bioinformatics Methods and Protocols (*Methods in Molecular Biology*, Vol. 132), Humana Press. In addition to identifying identical sequences, the programs mentioned above typically provide an indication of the degree of identity. In some embodiments, two sequences are considered to be substantially identical if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are identical over a relevant stretch of residues. In some embodiments, the relevant stretch is a complete sequence. In some embodiments, the relevant stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, or more residues.

The phrase “targeting vector” or “targeting construct”, as used herein, refers to a polynucleotide molecule that comprises a targeting region. A targeting region comprises a sequence that is identical or substantially identical to a sequence in a target cell, tissue or animal and provides for integration of the targeting construct into a position within the genome of the cell, tissue or animal via homologous recombination. Targeting regions that target using site-specific recombinase recognition sites (e.g., loxP or Frt sites) are also included. In some embodiments, a targeting construct of the present invention further comprises a nucleic acid sequence or gene of particular interest, a selectable marker, control and/or regulatory sequences, and other nucleic acid sequences that allow for recombination mediated through exogenous addition of proteins that aid in or facilitate recombination involving such sequences. In some

embodiments, a targeting construct of the present invention further comprises a gene of interest in whole or in part, wherein the gene of interest is a heterologous gene that encodes a protein, in whole or in part, that has a similar function as a protein encoded by an endogenous sequence. In some embodiments, a targeting construct of the present invention further comprises a humanized gene of interest, in whole or in part, wherein the humanized gene of interest encodes a protein, in whole or in part, that has a similar function as a protein encoded by the endogenous sequence.

The term “variant”, as used herein, refers to an entity that shows significant structural identity with a reference entity, but differs structurally from the reference entity in the presence or level of one or more chemical moieties as compared with the reference entity. In many embodiments, a “variant” also differs functionally from its reference entity. In general, whether a particular entity is properly considered to be a “variant” of a reference entity is based on its degree of structural identity with the reference entity. As will be appreciated by those skilled in the art, any biological or chemical reference entity has certain characteristic structural elements. A “variant”, by definition, is a distinct chemical entity that shares one or more such characteristic structural elements. To give but a few examples, a small molecule may have a characteristic core structural element (e.g., a macrocycle core) and/or one or more characteristic pendent moieties so that a variant of the small molecule is one that shares the core structural element and the characteristic pendent moieties but differs in other pendent moieties and/or in types of bonds present (single vs. double, E vs. Z, etc.) within the core, a polypeptide may have a characteristic sequence element comprised of a plurality of amino acids having designated positions relative to one another in linear or three-dimensional space and/or contributing to a particular biological function, a nucleic acid may have a characteristic sequence element comprised of a plurality of nucleotide residues having designated positions relative to one another in linear or three-dimensional space. For example, a “variant polypeptide” may differ from a reference polypeptide as a result of one or more differences in amino acid sequence and/or one or more differences in chemical moieties (e.g., carbohydrates, lipids, etc.) covalently attached to the polypeptide backbone. In some embodiments, a “variant polypeptide” shows an overall sequence identity with a reference polypeptide that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99%. Alternatively or additionally, in some embodiments, a “variant polypeptide” does not share at least one characteristic sequence element with a reference polypeptide. In some embodiments, the reference polypeptide has one or more biological activities. In some embodiments, a “variant polypeptide” shares one or more of the biological activities of the reference polypeptide. In some embodiments, a “variant polypeptide” lacks one or more of the biological activities of the reference polypeptide. In some embodiments, a “variant polypeptide” shows a reduced level of one or more biological activities as compared with the reference polypeptide. In many embodiments, a polypeptide of interest is considered to be a “variant” of a parent or reference polypeptide if the polypeptide of interest has an amino acid sequence that is identical to that of the parent but for a small number of sequence alterations at particular positions. Typically, fewer than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% of the residues in the variant are substituted as compared with the parent. In some embodiments, a “variant” has 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 substituted residue as compared with a parent. Often, a “variant” has a very small number (e.g.,

fewer than 5, 4, 3, 2, or 1) number of substituted functional residues (i.e., residues that participate in a particular biological activity). Furthermore, a “variant” typically has not more than 5, 4, 3, 2, or 1 additions or deletions, and often has no additions or deletions, as compared with the parent. Moreover, any additions or deletions are typically fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly are fewer than about 5, about 4, about 3, or about 2 residues. In some embodiments, the parent or reference polypeptide is one found in nature. As will be understood by those of ordinary skill in the art, a plurality of variants of a particular polypeptide of interest may commonly be found in nature, particularly when the polypeptide of interest is an infectious agent polypeptide.

The term “vector”, as used herein, refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is associated. In some embodiment, vectors are capable of extra-chromosomal replication and/or expression of nucleic acids to which they are linked in a host cell such as a eukaryotic and/or prokaryotic cell. Vectors capable of directing the expression of operatively linked genes are referred to herein as “expression vectors.”

The term “wild-type”, as used herein, has its art-understood meaning that refers to an entity having a structure and/or activity as found in nature in a “normal” (as contrasted with mutant, diseased, altered, etc.) state or context. Those of ordinary skill in the art will appreciate that wild-type genes and polypeptides often exist in multiple different forms (e.g., alleles).

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

The present invention provides, among other things, improved and/or engineered non-human animals having humanized genetic material encoding a cluster of differentiation 47 (CD47) gene for determining the therapeutic efficacy of CD47 antagonists (e.g., an anti-CD47 antibody) for the treatment of cancer, and assays in transplant engraftment, activation and phagocytosis and signal transduction. It is contemplated that such non-human animals provide an improvement in determining the therapeutic efficacy of CD47 antagonists and their potential for CD47 blockade. It is also contemplated that such non-human animals provide an improvement in transplant engraftment of human cells. Therefore, the present invention is particularly useful for the development of anti-CD47 therapies for the treatment of various cancers, as well as for maintaining human hematopoietic cells in non-human animals. In particular, the present invention encompasses the humanization of a murine CD47 gene resulting in expression of a humanized CD47 protein on the surface of cells of the non-human animal. Such humanized CD47 proteins have the capacity to provide a source of human CD47⁺ cells for determining the efficacy of anti-CD47 therapeutics to activate phagocytosis of tumor cells. Further, such humanized CD47 proteins have the capacity to recognize engrafted human cells via engagement of other cell surface proteins and ligands present on the surface of the engrafted human cells (e.g., SIRPs). In some embodiments, non-human animals of the present invention are capable of activating phagocytosis via blockade of CD47 signaling through the humanized CD47 protein expressed on the surface of cells of the non-human animal. In some embodiments, non-human animals of the present invention are capable of receiving transplanted human hematopoietic cells; in some embodiments, such non-human mammals

develop and/or have an immune system comprising human cells. In some embodiments, humanized CD47 proteins have a sequence corresponding to the N-terminal immunoglobulin V domain of a human CD47 protein. In some embodiments, humanized CD47 proteins have a sequence corresponding to an N-terminal portion of a human CD47 protein that comprises an extracellular portion and a transmembrane portion of a human CD47 protein, wherein the extracellular portion includes the N-terminal immunoglobulin V domain of the human CD47 protein and the transmembrane portion includes the five transmembrane domains of the human CD47 protein. In some embodiments, humanized CD47 proteins have a sequence corresponding to the intracytoplasmic tail of a non-human (e.g., murine) CD47 protein. In some embodiments, humanized CD47 proteins have a sequence corresponding to amino acid residues 19-292 (or 19-141, or 19-127) of a human CD47 protein. In some embodiments, non-human animals of the present invention comprise an endogenous CD47 gene that contains genetic material from the non-human animal and a heterologous species (e.g., a human). In some embodiments, non-human animals of the present invention comprise a humanized CD47 gene, wherein the humanized CD47 gene comprises exons of a human CD47 gene that encode an extracellular portion including the N-terminal immunoglobulin V domain of a human CD47 gene. In some embodiments, the humanized CD47 gene comprises human CD47 exons, e.g., exons 2-7, encoding an N-terminal portion of a human CD47 protein that comprises an extracellular portion and a transmembrane portion of a human CD47 protein, wherein the extracellular portion includes the N-terminal immunoglobulin V domain of the human CD47 protein and the transmembrane portion includes the five transmembrane domains of the human CD47 protein. In some embodiments, the humanized CD47 gene comprises non-human CD47 exons that encode the signal peptide, in whole or in part, and the intracytoplasmic tail of a non-human CD47 protein. In some embodiments, the humanized CD47 gene comprises non-human CD47 exon 1 and exon(s) downstream of exon 7 that encode the intracytoplasmic tail and the 3' UTR. Depending on the isoforms, there may be one or more exons downstream of exon 7, with the stop codon and the 3' UTR being present in the last exon for all isoforms. For example, isoform 2 of both mouse and human CD47 shown in Table 3 have two exons downstream of exon 7, designated as exon 8 and 9.

Various aspects of the invention are described in detail in the following sections. The use of sections is not meant to limit the invention. Each section can apply to any aspect of the invention. In this application, the use of “or” means “and/or” unless stated otherwise.

Cluster of Differentiation 47 (CD47) Gene

CD47, originally named integrin-associated protein (IAP) for its role in signal transduction from integrins on immune cells, is a transmembrane protein that includes an N-terminal immunoglobulin V (IgV) domain, five transmembrane domains, and a short C-terminal intracytoplasmic tail. The intracytoplasmic tail differs in length according to four alternatively spliced isoforms that have been identified. CD47 (or IAP) was initially described as being expressed on all tissues (isoform 2), neurons (isoform 4) and keratinocytes and macrophages (isoform 1; see Reinhold et al. (1995) *J. Cell Sci.* 108:3419-3425). Little is known about isoform 3 despite this form having the second longest intracytoplasmic tail among the four isoforms. In addition to integrins, CD47 is known to interact with several other cell surface proteins such as, for example, thrombospondin and

members of the SIRP family. Most notably, CD47 interacts with SIRP α and leads to bidirectional signaling that regulates a variety of cell-to-cell responses such as, for example, inhibition of phagocytosis and T cell activation. Indeed, CD47-SIRP α interaction has come into focus in recent years for its role in providing tumor cells with the capacity to evade immune surveillance. CD47 binding to SIRP α normally provides protection through anti-phagocytic signals ("don't eat me") for normal cells. However, it has been discovered that tumors also express anti-phagocytic signals, including CD47, to evade destruction by phagocytosis. Interestingly, CD47 is known to be upregulated in several hematologic cancers and contribute to both the growth and dissemination of tumors (Chao et al. (2012) *Curr Opin Immunol.* 24(2): 225-232).

The complete effects of targeting CD47 and the CD47-SIRP α pathway as a new treatment for cancer are unknown and some possible toxicities have been explored. A more

thorough and detailed understanding of CD47 signaling and the CD47-SIRP α pathway is needed to develop better targeted therapies for cancer treatment of the future.

CD47 Sequences

Exemplary CD47 sequences for mouse and human are set forth in Table 3. For mRNA sequences, bold font indicates coding sequence, and consecutive exons, where indicated, are separated by alternating underlined text. For mouse and human protein sequences, signal peptides are underlined, extracellular sequences are bold font and intracytoplasmic sequences are italicized. For humanized protein sequences, non-human sequences are indicated in regular font, human sequences are indicated in bold font, and signal peptides are underlined. As shown, the isoforms differ in the number of exons. For example, isoforms 1-4 of the human CD47 gene have a total of 8, 9, 10 and 11 exons, respectively, with exons 2-7 of each isoform encoding the extracellular domain and the five transmembrane domains.

TABLE 3

Mouse CD47 mRNA isoform 1 (XM_006521810.1)	
(SEQ ID NO: 1)	
GCCTACACCGGGAGAGCAGGGAGGAGTTGGACTGAGGTTGGCGGCTC	
CGAGGTCCAGGGCGAGCTTGGCCAGAGGAGTAGAGAGCAGCGGGCTGC	
GCAGGGACCGTGCCGTGAGTTCCCGTGACCGTGTGTCCCATGCTCCCGT	
CTTCAGGGCGGCCAGGACACGAAGCCGAAGAGAGCTGGCTGGAGGGAC	
GGGGGCCGTGAGCAGAGAGTGCAACCCGCGCAGCCCCGGGACAGGCTGA	
TTCTTGGCCTCTCCGCCAGGCCTGCCAGGGCTGGGTGTGAGGCTGGCGT	
CACGTCAACGAGCAGAGCGGCCAGGCGGGCGAGTGCCTGCGCTGCGCGG	
GCGGCGAGCACCGCGCGCGCACCCTGGGAGCCTGGCGGCCGCTCC	
TGCCTGTCAGTGTGCGGCGCTGCTGGTCGGTCGTTCCCTGAAGGCAGCA	
GCGGAGGCAGCGCGCTGCTCCAGACACCTCGCGCGCAGCCCCGGCGCG	
CGGAGATGTGGCCCTTGGCGCGCGCTGTTGCTGGCTGGCTCTGCTGCT	
GCGGTTCACTACTGTTAGTAACGTCACTCCATAGAGTTAC	
TTCATGCAATGAAACTGTGGTCATCCCTGCATGTCCTGTAATGTGGAG	
GCGCAAAGCACCGAAGAAATGTTGTGAAGTGAACAAATCG	
TATATTTCATCTATGATGAAATAAAATAGCACTACTACAGATCAA	
ACTTTTACAGTGCACAAATCTCAGTCTCAGACTTAATCAATGGCATTGC	
CTCTTTGAAAATGGATAAGCGCGATGCCATGGGGAAACTACACTTGC	
GAAGTGACAGAGTTATCCAGAGAAGGAAACAGTTATAGAGCTGAAA	
AACCGCACGGCCTCAACACTGACCAAGGATCAGCCTGTTCTACGAGG	
AGGAGAAAGGAGGTTGCAAATTAGTTCTGGTTCTCCAAATGAAAA	
GATCCTCATGGTATTTCCAATTTGGCTACTCCTGTTCTGGGAA	
AGTTGGTATTTAACACTCAAATAAACGCCATACGAATAAGAG	
AATCATTCTGCTGCTCGTTGCCGGCTGGTGTACAGTCATCGTGGTT	
GTTGGAGCCATCCTCTCATCCCAGGAGAAAGCCCGTGAAGAATGCTT	
CTGGACTTGGCCTCATTGTAATCTACGGGATATTAATACTACTTCA	
GTACAATGTGTTATGACAGCTTGGATGACCTCTTACCCATTGCC	
ATATTGATCACTCAAGTGTGGCTACGTCTTGCTGGCTGTGCGCTGT	
GTCTCTGCATCATGGCATGTGAGGCCAGTGCACGGCCCCCTTTGATTTC	

TABLE 3 - continued

AGGTTTGGGGATCATAGCTCTAGCAGAACTACTTGGATTAGTTATATG
 AAGTTTGTGAAATAGGTGAAGGGAAAGTGACGGACTGTAACCTTGGAAAGTC
 GAAATGGAAGAACATACAGTTGCTAACGCACCAGGTCTTCACGACTCACAGCT
 GGAAGGAACAGAACAGTAACGTGACTTCCATCCAGGAAAACATGTCACAT
 AAATGATTACTAAGTTATTCAAAGCAGCTGTACTTACATAATAAAAAA
 AATATGATGTGCTGTAACCAATTGGAATCCCATTTCCTATTGTTCTACT
 CAACTAGGGGCAACCGTTCAAGGGCAACTTCCAAGAATGATGCTGTGTTAG
 ATCCTAGAGTCTCTGAACACTGAGTTAAATTGATTCCGAGTGAGACTGCC
 AACGCACTAACCTGAGGGTAGTTACCCAGAGATAACCTATGAAAAACAGTGG
 TATCCAGCAAGCCTAGTAAACTCAGGTTGCCAGCAGCTTGCCTTCCGC
 TGCTAGCTGAATAACAAGACTGCCACTCTGGGTATAGTGATAGAGACTG
 AAGTAGAAAAACGAATGTGGTGGCAAATCCGTGTTGGCCCTCTGTGTTG
 CTATGATATTGATGGCACTGGTCTTCATTCTGGGGTTGCCATCATTAC
 ACACACCCCCCTTGACACATACAGTCACCCAGTTGAATACATTTTTTGCA
 CCCTGTCCTGCTACTTGATTTGCGTTATGATATATATATATATAT
 AATACCTTTCTCCTCTTAAACATGGTCCTGTGACACAATAGTCAGTTGCA
 GAAAGGAGCCAGACTTATCGCAAAGCACTGTGCTCAAACCTTCAGAAAA
 AAAGGAAAAAAAGCTATAGTTGTAACATATGTATTCCAGACCTCT
 GGTTTAAAGGAAAAGAAAAAAATCTACAGTGTCTCATGTTCTG
 ATCGGAGGCATGACAAGCAAGACTGAAATCTGAACGTGTCCTGCATG
 GCAACACGTGTCCTCGTCAGGCCCTCGCAAGGCCGGGAGGGGTTCTAC
 GCCTCTGTCTTGTGCTGACACTCATGCCCTCTGTATCC
 TGCTCCTGCACCCCTCCCTTCCCTCCCTCTTCCCTCTTCCCTCTTCC
 TCCTCCTCTTCCCTCAAGTTGAAAGGTCAAACAAAACCTACACATTCC
 CTACCCAGTTAGAAGAAAACCACCGTCTGACAGTTGATCGCATGGAGT
 ACTTTAGATTATTAGCACCTGTTTACCTCGTTGTGGCGTGTGTTGATG
 TGCACATGTATGAAGTCGGCACATGCACCTCTGTATGGCAGAGCGTGG
 CATCTACAGAAGAGCAGATGCCAATTGCTGTTTAGTGAATACATTAAAA
 AAAAAAAACCAACGGCTTATTGAGTGGATTCTATTGATGCAAATATTT
 GAGCTCTTAAGACTTAAACATGATAATGTGCAAGCTTTAGGACTGCT
 CACCACTGCCCTCTGAAGAAAACACCAACTTTCTGTTGTGTAATAAA
 GGCATATTGTTGCTTGTGATCACTAATGGTTATTCTCTTAGTCCAC
 TGAATGTTCCATGTGCCCTCGTATGCCAATTGTCATCTTCATGTG
 GGGACCAAATGGTTGTGCTGTGGCAACCTAAACCTATGACCTGCTGAGGCC
 TCTCAGAAAACGACACAGTACCAAGATAGTACTTCGCAAAGAAAAGTAG
 GTTCCCTCCCTGGTTGTAGCTGTCGCCAATTAGCGTAATTCCAAGGAG
 CTGAACGCCTTATATAATCTGATGGCACCTGATGCTTTAGTCTGAAAA
 TATTACACTCGGATCATGTTGATGACTTAAACAAAGTTGATGAAGA
 GAGCAAAAAAAAGCAGGTGGATTGGAACAGTTCAAGGTTTTGTT
 TTTGTTTGTGTTTTGTTTATTTGTTCTGTTCTGTTAG

TABLE 3 -continued

AAAAGTCAGGTCTCTGTCAGGCTATCTTATAGTCATTTTTTACGAA
 CTTAAGTAGCTACCTTTAACATGTAAGTCACGCCCTCTGCTGGGTTCAAG
 TTTGGGCTTAACCAAGCTGTATGTTCTATGCTGCCACTTGAGGCA
 CTGAGTGCCTAGACAGTCCCCTCGTGGTAGCCAGGGAAACGAAAGACGA
 ACTCAACTCTTGCCTCTAACATAACTCTCTGTATGAAGGATGGCAGCATT
 AAGAGTCCTCGCTGGCATTATTGGGCCAGTTCACCCCTTTAAATCAA
 ACCCGCAGTGGTCCCAGTCTCGTCCCATCAGATTAAATTGCTAACAGTA
 TGGGGGGACCACGCATCTGTTGTCACATGCGCTTCTCCCCAAA
 TCCCAGTTCTGCTGTATAGCCTCTATTCAATTTCATTATTGCTGCCCTC
 CACTTATAACAATCGTAGAGAGCAATGCCATTGTCACTTCTGCAACAGTT
 TTGAGCCTTATGGCTGAATCCATTTCCTCTCTCAAACAGTTGCTCC
 ATTGCTCTCCCGCACGGCTGCCGTACAGTCATCCCCTCCATCTGGGGCC
 TCTTCATCTCACCCCTCGGTGCTTCGTGGATCTCTGCTTACCTCTGTG
 GGTTTTTTTTTTTTGACTTATTCTCTCACTGGACTTTAAAGATTACTTC
 CACAGCAGAAAGTGCCTGCCCTTCTGCCAGTGTCTGCGTACTTTA
 GATACTACTCAGTGCTGACATTGATGGCAAAAGTTGCCACTAAATTT
 CTCTTTTAATAGGGTGAACTAGAGTTGGAGTTCTCTCTCTCTCTCTCT
 CCTCCCTCCCTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
 TTCT
 GAATTATAAAAGGTGACAGTTCACCTGAAACACAGGTCTGGCTGTTAA
 ATTGTTGAGAAATATCCGATTTAAAGTCTTGTGGCTGTGCTTAAGGCTC
 TCTTCAGGACGTTGAGTCATAGAGTGCTGAACCATACTTGAGTTATA
 AAGCTCAAAACTGATGCACCCACTCTGCTATTATCGTGTAGTAAGAGTTC
 AGCTGTATATCATTGCTAGGTTATCTGCTCACAGTGGGTATTCAAATAT
 GCCCACCAGAGGATATGTGAAATATAAGCACCTGTATTTGCCCTGGTGA
 GAACTGGAGGGAAAACAAAAATGTCTGGCAACCCCTTGCTTAAACCGT
 AATTAATTGACAGTTTTAGAGATAAGAGTTCAAAATCTCTTAACGT
 CCACAAACCCACAGAGGGCTTGTGTTGCCATCTCAGTGGCTCACAGATAG
 ATCCAAGTTAACCTGAAAGAGATGAGCAGTACCCAGGAATTGCTGCCCT
 TAACTCTGGCTGCTCTTAATTATGACTGTTAATGCTGAATTTCATCCGTC
 TAGTGTGTTGAGGGTAAAGAAAAGCCTTTAAATAAGTATTCTGTAAC
 GGCATCGGTGGATCTCTGTGCTATCACGGGTGAAAGAGGGAAACAT
 TTCTTATTTTATTAAGCAGAGCATTATTCAGAAAAGCCATTGTTGAGAATT
 AGTTCCCACATCATATAATATCCATTAACCATTCTAAATTGTAAGAGAACT
 CCAGTGTTGCTATGCACAAGGAACCTCTGGGGCTTTTGCTAGCA
 ATTAAGGTATGCTATTGTCAGTAGCCATTGTCAGTGAATTAAAGACC
 AAAGTTGTTTACAGCTGTGTTACCCCTAAAGGTTTTTATGTTAAG
 TCAATTATCACTGTTGAAGCTTGAAATACCTGCAATCTTGCCAAGATACT
 TTTTATTTAAAAAAATAACTGTGAAATATTACCCGTAAATATTATATAC

TABLE 3 -continued

TTAATAAAACATTTAACGCTA

Mouse CD47 amino acid isoform 1 (XP_006521873.1)
 (SEQ ID NO: 2)
MWPLAAALLGSCCCGSAQLLFSNVNSIEFTSCNETVVIPIVCIRNVEAQSTEE

MFVKWKLNKSYIFIYDGKNNSTTDQNFTSAKISVSDLINGIASLKMDFRDA

MVGNYTCEVTELREGKTVIELKNRTAFNTDQGSACSYEEKGCKLVSW

FSPNEKILIVIPIPLAILFWGKFGILTLYKSSHTNKRIILLVAGLVLTVIVVVG

AILLIPGEKPVKNASGLGLIVISTGILILLQYNVFMTAFGMTSFTIAILITQVLGYV

LALVGLCLCIMACEPVHGPLLISGLGIIALAELLGLVYMKFVE

Mouse CD47 mRNA isoform 2 (XM_006521811.1)
 (SEQ ID NO: 3)

GCCTACACCGGGAGAGCAGGGAGGAGTGGACTGAGGTTGGCGGCTC

CGAGGGTCAGGGCGAGCTGGCCAGAGGGAGTAGAGAGCAGGGGCTGC

GCAGGGACGCGTGCCGTGAGTCCGGTGAGCGTGTGTCCCAGCTCCCGT

CTTCAGGCCGCCAGGACACGAAGCCGAAGAGAGCTGGCTGGAGGGAC

GGGGGCCGTGAGCAGAGAGTGAACCCGCGCAGCCCCGGGACAGGCTGA

TTCTGGCGCTCCGCGGAGCCTGCCAGGGCTGGTGTGAGGCTGGCGT

CACGTCAACGAGCAGAGGCCAGGCGGGAGTGCCTGGCTGGCGCTGG

GCGCGAGCACCGCGCGCGCAGCCCCGGGAGCTGGCGGGCTCC

TGCGCTGTCAGTGCCTGGCGCTGGCTGGCTGGCTGGCGCTGGCGT

GCGGAGGCGCCCTGGCGCGCTGGCTGGCTGGCTGGCGT

CGGAGATGTGGCCCTTGCGGGCGCTGGCTGGCTGGCTGGCGT

GCGGTTCACTGCTGGCTGGCTGGCTGGCTGGCTGGCGT

TTCATGCAATGAAACTGTGGCATGCCCTGCACTGGCTGGCTGGAG

GCGCAAAGCACCGAAGAAATGTTGTGAAGTGAAGTTGAACAAATCG

TATATTTCATATGATGAAATAAAATAGCACTACTACAGATCAA

ACTTTACCAAGTGCAAAATCTCAGTCTCAGACTTAATCAATGGCAT

CTCTTGAAAATGGATAAGCGCGATGCCATGGTGGAAACTACACTTG

GAAGTGACAGAGTTATCCAGAGAAGGCAAAACAGTTAGAGCTGAA

AACCGCACGGTTTCGTGGTTCTCCAATGAAAAGATCCTATTGTTA

TTTCCCAATTTGGCTACTCCTGTTCTGGGAAAGTTGGTATTTA

ACACTCAAATAAAATCCAGCCATACGAATAAGAGAATCATTCTGCTG

TCTGGTGGGGCTGGTGTCAAGTCATCGTGGTTGGAGGCCATCCT

TCTCATCCCAGGAGAAAAGCCCGTGAAGAATGCTCTGGACTTGGC

ATTGTAATCTACGGGATATTAATACTACTTCAGTACAATGTGTTAT

GACAGCTTTGGAATGACCTCTTCACCATTGCCATATTGATCACTCAA

GTGCTGGCTACGTCTTGCTTGGTGGCTGTGTCTCTGCATCATGG

CATGTGAGCCAGTGACGGCCCCCTTGTGTTAGGTTGGGATCAT

AGCTCTAGCAGAACTACTGGATTAGTTATGAAAGTTGCGCTTCC

AACCAAGAGGACTATCCAACCTCTAGGAATAGGTGAAGGAAAGTGACGG

ACTGTAACCTGGAAGTCAGAAATGGAAGAATACAGTGTCAAGCACCAGG

TCTTCACGACTCACAGCTGGAGGAACAGACAACAGTAACTGACTTCCATC

TABLE 3 - continued

CAGGAAAACATGTCACATAAATGATTACTAAGTTATATTCAAAGCAGCTGT
 ACTTTACATAATAAAAAAAATGATGTGCTGTAAACCAATTGGAACTCCCA
 TTTTCTATTGTTCTACTCAACTAGGGCAACGTTCAAGGGCAACTCCA
 AGAATGATGCTGTTAGATCCTAGAGTCTCTGAACACTGAGTTAAATTGAT
 TCCGAGTGAGACTCGCCAAGCACAACCTGAGGGTAGTTACCCAGAGATA
 CCTATGAAAAACAGTGGTATCCAGCAAGCCTAGTAAACTCAGGTTGCCAG
 CAGCTTGCCACTTCCGCTGCTAGCTGAATAACAAGACTGCCACTCTGGGT
 CATAGTGATAGAGACTGAAGTAGAAAAACGAATGTGGTTGGCAAATCCCG
 TGTGGCCCTCTGTGTCTATGATATTGATGGCACTGGTGTCTTATTCTTGG
 GGTTGCATCATCACACACACCCCTTGACATACAGTGCACCCAGTTTT
 GAATACATTTTTTGACCCCTGTCCGTTCTGCTACTTTGATTTGCGTTATG
 ATATATATATATATATAACCTTTCTCTTTAAACATGGCCTGTGA
 CACAATAGTCAGTTGCAGAAAGGAGCCAGACTATTGCAAAGCACTGTGC
 TCAAACTCTTCAGAAAAAGGAAAAAGCTATAGTTGTAACAT
 ATGTTATTCAGACCTCTGGTTAAAGGCAAAGGAAAAAGCTACAGTGT
 TTCTTCTCATGTTCTGATCGGAGGCATGACAAGCAAGACTGAAATCTGA
 ACTGTGTCTCCTGCATGGCAACACGTGTCTCCGTAGGCCCTCGCAAGGCC
 GGGGAGGGGTTCTACGCCCTTGCTCTTGTGATGCTGAACACTCATC
 GCCTCCTACTGTATCCTGCCCTTGAGCCTCCCTTCCCTCCCTTCC
 CTCCTCTCCCTCCCTCCCTCTCCCTCCAGTTGAAAGGTCAAAC
 AAAACTACCACATTCCCTACCCAGTTAGAAGAAAACCACCGTCTGACAGTT
 GTGATCGCATGGAGTACTTTAGATTAGCACCTGTTTACCTCGTTGT
 GGGCGTGTGTTGATGTGCACATGTATGAAGTCCGCACATGCACCTCTGTAT
 GGGCAGAGGCGTGGCATCACAGAAGAGCAGATGCCAACTTGTGCTTTA
 GTGAATACATTAACCAACGGTCTTATTGAGTGGAAATTCTA
 TTGATGCAAATATTGAGCTTTAAGACTTAAACTAGATAATGTGCCA
 AGCTTTAGGACTGCTACCAGGCCCTGTAGAAGAAAACACCAGTACTTTTC
 CTGTTGTGTAATAAGGCATTTGTATTGTTGCTACACTAATGGTTA
 TTTCTTCTTAGTCCACTGAATGTTCCATGTGCCCTCGTATGCCAACTTTT
 TGTCATTTCTATGTGGGACCAATGGTTGCTGTGCAACCTAAACCT
 ATGACCTGCTGAGGCCCTCAGAAAATGACACAGTACCAAGATACT
 TCGCAAAGAAAAGTAGGTCCTCCCTGGTTGATGCTGTGCCAACTATT
 CGCTAATTCCAAGGAGCTGAACGCCCTTATAAAACTGATGGCACCTGATG
 CTTTAGTTCTGAAATTTACACTCGGATCATGTTGTTGACTAAACA
 AAGTTTGATGAAGAGAGCAAAAAAGCAGGTGGATTGGAACAGTTTC
 AGGGTTTTTTGTTTGTGTTTGTGTTTGTGTTTTTTTTTTTTTTGTTT
 TTCTGTTCTCTGTTAGAAAAGTCAGGTGTTCTGTGTCAGGCTATCTTATAGT
 CAATTTTTTACGAACTAAAGTAGTACCTTTAATATGTTAGTCACGCCCT
 CTGCTCGGGGTTCAAGTTGGCTTAACCAAGCTGTATGTTCTATGCTGC
 CTGCCACTTGAGGCACTGAGTGCCCTAGACAGTCCCCTGGTAGCCAG

TABLE 3 -continued

GGAAACGAAAGACGAACCTCAACTCTTGCTCCTAATAATCAACTCTCTGTATG
 AAGGATGGCAGCATTAAGAGTCTCTGCCTGGGCATTATTGGGCCAGTTCA
 CCCTCTTAAATCAAACCCGAGTGGCTCCCAGTTCTCGTCCCATCAGATT
 AAATTGCTAACAGTATGGGGGCACCACGCATCTGTTGTCCCACAATGCG
 CTTTCTCTCCAAATCCGATTCTGCTGTATAGCCTATTCATAAATTTAT
 TTATTGCTGCCTCCACTTACAATCGTAGAGAGCAATGCCATTGTCACT
 TTCTGCAACAGTTTGAGCCTTATGGCTGAATCCCATTCTCTTT
 AAACTGTTGCTCCATTGCTCTCCGCACGGCTGTCCGTACAGTCATCCC
 CCATCTGGGGCCTTTCATCTCACCCCTCTGGTGCTCGTGGATCTCT
 GCTTACCTCTGTGGTTTTTTTTTGACTTATTCTCTACTGGACT
 TTAAGATTACTCCACAGCGAAAGTGCTGCCTCCCTTCTGCCCGCAGTGT
 CTGCGTACTTAGATACTACTCAGTGCTGACATTGATGGAAAAGTTGCCT
 GCACCTAAATTCCTTTAAAGGGTGAACTAGAGTTGGAGTTTTCTC
 TTTTTCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
 CCCTCCCTCCCTCCCTCCCTCCCTCCCTCTCTCTCTCTCTCTCTCT
 TTTCTTCTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT
 CACAGGCTTGAGAATTATAAAAGGTGACAGTCACCTGAAAATCACAGG
 CTGGTCTGTTAAATTGAGAAATATCCGATTAAAGTCTGTGGCTGTG
 TCCTAATAGGCTCTTCAAGGACGTTGAGTCATAGAGTGGCTGAACCAT
 ACTTGAGTTATAAAAGCTAAAAACTGATGCACCCACTCTGCTATTATCG
 TTAGTAAGAGTTCAAGCTGTATCATGGCTAGGTTATCTGTCCCTACAGT
 GGTATTCAAATATGCCACCAGAGGATATGTGAAATATAAGCACCTGTATT
 TGCTGTTGAGAACTGGAGGGAAAACAAAAATGCTGCCAACCTTT
 GCCTTTAACCGTAATTAAATTGACAGTTATTAGAGATAAGAGTTCAA
 AAATCTCTTAACGCCAACCCACAGAGGGCTTGTGTTGCCATCTCAGT
 GGCTCACAGATATGATCCAAGTTAACCTGAAAGAGATGAGCAGTACCC
 AAATTGCTGCCTTAACCTGGCTGTCTTAATTATGACTGTTAATGCTG
 AATTTCATCCGCTAGTGGTGGAGGTAAGAAAAGCCTTTAAATA
 GTATTCTGTAAAACGGCATGGTGGATCTCTGTGCTATCACGGTG
 AAAGAGGGAAACATTCTTATTAAAGCAGAGCATTATTACAGAAAG
 CAATTGAGAAATTAGTCCACATCATATAAATATCCATTAAACCA
 ATTGTAAGAGAACTCCAGTGTGCTATGCACAAGGAACCTCCCTGGGG
 CTTTTTGATAGCAATTAAAGGTATGCTATTGTCAGTAGCCATTG
 AGTATTAAAGACCAAGTTACAGCTGTGTTACCCCTAAAGGTTT
 TTTTTATGTATTAATCAATTACTGTTGAAGCTTGAATACCTGCAA
 TCTTGCAAGATACTTTTATTAAAAAAATACTGTGAAATATTACCC
 GTAATATTATATACTTAATAAAACATTAAAGCTA

Mouse CD47 amino acid isoform 2 (XP_006521874.1)
(SEQ ID NO: 4)

MWPLAAALLLGSCCCGSAQLLFSNVNSIEFTSCNETVVIPCIVRNVEAQSTEE

MFVKWLNKSYIFIYDGKNSTTDQNFTSAKISVSDLINGIASLKMDKRDA

TABLE 3 -continued

MVGNYTCEVTELREGKTVIELKNRTVSWFSPNEKILIVIPIPLAILFWGKFG
 IILTLKYSSHTNKRIILLLVAGLVLTVIVVVAIILIPGEKPVKNASGLGLIVISTG
 ILILLQYNVFMTAFGMTSFTIAILITQVLGYVLALVGLCLCIMACEPVHGPLLISG
 LGIIIALAELLGLVYMKFVASNQRTIQPPRNR
 Mouse CD47 mRNA isoform 3 (XM_006521807.1)
 (SEQ ID NO: 5)
 GCCTACACCGGGAGAGCAGGGAGGAGTTGGACTGAGGTTGGCGGCTC
 CGAGGGTCAGGGCGAGCTTGGCCAGAGGGAGTAGAGAGCAGCGGGCTGC
 GCAGGGACGCGTGCCGTGAGTCCGGTGAGCGTGTGTCCCAGCTCCCCTG
 CTTTCAGGCCGCCAGAACGAAGCCGAAGAGAGCTGGCTGGAGGGAC
 GGGGCCGTGAGCAGAGAGTGCACACCCGCGCAGCCCCGGGACAGGCTGA
 TTCTGGCGCTCCGGAGCCTGCCCAGGGCTGGGTGTGAGGCTGGCGT
 CACGTCAACGAGCAGAGGGCCAGGCGGGAGTGCAGCTGGCTGGCG
 GCGCGAGCACCGCGCGCGCACCCCCGGCAGCCTGGCGGGCTCC
 TGCCTGTCAGCTGCGCGCTGCTGGTCGGTCTGAAGGCAGCA
 GCGGAGGGCGCGCTGCTCCAGACACCTGCGCGGGCACCCCCGGCG
 CGGAGATGTGGCCCTTGGCGGGCGCTGGCTGGCTGGCTGGCTGCT
 GCGGTTCAGCTCAACTACTGTTAGTAACGTCAACTCCATAGAGTTCAC
 TTCTGCAATGAAACTGTGGTCATCCCTGCACTGCTGGCTGGAG
 GCGCAAAGCACCGAAGAAATGTTGTGAAGTGGAAAGTTGAACAAATCG
 TATATTTCATCTATGATGAAATAAAATAGCACTACTACAGATCAA
 ACTTTACCAAGTSCAAAATCTCAGTCTCAGACTTAATCAATGGCATTGC
 CTCTTGAAAATGGATAAGCGCGATGCCATGGTGGAAACTACACTTGC
 GAAAGTACAGAGTTATCCAGAGAAGGCAAAACAGTTAGAGCTGAAA
 AACCGCACGCCCTAACACTGACCAAGGATCAGCCTGTTTACGAGG
 AGGAGAAAGGAGGTTGCAAATTAGTTCTGGTTCTCAAATGAAAA
 GATCCTCATTGTTATTTCCAATTGGCTAACTCCTGTTCTGGGAA
 AGTTGGTATTTAACACTCAAATATAATCCAGCCATACGAATAAGAG
 ATACATTCTGCTGCTCGTGGCGGGCTGGTGTCAAGTCATCGTGGTT
 GTGGAGCCATCCTCTCATCCCAGGAGAAAAGCCGTGAAGAATGCTT
 CTGGACTTGGCTCATTGTAATCTACGGGGATATTAATACTACTTCA
 GTACAATGTGTTATGACAGTTGGAAATGACCTCTTCAACCATTGCC
 ATATTGATCACTCAAGTGTGGCTACGTCTGGCTGGTGGCTGT
 GTCTCTGCATCATGGCATGTGAGCCAGTGCACGGCCCCCTTGTGATT
 AGGTTGGGATCATAGCTAGCAGAAACTACTGGATTAGTTATATG
 AAGTTGTCGCTTCCAACCAGAGGACTATCCAACCTCTAGGAAAGCTG
 TAGAGGAACCCCTAACGAATAGGTGAAGGAAAGTGACGGACTGTAAC
 GGAAGTCAGAAATGGAAGAATACAGTTGTCAAGCACCAGGTCTCACGAC
 TCACAGCTGGAGGAACAGACAAACAGTAACGTGACTCCATCCAGGAAACA
 TGTCACATAATGATTACTAAAGTTATATTCAAAGCAGCTGACTTACATA
 ATAAAAAAAAATGATGTGCTGTGTAACCAATTGGAATCCCATTTCATT

TABLE 3 -continued

GTTTCTACTCAACTAGGGCAACGTTCAGGGCAACTCCAAGAATGATG
 CTTGTTAGATCTTAGAGTCTCTGAACACTGAGTTAAATTGATTCCGAGTG
 GACTCGCAAGCACTAACCTGAGGGTTAGTTACCCAGAGATACTATGAAA
 AACAGTGGTATCCAGCAAGCCTAGTAAACTCAGGTGCCAGCAGCTTGCC
 ACTTCGCGTCTAGCTGAATAACAAGACTGCCACTCTGGGTATAGTGATA
 GAGACTGAAGTAGAAAAACGAATGTGGTTGGCAAATCCGTGCCCCCT
 CTGTGTGCTATGATATTGATGGCACTGGTGTCTTCATTCTGGGGTTGCCAT
 CATTACACACACACCCCTTGACATACAGTCACCCCAGTTGAATACATTT
 TTTTGACCCCTGCTCCGTTCTGCTACTTGATTTGCGTTATGATATATAT
 ATATATATAATACCTTTCTCCTTTAAACATGGCTGTGACACAATAGTC
 AGTTGCAGAAAGGAGCCAGACTTATCGCAAAGCACTGTGCTCAAACCTTC
 AGAAAAAAAGGAAAAAAAAAAAGCTATAGTTGTAACATATGTATTCCAG
 ACCTCTGGTTAAAGGCAAAAGAAAAAAATCACAGTGTCTTCTCATGT
 TTTCTGATCGGAGGCATGACAAGCAAGACTGAAATCTGAACGTGTCTCCT
 GCATGGCAACACGTCTCCGTCAGGCCCTCGCAAGGCCGGGGAGGGGT
 TCTACGCTCTTGCTCTTGATGCTGAAACACTCATGCCCTCCTACTG
 TATCCTGCCTCCTGCAGCCTCCCTCCCTCCCTCCCTCCCTCCCTCT
 CCTCCCTCCCTCTCCCTCCCTCCAGTTGAAAGGTCAAACAAACTACCAC
 ATTCCCTACCCAGTTAGAAGAAAACCACCGTCTGACAGTTGATCGCATG
 GAGTACTTTAGATTATTAGCACCTGTTTACCTGTTGTTGGCGTGTGTTG
 TATGTCACATGATGAAGTCGGCACATGCACCTCTGTATGGCAGAGGCG
 TGGCATCTACAGAAGAGCAGATGCCACTTGTGCTTTAGTGAACATATTA
 AAAAAAAACCAACGGCTTATTGAGTGAATTCTATTGATGCCAAAT
 ATTTGAGCTTTAAGACTTTAAACTAGATAATGTGCCAGTTAGGAC
 TGCTCACCACTGCCCTCTGAAGAAACACCAAGTACTTTCTGTTGTGTAAT
 AAAGGCATATTTGATTTGCTTGATCCTGAACTATGGTTATTCTTAGTC
 CACTGAATGTTCCATGTCCTCGTATGCCAAACTTTGTCATCTTCAT
 GTGGGGACCAATGGTTGCTGTGGCAAACCTAAACCTATGACCTGCTGAG
 GCCTCTCAGAAAATGACCACAGTACCAAGATACTTCGCAAAGAAAAG
 TAGGTTCCCTCCCTGGTTGAGCTGTCGCCAATTAGCGTAATTCCAAG
 GAGCTGAACGCCCTTATATAAATCTGATGGCACCTGATGCTTTAGTCTGA
 AAATATTACACTCGGATCATGTTGATGACTAAACAAAGTTTGATG
 AGAGAGCAAAAAAGCAGGTGGATTGGAACAGTTCAGGGTTTTTT
 GTTTTTGTTTTGTTGTTGTTTTTTTTTTTTTATTTGTTCTGTTCTG
 TTAGAAAAGTCAGGTGTTCTGTCAGGCTATCTTATAGTCATTTTTTA
 CGAAACTAAAGTAGTACCTTTAATATGAGTCACGCCCTGCTGCCACTG
 TCAGTTGGCTTAACCAGCTGATGTTCTATGCTGCCACTG
 GGCAGTGGCTAGACAGTCCCATCGGTGGTAGCCAGGGAAACGAAAG
 ACGAACTCAACTCTGCTCTAATAATCAACTCTGATGAAGGATGGCAG
 CATTAAGAGTCCTCCTGCCCTGGCATTATTGGCCAGTTCACCCCTTTAAA

TABLE 3 -continued

TCAAACCCGCAGTGGCTCCCAGTTCTCGTCCCACAGATTAAATTGCTAAC
 AGTATGGGGGCACCACGCATCTGTTGTCCACAATGCCCTTTCTCTC
 CAAATCCCGATTCTGCTGTCAAGCCTCTATTCAATTTTATTGTCTG
 CCCTCCACTTACAATCGTAGAGAGCAATGCCATTGTCACTTCTGCAAC
 AGTTTTTGAGCCTTATGGCTGAATCCCATTTCCTCTCTCAAAGTCTT
 GCTCCATTGCTCTCCGCACGGCTGTCGTACAGTCATCCCACATCTGG
 GGGCCTTTCTCTCACCCCTGGTGTGGATCTCTGCTTACCT
 CTGTGGGTTTTTTTTTGACTTATTCTCTCACTGGACTTTAAGATT
 ACTTCCACAGCGAAAGTGCCTGCCCTTGCCCCGAGTGTCTGCGTA
 CTTTAGATACTCAGTGCTGACATTGATGCCAAAAGTGCCTGCACCTTA
 AATTCTCTTTAATAGGGTGAAGTAGAGTTGGAGTTCTCTCTCTCTCT
 CTTTCT
 CCCTCCCTCCCTCCCTCCCTCTCTCTCTCTCTCTCTCTCTCTCT
 TTTCTTCTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT
 TTGAGAATTATAAAAGGTGACAGTTCACCTGAAATCACAGGTCTGGTCTG
 TTAAATTGTTGAGAAATATCCGATTAAGAGTCTTGTGGCTGTGCTTAATA
 GGCTCTCTTCAGGACGTTGAGTCATAGAGTGGCTGAACCATACTGAGT
 TTATAAAGCTCAAAACTGATGCCACCCACTCTGCTATTATCGTGTAGTAAG
 AGTCAGCTGTATATCATTGCTAGGTTATCTGCTCACAGTGGGTATTCA
 AATATGCCACACAGAGGATATGTGAAATATAAGCACCTGTATTGCTGTT
 GTTGAGAACTGGAGGGAAACAAAAATGTCTGGCAACCTTGCTTCTT
 ACCGTAATTAGACAGTTATTAGAGATAAGAGTTCAAAATCTCTT
 AACTGCCACAACCCACAGAGGGCTTGTGCTTGCATCTCAGTGGCTCACAG
 ATATGATCCAAGTTAACCTGAAAGAGATGAGCAGTACCCAGGAAATTGTCC
 TGCTTTAACTCTGGCTGTCCTTAATTATGACTGTTAATGCTGAATTTC
 TCCGTCTAGTGTGAGGGATAAGAAAAGCCTTTAAATAAGTATTCTG
 TAAACGGCATCGGTGGGATCTCTGTGTTGCTACGGGTGAAAGAGGG
 AACATTTCTTATTAAAGCAGAGCATTATTACAGAAAGCCATTGTT
 GAGAATTAGTCCCACATCATATAATATCCATTAACCATTCAAATTGTA
 GAGAACTCCAGTGTGCTATGACAAGGAACCTCCTGGGGCTTTTG
 CATAGCAATTAAAGGTATGCTATTGTCAGTAGCCATTGGCAGTGATT
 AAAGACCAAAAGTGTGTTACAGCTGTGTTACCCCTAAAGGTTTTTATG
 TATTAATCAATTACTGTTGAAGCTTGAATAACCTGCAATTGCA
 AGATACTTTTATTAAAAAAATACTGTGAAATTACCCGTAAATT
 TATATACTTAATAAAACATTAAAGCTA
 Mouse CD47 amino acid isoform 3 (XP_006521870.1) (SEQ ID NO: 6)
MWPLAAALLGSCCGSAQLLFSNVNSIEFTSCNETVVIIPCIVRNVEAQSTEE
 MFVKWKLNKSYIFIYDGKNNSTTDQNFTSAKISVSDLINGIASLKMDFRDA
 MVGNYTCEVTELSREGKTVIELKNRTAFNTDQGSACSYEEKGGCKLVSW
 FSPNEKILIVIPIPLAILLFWGKFGILTLYKSSHTNKRIILLVAGLVLTVIVVVG

TABLE 3 -continued

AILLIPGEKPVKNASGLGLIVISTGILILLQYNVFMTAFGMSTSFTIAILITQVLGYV
 LALVGLCLCIMACEPVHGPLLISGLGIIALAELLGLVYMKPVASNQRTIQPPRKA
 EEPLNE
 Mouse CD47 mRNA isoform 4 (XM_006521808.1)
 (SEQ ID NO: 7)
 GCCTACACCGGGAGAGCAGGGAGGGAGTTGGACTGAGGTTGGCGGCTC
 CGAGGTCCAGGGCGAGCTTGGCCAGAGGGAGTAGAGAGCAGGGGGCTGC
 GCAGGGACGCGTGCCTGAGTCCGGTGAGCGTGTGTCCCAGCTCCGT
 CTTTCAGGCCGCCAGGACACGAAGCCGGAGAGAGCTGGCTGGAGGGAC
 GGGGCCGTGAGCAGAGAGTGCACCCGCGCAGCCCCGGGACAGGCTGA
 TTCTGGCGCTCCCGGGAGCCCTGCCAGGGCTGGGTGTGAGGCTGGCGT
 CACGTCAACGAGCAGAGGGCCAGGCGGGGGAGCTGGCTGGCGTGC
 GCGCGAGCACCGCGCGCGCACCCCGGGCAGCCTGGCGGCCGCTCC
 TGCTGTCACTGCTGCCGCTGCTGGTCGGTCTGGCTGGCTGGCGTGC
 GCGGAGCGGGCGCTGCTCCAGACACCTGCGGGCGAACCCCGGGCG
 CGGAGATGTGGCCCTGGCGGGCGCTGTTGCTGGCTGGCTGGCGTGC
 GCGGTTCACTCAACTACTGTTAGTAACGTCAACTCCATAGAGTCAC
 TTCATGCAATGAAACTGTGGTCACTCCCTGCATCGTCCGTAATGTGGAG
 GCGCAAAGCACCGAAGAAATGTTGTGAAGTGAAGTTGAACAAATCG
 TATATTTCATCTATGATGAAATAAAATAGCACTACTACAGATCAA
 ACTTTACCAAGTSCAAAAATCTCAGTCTCAGACTTAATCAATGGCATTGC
 CTCTTGAAAATGGATAAGCGCGATGCCATGGTGGAAACTACACTTG
 GAAGTGACAGAGTTATCCAGAGAAGGCAAAACAGTTAGAGCTGAAA
 AACCGCACGGTTCTGGTTCTCAAATGAAAAGATCCTCATTGTTA
 TTTCTCAAATTTGGCTATACTCCTGTTCTGGGAAAGTTGGTATTTA
 AACACTCAAATATAATCCAGCCATACGAATAAGAGAATCATTGCTGC
 TCGTGGCGGGCTGGTCTCACAGTCATCGTGGTGTGGAGCCATCCT
 TCTCATCCCAGGAGAAAAGCCCGTGAAGAATGTTCTGGACTTGGCTC
 ATTGTAATCTCACGGGATATTAATACTACTTCAGTACAATGTGTTAT
 GACAGCTTTGGAATGACCTCTTCACCATTGCCATATTGATCACTCAA
 GTGCTGGCTACGTCCTGCTTGGTCGGCTGTGCTCTGCATCATGG
 CATGTGAGCCAGTGCACGGCCCCCTTGATTTCAAGGTTGGGATCAT
 AGCTCTAGCAGAAACTACTTGGATTAGTTATGAAAGTTGTGCTTCC
 AACCAAGAGGACTATCCAACCTCTAGAAAGCTGTAGAGGAACCCCTA
 ACGCATTAAAGAGTCAAAAGGAATGATGAATGACGAATAGGTGAAGGG
 AAGTGACGGACTGTAACCTGGAAGTCAGAAATGGAAGAACAGTTGTCTA
 AGCACCAGGTCTCACGACTCACAGCTGGAAGGAACAGACAAAGTAAC
 ACTTCCATCCAGGAAACATGTCACATAATGATTACTAAGTTATTC
 AGCAGCTGTAATTACATAATTTATGATGTGCTGTGTAACCAATT
 GGAATCCCATTTCATTGTTCTACTCAACTAGGGCAACGTTCAAGG
 GCAACTTCCAAGAATGATGCTGTTAGATCCTAGAGTCTGAAACACTGAGT

TABLE 3 -continued

TAAATTGATTCGAGTGAGACTCGCCAAGCACTAACCTGAGGGTTAGTTAC
 CCAGAGATACTATGAAAAACAGTGGTATCCAGCAAGCCTAGTAAACTCA
 GGTTGCCAGCAGCTTGCCACTTCCGTGCTAGCTGAATAACAAGACTGCCA
 CTTCTGGGTATAGTAGAGACTGAAGTAGAAAAACGAATGTGGTTGG
 CAAATCCCCTGTCGGCCCTCTGTGTCTATGATATTGATGGCACTGGTGTCT
 TCATTCTGGGGTTGCCATCATTACACACACCCCTTGACATACAGTGCA
 CCCCAGTTTGAAATACTTTTGACCCCTGTCCGTTCTGCTACTTTGATT
 TGCCTATGATATATATATATATAACCTTTCTCCTCTTAAACATG
 GTCCTGTGACACAATAGTCAGTGAGAAAGGAGCCAGACTTATTCGAAA
 GCACTGTGCTCAAACACTTCAGAAAAAAGGAAAAAAAAAGCTATAG
 TTGTAACATATGATTCCAGACCTCTGGTTAAAGGCAAAAGAAAAAAAT
 CTACAGTGTCTCTCATGTTCTGATCGAGGAGCATGACAAAGCAAGACT
 GAAATCTGAACGTGTCTCCTGCATGGCAACACGTGTCTCCGTCAAGGCCCTC
 GCAAGGCCGGGGAGGGGTTCTACGCTCTGTCTTTGTTGCATGCTGA
 AACACTCATGCCCTCTACTGTATCCTGCCCTGTCCGCTCCCTCTCC
 TCCCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCCAGTTGAA
 AGGTCAAACAAACTACCACATCCCTACCCAGTTAGAAGAAAACCACCGT
 CCTGACAGTTGATCGATGGAGTACTTTAGATTATTAGCACCTGTTTA
 CCTCGTTGTGGCGTGTGATGTGCACATGTATGAAGTGGCACATGCA
 CCTCTGTATGGCAGAGCGTGGCATCTACAGAAGAGCAGATGCCAACTT
 TGTGCTTTAGTGAATACATTAACGGTCTTATTGAGT
 GGAATTCTATTTGATGCAAATTGAGCTTTAAGACTTAAACTAGAT
 AATGTGCCAAGCTTTAGGACTGCTACCACTGCCCTGTAAAGAAACACCA
 TACTTTCTGTTGTGTAATAAAGGCATATTGATTTGTTGCATCAC
 TAATGGTTATTCCTCTAGTCCACTGAATGTTCCATGTGCCCTCGTATGC
 CAAACTTTGTCATCTTCATGTGGGACCAATGGTTGCTGTGGCAA
 CCTAAACCTATGACCTGCTGAGGCCTCTCAGAAAACGACACAGTACCAA
 GATAGTACTCGCAAAGAAAAGTAGGTTCCCTCCGTGGTTGCTGTGCG
 CCAATATTAGCGTAATTCAAGGAGCTGAACGCCCTATATAATCTGATGG
 CACCTGATGCTTAGTCTGAAAATTTACACTCGGATCATGTTGATG
 ACTTAAACAAAGTTTGATGAAGAGAGCAAAAAAGCAGGTGGATTGG
 AACAGTTTCAGGGTTTTGTTGTTGTTGTTGTTGTTGTTTTTT
 ATTTTGTTTCTGTTCTGTTAGAAAAGTCAGGTGTTCTGTCAGGCTA
 TCTTATAGTCATTTTACGAACTAAAGTAGTACCTTTAATATGAGT
 CAACGCCCTCTGCTCGGGGTCAGTTGGCTTAACCAGCTGTCATGTC
 TCTATGCTGCCACTTGAGGCAGTGAGTCCCTAGACAGTCCCATCGGT
 GGTAGCCAGGGAAACGAAAGACGAACCTCAACTCTGCTCCTAATAAC
 TCTCTGTATGAAGGATGGCAGCATTAGAGCTCTGCTGGCATTATTG
 GCCAGTCACCCCTTTAAATCAAACCCGAGTGGCTCCAGTTCTCGTCC
 CATCAGATTTAAATTGCTAACAGTATGGGGGCACACGCATCTGTTTGTC

TABLE 3 -continued

CCACAATGCGCTTTCTCTCCAAATCCGATTCTGCTGTCAAGCCTCTAT
 TCAATTCTTATTGTCCTGCCCTCCACTTACAAATCGTAGAGAGCAATGC
 CATTGTCACCTCTGCAACAGTTTGAGCCTTATGGCTGAATCCCATT
 TTCTCTCTTCAAACGTGGCTCCATTGCTCCTCCGCACGGCTGTCCGTA
 CAGTCATCCCATCCATGGGGCCTTTATCTCTCACCCCTGGTGCT
 TCGTGGATCTGCTTACCTCTGTGGGTTTTTTTTTGACTTATTCTT
 CTCACGGACTTAAGATTACTTCCACAGCGAAAGTGCTGCCTCCCTTCTG
 CCCGCAGTGTCTGCGTACCTAGATACTCAGTGCTGACATTGATGGC
 AAAAGTTGCCCTGCACTAAATTCTCTTTAATAGGGTGAACAGAGTTGG
 AGTTTTCTCTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
 CTCTCTCTCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCTCTCT
 TTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT
 TTTGACAAATCTCACAGGCTTGAGAATTATAAAAGGTGACAGTTCACCTGA
 AAATCACAGGCTGGCTGTTAAATTGTTGAGAAATATCCGATTAAAGTC
 TTGTTGCTGTGCTTAAGGCTCTTCCAGGACGTTGTAGTCATAGAGT
 GGCTGAACCATACTTGAGTTAAAGCTAAAAACTGATGCACCCACTCTG
 CTATTATCGTGTAGTAAGAGTCAGCTGTATATCATTGCTAGGTTATCTT
 GTCTACAGTGGGTATTCAAATATGGCACCCAGAGGATATGTTAAATATA
 AGCACCTGTATTGCCCTGTTGAGAACTGGAGGGAAAACAAAAATGTC
 TGGCAACCCCTTGCTTTAACCGTAATTAAATTGACAGTTATTAGAGATA
 AGAGTTTCAAAATCTTAACTGCCACAACCCACAGAGGGCTTGTTTG
 CCATCTTCAGTGGCTCACAGATATGATCCAAGTTACTGAAAGAGATGAGC
 AGTACCCAGGAATTGCTCTGCCCTTAACCTCGCTGTCTTAATTATGACT
 GTTTAATGCTGAATTTCATCGCTAGTGTGAGGGTAAAGAAAAGCCT
 TTTTAAATAAGTATTCTGTAACGGCATCGGTGGATCTCTGTGTTGCT
 ATCACGGGTAAAGAGGGAAACATTCTTATTAAAGCAGACATTAT
 TTACAGAAAGCCATTGTTGAGAATTAGTCCCACATCATATAAATATCATT
 AACCAATTCTAAATTGTAAGAGAACTCCAGTGTGCTATGCACAAGGAACCT
 CCTGGGGCCTTTTGCTAGCAATTAAAGGTATGCTATTGTCAGTAGC
 CATTGCTGAGTTAAAGACCAAGTTGTTACAGCTGTGTTACCCCT
 AAAGGTTTTTTTATGTATTAAATCAATTATCACTGTTGAAGCTTGAA
 TACCTGCAATCTTGCCAAGATACTTTTATTAAAAAAACTGTGTA
 ATATTACCTGTAATTATATACTTAATAAACATTAAAGCTA
 Mouse CD47 amino acid isoform 4 (XP_006521871.1) (SEQ ID NO: 8)
MWPLAAALLGSCCGSAQLLFSNVNSIEFTSCNETVVIIPCIVRNVEAQSTEE
 MFVKWKLNKSYIFIYDGKNKNSTTDQNFSAKISVSDLINGIASLKMDKRDA
 MVGNYTCEVTELSREGKTVIELKNRTVSWFSPNEKILIVIPIILFWGKFG
 ILTLKYKSHTNKRIILLLVAGLVLTVIVVVGAILLIPGEKPVKNASGLGLIVISTG
 ILLLQYNVFMTAFGMTSFTIAITLITQVLGYVLAIVGLCLCIMACEPVHGPLIISG
 LGIIALAEELLGLVYMKFVASNQRTIQOPPRKAVEEPLNAFKESKGMMNDE

TABLE 3 -continued

Human CD47 mRNA isoform 1 (XM_005247909.1)
 (SEQ ID NO: 9)

```

AGTGGGAGCGCCGTGCGCGGCCGTGCAGCTGGCAGTGGTCCTGCC
TGTGACCGCGCGCGCGGTCGGTCCTGCCTGTAACGGCGCGCGCTGCT
GCTCCGGACACCTGCGCGGGCGGCGACCCCGCGCGGGCGAGAT
GTGGCCCTGGTAGCGCGCTGTTGCTGGGCTCGCGTGCTGCGGATC
AGCTCAGCTACTATTAATAAAACAAAATCTGAGAATTACGTTTGTA
ATGACACTGTCGTCAATTCCATGCTTTGTTACTAATATGGAGGCACAAA
CACTACTGAAGTATACTGAAAGTGGAAATTAAAGGAAGAGATATTTAC
ACCTTTGATGGAGCTCTAACAAAGTCCACTGCCCCACTGACTTTAGTA
GTGCAAAATTGAAAGTCTCACAAATTACTAAAGGAGATGCCTCTTGAA
GATGGATAAGAGTGATGCTGTCACACACAGGAAACTACACTTGTGAA
GTAACAGAATTAAACCAGAGAAGGTGAAACGATCATCGAGCTAAATAC
GTGTTGTTCATGGTTCTCCAATGAAAATTCTTATTGTTATTTCT
CCAATTGGCTATACTCCTGTTCTGGGACAGTTGGTATTAACACAC
TAAATATAGATCCGGTGGTATGGATGAGAAAACAATTGCTTACTTGT
TGCTGGACTAGTGATCACTGTCATTGTCATTGGAGCCATTCTTTCT
GTCCCAGGTGAATATTCACTAAAGAATGCTACTGGCCTGGTTAATTG
TGACTTCTACAGGGATTAATTAATTACTTCACTACTATGTGTTAGTACA
GCGATTGGATTAACCTCCTCGTCATTGCCATTGGTTATTCAAGGTGA
TAGCCTATATCCTCGCTGTGGTGGACTGAGTCTCTGTATTGCGGGGTG
TATACCAATGCATGGCCCTTTCTGATTCAGGTTGAGTATCTAGCT
CTAGCACAATTACTGGACTAGTTATATGAAATTGTGAAACTGAA
GTGAAGTGATGGACTCCGATTTGGAGAGTAGTAAGACGTGAAAGGAATACA
CTTGTGTTAACGACCATGGCCTGATGATTCACTGTTGGGAGAAAGAAC
AGAAAAGTAACGGTTGTCACCTATGAGACCCCTACGTGATTGTTAGTAAG
TTTTATTCAAAAGCAGCTGTAATTAGTTAATAAAATAATTATGATCTATGTT
GTGGCCCAATTGAGATCCAGTTTTGTTGTTATTAAATCAATTAGGGC
AATAGTAGAATGGACAATTCCAAGAATGATGCCCTCAGGTCCTAGGGC
CTGGCCTCTAGGTAACCAGTTAAATTGGTCAGGGTGATAACTACTTAGCA
CTGCCCTGGTGAATTACCCAGAGATCATGAAACCACTGGCTTCCATCAA
ACCTTTGCCAACTCAGGTTCAAGCAGCTTGGCAGTTATGGCAGTATGGC
ATTAGCTGAGAGGGTGTGCCACTCTGGGCAATGGAATAATAAATTAAAGT
ACAGGCAGGAATTGGTTGGGAGCATCTGTATGATCTCGTATGATGTGAT
ATTGATGAGGAGATAGTGGTCCTCATTCTGGGGTTGCCATTCCCACATTCCC
CCTTCACAAACAGTGTAAACAGGTCCTCCAGATTAGGGTACTTTATTG
ATGGATATGTTCTTTATTACACATAACCCCTTGAAACCCCTGTCTTC
CCTGTTACTGCTCTGCTGTAACAGGTCCTCCAGATTAGGGTACTTTATTG
ATGGTCTAGTGACACGGTAGCAGCAGTTGCAGGAAGGAGCCAGACTTGTTC
TCAGAGCAGTGTGTTACACTTTCAAGAAAAATAGCTATGGTGTAAACATA
TGTATTCCCTTCCTCTGATTTGAAGGCAAAATCTACAGTGTTCCTTC

```

TABLE 3 - continued

TTTTCTGATCTGGGCATGAAAAAGCAAGATTGAAATTGAACATATGAGTC
TCCCTGCATGGCAACAAAATGTGTGTACCATCAGGCCAACAGGCCAGCCCTT
GAATGGGGATTATTACTGTTGTATCTATGTTGCATGATAAACATTACATCAC
CTTCCTCTGTAGTCCTGCCTCGTACTCCCCTCCCTATGATTGAAAAGTAA
ACAAAACCCACATTCCTATCCTGGTTAGAAGAAAATTAAATGTTCTGACAGT
TGTGATCGCCTGGAGTACTTTAGACTTTAGCATTGTTTTACCTGTTTG
TGGATGTGTGTTGTATGTGCATACGTATGAGATAGGCACATGCATCTCTG
TATGGACAAAGGTGGGTACCTACAGGAGAGCAAAGGTTAATTGTGCTT
TTAGAAAAACATTAAATACAAAGTTCTTATTGGGTGGAATTATATTGA
TGCAAATATTGATCACTTAAACACTTTAAACACTTAGGTAATTGCCACG
CTTTTGACTGCTCACCAATACCCCTGTAACAAATACGTAATTCTCCTGTTGT
GTAATAAGATATTCAATTGAGTTGCATTAATAATAGTTATTCTTAGTCC
ATCAGATGTTCCCGTGCCTTTATGCCAAATTGATTGTCATATTTCATG
TTGGGACCAAGTAGTTGCCATGGCAAACCTAAATTATGACCTGCTGAGG
CCTCTCAGAAAACGTGAGCATACTAGCAAGACAGCTCTTCTGAAAAAA
ATATGTATACACAAATATACGTATCTATATACGTATGTATACAC
ACATGTATATTCTCCTTGATTGTTGCTGAACTTACGTTAGTTGTTACTTAAACATATATA
GAGGGAGCTGATTCCCTTACAAATCTGATGGCTCCTGCAGCACTTTTC
CTTCTGAAAATATTACATTGCTAACCTAGTTGTTACTTAAACATCAGT
TTTGATGAAAGGAGGGAAAGCAGATGGACTTGAAAAAGATCCAAGCTCCT
ATTAGAAAAGGTATGAAAATCTTATAGTAAAATTTTATAAAACTAAAGTT
GTACCTTTAATATGAGTAAACTCTCATTATTGGGGTTGCTCTGGATC
TCATCCATCCATTGTTCTTTAATGCTGCCCTGGGAGGATTCACT
GCCTCTAGACAATGCCACCAGAGATAGTGGGGAAATGCCAGATGAAACCAA
CTCTTGCTCTCACTAGTTGTCAGCTCTGGATAAGTGACCAAGAGCAG
GAGTCCTCCTGTTGGCATCATGGCCAGTCCTCTTAAATCAGATT
TGTAATGGCTCCAAATTCCATCACATCACATTAAATTGCAAGACAGTGT
TGCACATCATGTATGTTGCCCCATAATGCTTTACTCCCTGATCCC
AGTTTCTGCTGTTGACTCTCATTCACTTTATTGTGTTCTCACAGT
GACACCAATTGCTCTTCTGCAACAAACCTTCCAGCTACTTTGCCAAATTC
TATTGCTCTCTCTTCAAAACATTCTCTTGCAGTCCTCTTCATCTGTGA
GCTGCTTTGCTCTTAACCTACCATTCCTATAGTACTTTATGCATCTGC
TTAGTTCTATTAGTTTGGCCTGCTCTCCTGATTAAATTCCCTC
TATAGCTAGAGCTTTCTTCATTCTCTTCAGTGAGAGTTGGCTGTATTC
ATCAGAAGCTAGGTACATAAGTTAAATGATTGAGAGTTGGCTGTATTC
TTATCACTTTTAATAGGGTGAGCTTGAGAGTTCTTCTGTTCTGTTT
TTTGTTTTTTTTTTTTTTTTTTTTTTGACTAATTCACTGCTCT
AAAAACCTCAAAGGTGATTATTTCTCCCTGGAAACTCCAGGTCCATTCTG
TTAAATCCCTAAGAATGTCAGAATTAAACAGGGCTATCCCGTAATTG
GAAATATTCTTTTCAGGATGCTAGTCATTAGTAAGTGACCAACCAA

TABLE 3 -continued

ATTGTTATTCGACTAACAAAGCTAAAACACGATAAGTTACTCCTCCATC
TCAGTAATAAATTAAGCTTAATCACCTCTAGGTTCTTGTCTTAA
AATGGGTATTCAAAAATGGGGATCTGTGGTGTATGTATGAAACACATACT
CCTTAATTACCTGTTGGAAACTGGAGAAATGATTGTCGGGCAACCGTT
TATTTTATTGTATTTATTTGGTGAGGGATTTTATAAACAGTTTACT
TGTGTCAATTAAATTAACTAACTGCCATCACCTGCTGGGTCTTGTAA
GTCATTTCAGTGACTAATAGGGATAATCCAGGTAACTTGAGAGATGA
GCAGTGAGTGACCAGGCAGTTCTGCCTTAGCTTGACAGTTAAATTA
AGATCATTGAAGACCAGCTTCTATAAATTCTTTGAAAAAAAGAAA
GCATTTGACTAAAGCTCTGTAAAGACAACATCTAAATCTAAAGTGT
GTTATCATGACTGGTGAGAGAAGAAAACATTGTTTATAATGGAGCA
TTATTTACAAAAGCATTGAGAATTAGATCCCACATCGTATAAATATC
TATTAACCAATTAAAGAGAACTCCAGTGTGCTATGTCAAGATCCT
CTCTTGAGCTTTGCATAGCAATTAAAGGTGTCTATTGTCAGTAGCC
ATTTTTGCACTGATTGAAGACCAAGTTTTACAGCTGTGTTACCGTT
AAAGGTTTTTTTTTATGTATTAAATCAATTACTGTTAAAGCTTT
GAATATCTGCAATCTTGCAAGGTACTTTTATAACTTAATAAACATTAAAGCT
TTGTAAATATTACCCGTAAATTATATACTTAATAAACATTAAAGCT

A

Human CD47 amino acid isoform 1 (XP_005247966.1)
(SEQ ID NO: 10)

MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFTVNMEAQNT

TEVYVKWFGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDAASKMDK
SDAVSHTGNYCEVTEL TREGETHIELKYRVVSWFSPNENILIVIPIFAILFW
GQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLI
VTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLI
SGLSILALAQLLGLVYMKFVE

Human CD47 mRNA isoform 2 (NM_198793.2)
(SEQ ID NO: 11)

GGGGAGCAGGGGGGGAGCGGGGGAGACAGTGGGAGCGCGCGGTGCGCG

CGGCCGTGCAGCTGGCAGTGGTCCTGCCTGTGACGCGCGCGGTGCGCG

GGTCCTGCTGTAACGGCGGGCGGTGCTGCTCCAGACACCTGCGCGCG

CGGGGGGAGCCCCGGGGGGGGAGATGTGGCCCTGGTAGCGGGCG

CTGTTGCTGGCTGGCGTGTGCGGATCAGCTCAGCTACTATTTAATA

AAACAAAATCTGAGAACCTACGTTTGTAAATGACACTGTCGTATTCC

ATGCTTGTACTAATATGGAGGCACAAACACTACTGAAGTATACTGA

AAAGTGGAAATTAAAGGAAGAGATATTACACCTTGATGGAGCTCTAA

ACAAGTCCACTGTCCCCACTGACTTTAGTAGTGCACAAATTGAAGTCTC

ACAATTACTAAAAGGAGATGCCTCTTGAGATGGATAAGAGTGATGCT

GTCTCACACACAGGAAACTACACTGTGAAGTAAACAGAATTAAACCAGAG

AAGGTGAAACGATCATCGAGCTAAATATCGTGTGTTCATGGTTTC

TCCAAATGAAAATATTCTTATTGTTATTTCCAATTGGCTATACTCC

TABLE 3 -continued

TGTTCTGGGGACAGTTGGTATTAAACACTTAAATATAGATCCGGTGG
TATGGATGAGAAAACAATTGCTTACTTGCTGGACTAGTGATCACT
GTCATTGTCATTGTTGGAGCCATTCTTCTGCCAGGTGAATATTCAATT
AAAGAATGCTACTGGCCTGGTTAATTGTGACTTCTACAGGGATATTA
ATATTACTTCACTACTATGTGTTAGTACAGCGATTGGATTAACCTCCTT
CGTCATTGCCATATTGGTTATTCAGGTGATGCCATACTCGCTGTG
GGTGGACTGAGTCTCTGATTGCGCGTGTATACCAATGCATGGCCCTC
TTCTGATTCAGGTTGAGTATCTTAGCTCTAGCACAATTACTGGACTA
GTTCATGAAATTGCTTCCAATCAGAACACTATACAACCTCCTA
GGAAATACTGAAGTGAAGTGATGGACTCCGATTGGAGAGTAGTAAGACG
TGAAAGGAATACACTTGTGTTAAGCACCATGGCCTGATGATTCACTGTTG
GGGAGAAGAAACAAGAAAAGTAACGGTTGTCACCTATGAGACCCTACGT
GATTGTTAGTTAAGTTTATTCAAAGCAGCTGAATTAGTTAATAAAATA
ATTATGATCTATGTTGCCCATTGAGATCCAGTTTTGTTGTTATT
AATCAATTAGGGCAATAGTAGAATGGACAATTCCAAGAATGATGCC
CAGGTCCCTAGGCCTCTGCCCTAGGTAACCAGTTAAATTGGTCAGGGT
GATAACTACTAGCACTGCCCTGGTATTACCCAGAGATATCTATGAAACC
AGTGGCTCCATCAAACCTTCCAACCTCAGGTCACAGCAGCTTGGCAG
TTATGGCAGTATGGCATTAGCTGAGAGGTGTCGCCACTCTGGTCATGG
AAAATAATAAGTACAGGCAGGAATTGGTGGAGCATTTGATGATC
TCCGTATGATGTGATATTGATGGAGATAGGGCCTCATTCTGGGTTGC
CATTCCCACATCCCCCTCAACAAACAGTGTAAACAGGTCTCCAGATT
AGGGTACTTTATTGATGGATATTGATGGAGATAGGGCCTTATTCAACATAACCC
ACCTGTCTGCTCTGTTACCTGCTGTCACAGGTCACCTTCAAGATGTAGCAC
TTCTCCTCTTGAAACATGGCTAGTGACACGGTAGCACCAGTGCAGGAAGG
AGCCAGACTGTCAGAGCACTGTTCACACTTCAAGCAAAATAGCT
ATGGTTGTAACATATGATTCCCTCTGATTTGAGGAAAGCTAC
GTGTTCTTCACTTTCTGATCTGGGAGTGAAGGAAAAAGCAAGATTGAAA
TTTGAACATGAGTCCTGCATGGCAACAAATGTGTACCCATCAGGCC
ACAGGGCAGCCCTGAATGGGAGTTATTACTGTTGATCTATGTCATG
ATAAACATTCATCACCTCCCTCTGATGCTGCCCTGTACTCCCTCC
ATGATTGAAAAGTAAACAAACCCACATTCTATCTGGTAGAAGAAAA
TTAATGTTCTGACAGTIGTGATGCCCTGGAGTACTTTAGACTTGTGATTC
GTTCCTTACCTGTTGGATGTGTTGATGTGTCATACGTATGAGATAGG
CACATGCATCTCTGATGGCAAAAGGTGGGTACCTACAGGAGAGCAAAG
GTAAATTGTCCTTGTAGTAAACATTTAAATACAAAGTCTTATTGGGT
GGAATTATATTGATGCAAATATTGATCACTTAAACCTTAAACTTCTA
GGTAATTGCCCCAGCTTGTGACTGCTCACCAATACCTGTAAAAACAGTA
ATTCTCTGTTGTTGTAATAAGATATTCAATTGAGTGTGATTAATAATA
GTTCATTCTTAGTCCATCAGATGTTCCCGTGTGCTCTTTATGCCAAATTGA

TABLE 3 - continued

TTGTCATATTCATGTTGGGACCAAGTAGTTGCCCATGGCAAACCTAAATT
 TATGACCTGCTGAGGCCTCTCAGAAAATGAGCATACTAGCAAGACAGCTC
 TTCTGAAAAAAAAAATATGTATACACAAATATACGTATCTATATATA
 CGTATGTATATACACACATGTATATTCTCCTGATTGTAGCTGTCCAAAA
 TAATAACATATATAGAGGGAGCTGTATTCTTATACAAATCTGATGGCTCC
 TGCAGCACTTTTCCTCTGAAAATTTACATTGCTAACACTAGTTGTTA
 CTTTAAAATCAGTTTGATGAAAGGAGGGAAAAGCAGATGGACTTGAAAA
 AGATCCAAGCTCTATTAGAAAAGGTATGAAAATCTTATAGTAAAATTTT
 TATAAACTAAAGTTGACCTTAATATGTAGTAAACTCTCATTATGGGG
 TCGCTCTGGATCTCATCCATTGTTCTCTTAAATGCTGCCTGCCTT
 TGAGGCATTCACTGCCCTAGACAATGCCACCAGAGATAGTGGGGAAATGC
 CAGATGAAACCAACTCTGCTCACTAGTTGTCAGCTCTGGATAAGTG
 ACCACAGAAGCAGGAGTCCTCTGCTGGCATCATGGCCAGTTCTTCT
 CTTTAAATCAGATTGTAATGGCTCCAAATCCATCACATCACATTAAATT
 GCAGACAGTGTGACATCATGTATCTGTTGCCCATAATATGCTTTT
 ACTCCCTGATCCCAGTTCTGCTGTTGACTCTCCATTCACTTTTATTG
 GTGTTCTCACAGTGACACCATTGTCCTTCTGCAACACCTTCAGCTAC
 TTTGCCAAATTCTATTGTCCTCCTTCAAAACATTCTCCTTGCAAGTC
 CTTCATCTGTAGCTGCTCTTGCTCTTAACCTACCTCTATAGTACTT
 TATGCATCTGCTTAGTTCTATTAGTTGGCCTTGCTCTCCTTGATT
 TAAAAATTCTCTATAGCTAGAGCTTCTTCTTCATTCTCTTCTGCA
 GTGTTTGCACTACATCAGAAGCTAGGTACATAAGTTAAATGATTGAGAGTTG
 GCTGTATTAGTTTACACTTTAAATAGGGTGAGCTTGAGAGTTTCTTC
 TTTCTGTTTTTTTTTTGTTTTTTTTTTTTTTTTTTTTTTGACTA
 ATTCACATGCTCTAAACCTCAAGGTGATTATTTCTCCTGGAAACTC
 CAGGCCATTCTGTTAAATCCCTAAGAATGTCAGAAATTAAACAGGGC
 TATCCCGTAATTGAAATATTCTTTCAAGGATGCTATAGTCATTAGTA
 AGTGACCAACAAATTGTTACTTGCACTAACAAAGCTAAACACGATAAGTT
 TACTCCTCCATCTCAGTAATAAAATTAGCTGAATCAACCTCTAGGTT
 CTCTGCTTTAAATGGTATTCAAAATGGGATCTGTTGAGGTTATG
 AACACACACTCTTAATTACCTGTTGAAACTGGAGAAATGATTGTC
 GGGCAACCGTTATTGTTATTGTTATTGTTGAGGGATTTTTATA
 AACAGTTTACTTGTCATATTAAATTACTAACTGCCATCACCTGCTGG
 GGTCTTGTAGGTCAATTCTAGTGAATAGGGATAATCCAGGTAACCT
 TGAAGAGATGAGCAGTGAGTGACCAGGCAAGTTCTGCCTTAGCTTGAC
 AGTTCTTAATTAGATCATTGAAGACCAGCTTCTCATAAATTCTCTTTG
 AAAAAAGAAAGCATTGACTAAGCTCTGTAAGACAACATCTAAAT
 CTAAAAAGTGTGTTATCATGACTGGTGGAGAGAAGAAAACATTGTTTA
 TTAATGGAGCATTATTACAAAAGCCATTGTTGAGAATTAGATCCCACAT
 CGTATAAATATCTATTAACCATTCTAAATAAGAGAACTCCAGTGTGCTAT

TABLE 3 -continued

GTGCAAGATCCTCTTGGAGCTTTGCATAGCAATTAAAGGTGTGCTAT
 TTGTCAGTAGCCATTGGTGCAGTGAGTGAAGACCAAAGTGTGCTACAGC
 TGTGTTACCGTAAAGGTTTTTATATGTATTAAATCAATTATCACT
 GTTAAAGCTTGAATATCTGCAATCTTGCAAGGTACTTTTATTAAAA
 AAAAACATAACTTGAAATATTACCTGTAATATTATATATACTTAATAAAA
 ACATTTAAGCTATTTGGCTATTCTATTGCTGCTACAGCAGACCACA
 AGCACATTCTGAAAAATTAAATTATTAATGTTAAGTTGCTTATATT
 CTAGGTAACAATGTAAGAATGATTTAAATTATTAATTGAAAGTTGAG
 TATAATAACCAATAAGCTTTAATTAGAGCAGAGTTAATTAAAAGTTA
 AATCAGTC
 Human CD47 amino acid isoform 2 (NP_942088.1) (SEQ ID NO: 12)
 MWPLVAALLLGSACCGSAQLLFNKTTSVEFTFCNDTVVIPCFTVNMEAQNT
TEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK
SDAVSHTGNYTCEVTEL TREGETHIELKYRVVSWFSPNENILIVIPPIFAILFW
GQFGI KTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPG EYSLKNATGLGLI
VTSTGILILLHHYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLI
SGLSILALAQLLGVYMKFVASNQKTIQPPRNN
 Human CD47 mRNA isoform 3 (XM_005247908.1) (SEQ ID NO: 13)
 AGTGGGAGCGCGCGTGCAGCGCGCCGTGCAGCCTGGCAGTGGTCCTGCC
TGTGACCGCGCGCGCGTCGGTCCTGCCTGTAACGGCGGGCGCGCTGCT
GCTCCGGACACCTGCGCGCGCGGCGACCCCGCGCGGGCGCGAGAT
GTGGCCCTGGTAGCGCGCGCTGGCTGGCTCGCGTGTGGATC
AGCTCAGCTACTATTAATAAAACAAATCTGTAGAATTCACTGTTGTA
ATGACACTGTCGTCAATTCCATGCTTGTACTAATATGGAGGACAAAAA
CACTACTGAAGTATACGTAAGTGGAAATTAAAGGAAGAGATATTAC
ACCTTTGATGGAGCTCTAACAAAGTCCACTGTCCCCACTGACTTTAGTA
GTGCAAAATTGAAGTCTCACATTACTAAAGGAGATGCCTTTGAA
GATGGATAAGAGTGATGCTGTCACACACAGGAAACTACATTGTGAA
GTAACAGAATTAAACAGAGAAGGTGAAACGATCATCGAGCTAAATAC
GTGTTGTTCATGGTTCTCCAAATGAAATTCTTATTGTTATTTC
CCAATTTTGCTATACTCCTGTTCTGGGACAGTTGGTATTAAACAC
TTAAATATAGATCCGGTGGTATGGATGAGAAAACAATTGCTTACTTGT
TGCTGGACTAGTGATCACTGTCATTGTCATTGGAGCCATTCTTTC
GTCGGAGGTGAATATTCACTAAAGAATGCTACTGGCCTGGTTAATTG
TGACTTCTACAGGGATATTAAATTACTTCACTACTATGTGTTAGTACA
GCGATTGGATTAACCTCCTCGTCATTGCCATTGGTTATTCAAGGTGA
TAGCCTATATCCTCGCTGTGGTGGACTGAGTCTCTGTATTGGCGCTG
TATACCAATGCAATGGCCCTTCTGATTCAGGTTGAGTATCTTAGCT
CTAGCACAATTACTGGACTAGTTATGAAATTGTGGCTTCCAATC
AGAAGACTATACAAACCTCCTAGGAAAGCTGTAGAGGAACCCCTTAATGA

TABLE 3 - continued

ATAACTGAAGTGAAGTGATGGACTCCGATTGGAGAGTAGTAAGACGTGAA
AGGAATACACTTGTGTTAACGCCATGGCCTGATGATTCACTGTTGGGA
GAAGAAACAAGAAAAGTAACGGTTGACCTATGAGACCCCTACGTGATT
GTTAGTTAAGTTTATTCAAAGCAGCTGTAATTAGTTAATAAAAATAATTAT
GATCTATGTTGTTGCCTAATTGAGATCCAGTTTGTGTTGTTATTTAATC
AATTAGGGCAATAGTGAATGGACAATTCCAAGAATGATGCCCTTCAGG
TCCTAGGGCCTGGCCTCTAGGTAACCGAGTTAAATTGGTCAGGGTGATA
ACTACTTAGCACTGCCCTGGTGAATTACCCAGAGATATCTATGAAAACAGTG
GCTTCCATCAAACCTTGCCAACTCAGGTTCACAGCAGCTTGGCAGTTAT
GCGAGTATGGCATTAGCTGAGAGGTGTCGCACTCTGGTCAATGGAATA
ATAAAATTAAAGTACAGGCAGGAATTGGTGGAGCATTTGTATGATCTCG
TATGATGTGATATTGATGGAGATAGTGGCCTCATTCTGGGGTTGCCATT
CCCACATTCCCCCTCAACAAACAGTGTAAACAGGTCTTCCCAGATTAGGG
TACTTTATTGATGGATATGTTCCCTTTATTCACATAACCCCTGAAACCC
TGTCCTGCTCTGTTACTTGCTCTGCTGTACAAGATGTAGCACCTTTCT
CCTCTTGAACATGGCTAGTGACACGGTAGCACCAGTTGCAGGAAGGAGC
CAGACTTGTCTCAGAGCACTGTGTTCACACTTTCAGCAAAATAGCTATG
GTTGTAACATATGATTCCCTCTGATTTGAAGGCAAAATCAGTGTG
TTCTTCACTTCTTCTGATCTGGGCATGAAAAAGCAAGATTGAAATT
GAACATGAGTCTCCTGCATGGCAACAAATGTGTGTCACCATCAGGCCA
CAGGCCAGCCCTGAATGGGATTATTACTGTTGATCTATGTTGATGAT
AAACATTCATCACCTCCTCCTGACTGCTGCTACTCCCCTCCCTAT
GATTGAAAAGTAAACAAAACCCACATTCTATCCTGGTTAGAAGAAAATT
AATGTTGACAGTTGTGATGCCCTGGAGTACTTTAGACTTTAGCTTCTG
TTTTACCTGTTGTGGATGTGTTGATGTGACAGTATGAGATAGGCA
CATGCATCTCTGATGGACAAAGGTGGGACCTACAGGAGAGCAAGG
TAATTTGCTTTAGTAAAACATTAAATACAAAGTTCTTATTGGGTGG
AATTATTTGATGCAAATATTGATCACTAAAACCTTAAACTCTAGGT
AATTGCCACGCTTTGACTGCTACCAATACCTGAAAAACAGTAATT
CTTCCTGTTGTAATAAGATATTCAATTGCTAGTTGCTTATGCCAAATTGATT
TCATATTCATGTTGGGACCAAGTAGTTGCCATGGCAAACCTAAATTAT
GACCTGCTGAGGCCTCTCAGAAAAGTACGAGCATACTAGCAAGACAGCTTCT
TGAAAAAAATATGTATAACAAATATACGTATATCTATATACGTA
TGTATATACACATGTATATTCTCCTGATTGTTGACTGTGCTGCAAAATA
AACATATATAGGGAGCTGATTCCCTTATACAAATCTGATGGCTCTGCA
GCACCTTCTGAAATATTACATTGCTAACCTAGTTGTTACTTT
AAAAATCAGTTGATGAAAGGAGGGAAAGCAGATGGACTTGAAAGA
TCCAAGCTCCTATTAGAAAAGTATGAAAATCTTATAGTAAATTTTAT
AAACTAAAGTTGACCTTTAATATGTAGTAAACTCTCATTATGGGGTTC

TABLE 3 -continued

GCTCTTGGATCTCATCCATCATTGTGTTCTCTTTAATGCTGCCGCCTTTG
AGGCATTCACTGCCCTAGACAAATGCCACCAGAGATA GTGGGGAAATGCCA
GATGAAACCAACTCTTGCTCTCACTAGTTGTCAGCTCTGGATAAGTGAC
CACAGAACAGGAGTCCTCGCTGGCATCATTGGCCAGTTCCCTCTCT
TAAATCAGATTGTAATGGCTCCAAATTCCATCACATCACATTAAATTG
CAGACAGTGTGTTGCACATCATGTATCTGTTGTCCCATAATATGCTTTA
CTCCCTGATCCCAGTTCTGCTGTTGACTCTTCATTCA GTTTATTTATTTG
TGTTCTCACAGTGACACCATTGTCCTTCTGCAACAACCTTCAGCTACT
TTTGCCAAATTCTATTGCTCTCCTTCAAAACATTCCCTTGAGTTCTC
TTCATCTGTGACTGCTCTTGTCTTAACCTACATTCTAGTACTTT
ATGCATCTCGCTTAGTTCTATTAGTTTGGCCTGCTCTCTCTTGATTT
AAAATTCTCTATAGCTAGAGCTTTCTTCTTCATTCTCTTCCTGCAG
TGTTTGCAACATCAGAACGCTAGGTACATAAGTTAAATGATTGAGAGTTGG
CTGTATTAGATTACCTTTAATAGGGTAGGTTGAGAGTTCTTCTTCT
TTCTGTTTTTTTTTTGTTTTTTTTTTTTTTTTTTTTTTGACTAA
TTTCACATGCTAAAAACCTCAAAGGTGATTATTTCTCCCTGGAAACTCC
AGGTCCATTCTGTTAAATCCCTAAGAACGTCAGAATTAAACAGGGCT
ATCCCGTAATTGAAATATTCCTTTTCAGGATGCTATAGTCATTAGTAA
GTGACCACCAATTGTTATTGCACTAACAAAGCTAAAACACGATAAGTTT
ACTCCTCATCTCAGTAATAAAATTAGCTGAATCAACCTCTAGGTTTC
TCTTGCTTAAATGGTATTCAAAATGGGATCTGTTGATGTTGATGAA
AACACATACTCCTTAAATTACCTGTTGGAAACTGGAGAAATGATTGCG
GGCAACCGTTTATTTTTATTGATTATTGTTGGAGGGATTTTTATAA
ACAGTTTACTTGTGTCATATTAAAATTACTAACGTCACCTGCTGG
GTCTTTGTTAGGTCAATTCACTGACTAACAGGATAATCCAGGTAACCTT
GAAGAGATGAGCAGTGAGTGACCGAGCAGTTCTGCCTTAGCTTGACA
GTCTTAATTAAGATCATTGAAGACCAGCTTCTCATAAATTCTTTGAA
AAAAAGAAAGCATTGACTAACGCTCTGTAAGAACACATCTAAATCT
TAAAAGTGTGTTATCATGACTGGTAGAGAGAAAACATTGTTTATT
AAATGGAGCATTATTCACAAAAGCCATTGTTGAGAAATTAGATCCCACATCG
TATAAAATCTATTAAACCATCTAAATAAGAGAACTCCAGTGTGCTATGT
GCAAGATCCTCTTGGAGCTTTGCAAGCAATTAAAGGTGTGCTATT
GTCAGTAGCCATTGGCAGTGATTGAAGACCAAGTTGTTACAGCT
GTGTTACCGTTAAAGGTTTTTTTATATGATTAAATCAATTATCACTG
TTTAAAGCTTGAATATCTGCAATCTTGCCTAGGACTTTTATTAAAAA
AAAACATAACTTGTAAATATTACCCCTGTAATATTATATACTTAATAAA
CATTTTAAGCTA
Human CD47 amino acid isoform 3 (XP_005247965.1)
(SEQ ID NO: 14)
MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIVPCFVTNMEAQNT
TEVYVKWKFKGRDIYTFD GALNKSTVPTDFSSAKIEVSQLLKGDA SKMDK

TABLE 3 -continued

SDAVSHTGNYTCEVTELREGETIIIELKYRVVSWFSPNENILIVIPPIFAILLFW
 GQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVVAGILFVPGEYSLKNATGLGLI
 VTSTGILILLHHYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLI
 SGSLISLALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNE
 Human CD47 mRNA isoform 4 (NM_001777.3)
 (SEQ ID NO: 15)
 GGGGAGCAGGCCGGGGAGCGGGCGGGAAAGCAGTGGGAGCGCGCGTGC
 CGCCGCTGCAGCTGGGCAGTGCGCTGTGACGCGCGCGCGTC
 GGTCCCTGCCTGTAACGGCGGGCGGCTGCTGCTCCAGACACCTGCGCG
 CGCGCGCGACCCCGCGCGGGCGGAGATGTGGCCCTGGTAGCGCGCG
CTGTTGCTGGCTCGCGTGCGCGATCAGCTCAGCTACTATTAAATA
AAACAAAATCTGTAGAATTCACAGTTTGTAATGACACTGTCGTCATTCC
ATGCTTTGTTACTAATATGGAGGCACAAAACACTGAAGTATACGTA
AAGTGGAATTAAAGGAAGAGATATTACACCTTGATGGAGCTCAA
ACAAGTCCACTGTCCCCACTGACTTTAGTAGTGCAAAATTGAAGTCTC
ACAATTACTAAAAGGAGATGCCTCTTGAAGATGGATAAGAGTGAGCT
GTCTCACACACAGGAAACTACTGTGAAGTAACAGAATTAAACCAGAG
AAGGTGAAACGATCATCGAGCTAAATATCGTGTGTTCATGGTTTC
TCCAATGAAAAATATTCTTATTGTTATTTCCAATTTGCTATACTCC
TGTTCTGGGACAGTTGGTATTAAACACTAAATATAGATCCGGTGG
TATGGATGAGAAAACAATTGCTTACTTGCTGGACTAGTGATCACT
GTCATTGTCATTGTTGGAGCCATTCTTCGCCCAGGTGAATATTCAT
AAAGAACGCTACTGGCCTGGTTAATTGTGACTTCTACAGGGATATTA
ATATTACTTCACTACTATGTGTTAGTACACCGATTGGATTAACCTCCTT
CGTCATTGCCATATTGGTTATTCAGGTGATAGCCTATATCCTCGCTGTG
GTTGGACTGAGTCTGTATTCGGGCGTGATACCAATGCATGGCCCTC
TTCTGATTCCAGGTTGAGTATCTTAGCTAGCACAATTACTTGACTA
GTTTATGAAATTGCTTCAATCAGAACGACTATACAACCTCCTA
GGAAAGCTGTAGAGGAACCCCTTAATGCATTCAAAGAAATCAAAGGAAT
GATGAATGATGAAAACTGAAGTGAAGTGATGGACTCCGATTGGAGAGT
AGTAAGACGTGAAAAGGAATACATTGTTAACGACCATGGCCTTGATGA
TTCACTGTTGGGAGAAGAAACAAAGAAAAAGTAACTGGTTGTCACCTATGAG
ACCCCTTACGTGATTGTTAGTTAAGTTTATTCAGCAGCTGTAATTAGTT
AATAAAATAATTATGATCTATGTTGTTGCCAATTGAGATCCAGTTTTGT
TGTTATTTATAATTCAATTAGGGCAATAGTGAATGGACAATTCCAAGAAT
GATGCCTTTCAGGTCTAGGCCCTGGCCTCTAGGTAACCAGTAAATTG
GTTCAGGGTGATAACTACTTAGCACTGCCCTGGTATTACCCAGAGATATCT
ATGAAAACCAGTGGCTCCATCAAACCTTGCCAACTCAGGTCACAGCAGC
TTGGGCAGTTAGGCAGTATGGCATTAGCTGAGAGGTGTCTGCCACTCTG
GGTCAATGGAATAATAATTAAAGTACAGGCAGGAATTGGTTGGAGACATC
TTGTATGATCTCGTATGATGTGATATTGATGGAGATAGTGGCTCTCATTCTT

TABLE 3 -continued

GGGGGTTGCCATTCCCACATTCCCCCTTCAACAAACAGTGTAAACAGGTCTT
 CCCAGATTTAGGGTACTTTATGATGGATATGTTTCCTTTATTACATAA
 CCCCTTGAAACCCCTGTCTGCTCCTGTTACTTGCTCTGCTGTACAAGATG
 TAGCACCTTTCTCCTCTTGAAACATGGTCTAGTGACACGGTAGCACCAGTT
 GCAGGAAGGAGGCAGACTTGTCTCAGAGCACTGTGTTCACACTTTCAGCA
 AAAATAGCTATGGTTGTAACATATGATTCCCTCCTGATTGAGGCAA
 AAATCTACAGTGTCTTCACTTCTGATCTGGGCATGAAAAAGCA
 AGATTGAAATTGAACTATGAGTCTCCTGCATGGCAACAAAATGTGTGTCAC
 CATCAGGCCAACAGGCCAGCCCTGAATGGGATTATTACTGTTGTATCTA
 TGTGCGATGATAAACATTCACTCACCTCCTCCTGAGTCCTGCCCTGTA
 CCTTCCCTATGATTGAAAAGTAAACAAAACCCACATTCCCTATCCTGGTTA
 GAAGAAAATTAAATGTTCTGACAGTTGTGATGCCCTGGAGTACTTTAGACTT
 TTAGCATTGTTTTTACCTGTTGATGTTGATGTCATACGTA
 TGAGATAGGCACATGCATCTCTGATGGACAAAGTGGGACCTACAGG
 AGAGCAAAGGTTAATTTGTGTTTAGTAAAAACATTAAATACAAAGTTC
 TTTATTGGTGAATTATTTGATGCAAATATTGATCACTAAACATTAA
 AAACCTCTAGGTAATTGCCACGCTTTGACTGCTCACCAATACCTGTAA
 AAATACGTAACTCTGTTGTGAATAAGATATTCACTATTGAGTTGCA
 TTAATAATAGTTATTCTTAGTCCATCAGATGTTCCGTGTCCTTTATG
 CCAAATTGATTGTCATATTGATGGGACCAAGTAGTTGCCCATGGCAA
 ACCTAAATTATGACCTGCTGAGGCCTCTCAGAAAATGAGCATACTAGCAA
 GACAGCTTCTGAAAAAAATATGTATACACAAATATACGTATATC
 TATATATACGTATGTATACACACATGTATATTCTCCTTGATTGTTGAGCT
 GTCCAAAATAATAACATATATAGAGGGAGCTGATTCTTACAAATCTG
 ATGGCTCTGCAGCACTTTCTGAAATATTACATTGCTAACCTA
 GTTGTACTTTAAAAACTGAGTTGATGAAAGGAGGGAAAGCAGATGGA
 CTTGAAAAAGATCCAAGCTCTTACAGTAAAGGTATGAAATCTTATAGTA
 AAATTTTTATAAAACTAAAGTTGACCTTTAATATGTAGTAAACTCTCATT
 ATTGGGGTTCGCTTGGATCTCATCCATCCATTGTTCTTTAATGCTG
 CCTGCCTTGGAGGCATTCACTGCCCTAGACAATGCCACAGAGATAGTGG
 GGAATGCCAGATGAAACCAACTCTGCTCTCACTAGTTGTGAGCTCTG
 GATAAGTGACACAGAAGCAGGAGTCCTGCTGGCATTGGCCA
 GTTCCTCTTTAAACTCAGATTGTAATGGCTCCAAATTCCATCACATCAC
 ATTTAAATTGCGACAGTGTGTTGCACATCATGTATCTGTTGTCCCATAA
 ATGCTTTACTCCCTGATCCAGTTCTGCTGTTGACTCTCCATTGCTTT
 ATTTATTGTGTTCTCACAGTGACACCATTGCTCTTCTGCAACAAACCTT
 TCCAGCTACTTTGCCAAATTCTATTGTCTCCTTCAAAACATTCTCCTT
 GCAGTTCTCTTCACTCTGCTAGCTGCTCTTGTCTTAACTTACCA
 ATAGTACTTTATGCATCTGCTTAGTTCTATTAGTTTGGCCTGCTCTC
 TCCTTGATTTAAAATTCCCTATAGCTAGAGCTTTCTTCTTCATTCTC

TABLE 3 -continued

CTTCCCTGCAGTGTTCATACATCAGAAGCTAGGTACATAAGTTAAATGAT
 TGAGAGTTGGCTGTATTAGATTATCACTTTAATAGGGTGAGCTTGAGA
 GTTTCTTCTTCTGTTTTTTTTGTTTTTTTTTTTTTTTTTTTTTTTT
 TTTTGACTAATTTCACATGCTCTAAAACCTCAAAGGTGATTATTTCTCC
 TGGAAACTCCAGGTCCATTCTGTTAAATCCCTAAGAATGTCAGAATTTAA
 TAACAGGGCTATCCGTAATTGGAAATATTCCTTTCTAGGATGCTATAGT
 CAATTAGTAGTGAACACCAATTGTTATTCGACTAACAAAGCTAAAAC
 ACGATAAGTTACTCCTCCATCTCAGTAATAAAATTAAGCTGTAATCAACC
 TTCTAGGTTCTTGCTTTAAATGGGTATTCAAAATGGGATCTGTGGT
 GTATGATGGAAACACATACTCTTAATTTACCTGTTGGAAACTGGAGA
 AATGATTGTCGGCAACCGTTATTTTATTGTATTTATTGGTTGAGGGA
 TTTTTTATAAACAGTTTACTTGTCATATTTAAATTACTAACTGCCAT
 CACCTGCTGGGCTTGTAGGTCTTCAAGTCAATAGGGATAATC
 CAGGTAATTGAAGAGATGAGCAGTGAGTGAACAGGAGTTCTGCCTT
 TAGCTTGACAGTTCTAATTAGATCATTGAAGACAGCTTCTCATAAAT
 TTCTCTTTGAAAAAAAGAACGATTGTACTAAGCTCCTGTAAAGACAA
 CATCTTAAATCTTAAAGTGTGTTATCATGACTGGTGAGAGAACAT
 TTGTTTTTATTAAATGGAGCATTTACAAAAAGCATTGTTGAGAACATTA
 GATCCCACATCGTATAATATCTTAAACCATCTAAATAAGAGAACTCCA
 GTGTTGCTATGTGCAAGATCCTCTTGAGCTTTGCATAGCAATTAAA
 GGTGTGCTATTGTCAGTAGCCATTGGAGCTTGCAGTGAAGACCAAGT
 TGTTTACAGCTGTGTTACCGTTAAAGGTTTTTTTATATGTATTAAATC
 ATTATCACTGTTAAAGCTTGAAATATCTGCAATCTTGCAGGTACTTT
 TTATTTAAAAAAACATAACTTGTAATATTACCCGTAAATTTATAT
 ACTTAATAAAACATTAAAGCTATTGTTGGCTATTCTATTGCTGCTACA
 GCAGACCACAAGCACATTCTGAAAAATTAAATTAAATGTATTAAAG
 TTGCTTATATTCTAGGTAACAATGTAAGAATGATTAAATATTAAATG
 AATTGGAGTATAATACCAATAAGCTTTAATTAGAGCAGAGTTAAATT
 AAAAGTTTAAATCAGTC
 Human CD47 amino acid isoform 4 (NP_001768.1) (SEQ ID NO: 16)
MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFTVNMEAQNT
 TEVYVKWFKGDIYTFDGAJNKSTVPTDFSSAKIEVSQLLKGDAJLMDK
 SDAVSHTGNYTCEVTELREGETHIELKYRVVSWFSPNENILIVIPPIFAILFW
 QFGFIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLI
 VTSTGILILLHYYVSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLI
 SGSLISLALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
 Humanized CD47 amino acid isoform 1 (SEQ ID NO: 17)
MWPLAAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFTVNMEAQNT
 TEVYVKWFKGDIYTFDGAJNKSTVPTDFSSAKIEVSQLLKGDAJLMDK
 SDAVSHTGNYTCEVTELREGETIIELKYRVVSWFSPNENILIVIPPIFAILFW

TABLE 3 -continued

WGQFGIKTLKYRSGGMDEKTIAALLVAGLVITVIVIVGAILFVPGESLKNAT
 GLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
 PMHGPLLISGLSILALAQLLGLVYMKFVE
 Humanized CD47 amino acid isoform 2
 (SEQ ID NO: 18)
MWPLAAALLLGSCCCGSAQLLFNKTKSVEFTFCNDTVVIPCFTVNMEAQNT
 TEVYVKWFGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKM**D**K
 SDAVSHTGNYTCEVTELREGETHIELKYRVVSWFSPNENILIVIPPIFAILLF
 WGQFGIKTLKYRSGGMDEKTIAALLVAGLVITVIVIVGAILFVPGESLKNAT
 GLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
 PMHGPLLISGLSILALAQLLGLVYMKFVASNQRTIQPPRN**R**
 Humanized CD47 amino acid isoform 3
 (SEQ ID NO: 19)
MWPLAAALLLGSCCCGSAQLLFNKTKSVEFTFCNDTVVIPCFTVNMEAQNT
 TEVYVKWFGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKM**D**K
 SDAVSHTGNYTCEVTELREGETHIELKYRVVSWFSPNENILIVIPPIFAILLF
 WGQFGIKTLKYRSGGMDEKTIAALLVAGLVITVIVIVGAILFVPGESLKNAT
 GLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
 PMHGPLLISGLSILALAQLLGLVYMKFVASNQRTIQPPRKAVEEPL**N**E
 Humanized CD47 amino acid isoform 4
 (SEQ ID NO: 20)
MWPLAAALLLGSCCCGSAQLLFNKTKSVEFTFCNDTVVIPCFTVNMEAQNT
 TEVYVKWFGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKM**D**K
 SDAVSHTGNYTCEVTELREGETIIELKYRVVSWFSPNENILIVIPPIFAILLF
 WGQFGIKTLKYRSGGMDEKTIAALLVAGLVITVIVIVGAILFVPGESLKNAT
 GLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
 PMHGPLLISGLSILALAQLLGLVYMKFVASNQRTIQPPRKAVEEPLNAFK**S**K**G**
 MMNDE

Humanized CD47 Non-Human Animals

Non-human animals are provided that express humanized CD47 proteins on the surface of cells of the non-human animals resulting from a genetic modification of an endogenous locus of the non-human animal that encodes a CD47 protein. Suitable examples described herein include rodents, in particular, mice.

A humanized CD47 gene, in some embodiments, comprises genetic material from a heterologous species (e.g., humans), wherein the humanized CD47 gene encodes a CD47 protein that comprises the encoded portion of the genetic material from the heterologous species. In some embodiments, a humanized CD47 gene of the present invention comprises genomic DNA of a heterologous species that encodes the extracellular portion of a CD47 protein that is expressed on the plasma membrane of a cell. In some embodiments, a humanized CD47 gene of the present invention comprises genomic DNA of a heterologous species that encodes the extracellular portion and the transmembrane portion of a CD47 protein that is expressed on the plasma membrane of a cell. Non-human animals, embryos, cells and

targeting constructs for making non-human animals, non-human embryos, and cells containing said humanized CD47 gene are also provided.

In some embodiments, an endogenous CD47 gene is deleted. In some embodiments, an endogenous CD47 gene is altered, wherein a portion of the endogenous CD47 gene is replaced with a heterologous sequence (e.g., a human CD47 sequence, in whole or in part). In some embodiments, all or substantially all of an endogenous CD47 gene is replaced with a heterologous gene (e.g., a human CD47 gene). In some embodiments, a portion of a heterologous CD47 gene is inserted into an endogenous non-human CD47 locus. In some embodiments, the heterologous gene is a human gene. In some embodiments, the modification or humanization is made to one of the two copies of the endogenous CD47 gene, giving rise to a non-human animal that is heterozygous with respect to the humanized CD47 gene. In other embodiments, a non-human animal is provided that is homozygous for a humanized CD47 gene.

A non-human animal of the present invention contains a human CD47 gene, in whole or in part, at an endogenous

non-human CD47 locus. Thus, such non-human animals can be described as having a heterologous CD47 gene. The replaced, inserted, modified or altered CD47 gene at the endogenous CD47 locus can be detected using a variety of methods including, for example, PCR, Western blot, Southern blot, restriction fragment length polymorphism (RFLP), or a gain or loss of allele assay. In some embodiments, the non-human animal is heterozygous with respect to the humanized CD47 gene. In some embodiments, the non-human animal is homozygous for the humanized CD47 gene.

In various embodiments, a humanized CD47 gene according to the present invention includes a CD47 gene that has a second, third, fourth, fifth, sixth and seventh exon each having a sequence at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a second, third, fourth, fifth, sixth and seventh exon that appear in a human CD47 gene of Table 3.

In various embodiments, a humanized CD47 gene according to the present invention includes a CD47 gene that has a first exon and exon(s) downstream of exon 7 (e.g., eighth and ninth exons of isoform 2) each having a sequence at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a respective exon that appears in a mouse CD47 gene of Table 3.

In various embodiments, a humanized CD47 gene according to the present invention includes a CD47 gene that has a 5' untranslated region and a 3' untranslated region each having a sequence at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a 5' untranslated region and a 3' untranslated region that appear in a mouse CD47 gene of Table 3.

In various embodiments, a humanized CD47 gene according to the present invention includes a CD47 gene that has a nucleotide coding sequence (e.g., a cDNA sequence) at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a nucleotide coding sequence that appears in a human CD47 nucleotide coding sequence of Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an extracellular portion having an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an extracellular portion of a human CD47 protein that appears in Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an extracellular portion having an amino acid sequence that is identical to amino acid residues 19-141 that appear in a human CD47 protein of Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an N-terminal immunoglobulin V domain having an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an N-terminal immunoglobulin V domain of a human CD47 protein that appears in Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an N-terminal immunoglobulin V domain having an

amino acid sequence that is identical to amino acid residues 19-127 that appear in a human CD47 protein of Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an N-terminal immunoglobulin V domain and five transmembrane domains each having a sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an N-terminal immunoglobulin V domain and five transmembrane domains of a human CD47 protein that appears in Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an intracytoplasmic tail having a sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an intracytoplasmic tail of a mouse CD47 protein that appears in Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to amino acid residues 16-292 that appear in a human CD47 protein of Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to amino acid residues 19-292 that appear in a human CD47 protein of Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an amino acid sequence that is identical to amino acid residues 19-292 (or 16-292) that appear in a human CD47 protein of Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an amino acid sequence of a humanized CD47 protein that appears in Table 3.

In various embodiments, a humanized CD47 protein produced by a non-human animal of the present invention has an amino acid sequence that is identical to an amino acid sequence of a humanized CD47 protein that appears in Table 3.

Compositions and methods for making non-human animals that express a humanized CD47 protein, including specific polymorphic forms, allelic variants (e.g., single amino acid differences) or alternatively spliced isoforms, are provided, including compositions and methods for making non-human animals that express such proteins from a human promoter and a human regulatory sequence. In some embodiments, compositions and methods for making non-human animals that express such proteins from an endogenous promoter and an endogenous regulatory sequence are also provided. The methods include inserting the genetic material encoding a human CD47 protein in whole or in part at a precise location in the genome of a non-human animal that corresponds to an endogenous CD47 gene thereby creating a humanized CD47 gene that expresses a CD47 protein that is human in whole or in part. In some embodiments, the methods include inserting genomic DNA corresponding to exons 2-7 of a human CD47 gene into an

endogenous CD47 gene of the non-human animal thereby creating a humanized gene that encodes a CD47 protein that contains a human portion containing amino acids encoded by the inserted exons.

Where appropriate, the coding region of the genetic material or polynucleotide sequence(s) encoding a human CD47 protein in whole or in part may be modified to include codons that are optimized for expression in the non-human animal (e.g., see U.S. Pat. Nos. 5,670,356 and 5,874,304). Codon optimized sequences are synthetic sequences, and preferably encode the identical polypeptide (or a biologically active fragment of a full length polypeptide which has substantially the same activity as the full length polypeptide) encoded by the non-codon optimized parent polynucleotide. In some embodiments, the coding region of the genetic material encoding a human CD47 protein, in whole or in part, may include an altered sequence to optimize codon usage for a particular cell type (e.g., a rodent cell). For example, the codons of the genomic DNA corresponding to exons 2-7 of a human CD47 gene to be inserted into an endogenous CD47 gene of a non-human animal (e.g., a rodent) may be optimized for expression in a cell of the non-human animal. Such a sequence may be described as a codon-optimized sequence.

A humanized CD47 gene approach employs a relatively minimal modification of the endogenous gene and results in natural CD47-mediated signal transduction in the non-human animal, in various embodiments, because the genomic sequence of the CD47 sequences are modified in a single fragment and therefore retain normal functionality by including necessary regulatory sequences. Thus, in such embodiments, the CD47 gene modification does not affect other surrounding genes or other endogenous CD47-interacting genes (e.g., thrombospondin, SIRPs, integrins, etc.). Further, in various embodiments, the modification does not affect the assembly of a functional CD47 transmembrane protein on the plasma membrane and maintains normal effector functions via binding and subsequent signal transduction through the cytoplasmic portion of the protein which is unaffected by the modification.

A schematic illustration (not to scale) of the genomic organization of an endogenous murine CD47 gene and a human CD47 gene is provided in FIG. 1. An exemplary method for humanizing an endogenous murine CD47 gene using a genomic fragment containing exons 2-7 of a human CD47 gene is provided in FIG. 2. As illustrated, genomic DNA containing exons 2-7 of a human CD47 gene is inserted into an endogenous murine CD47 gene locus by a targeting construct. This genomic DNA includes the portion of the gene that encodes an extracellular portion and transmembrane domains (e.g., amino acid residues 16-292) of a human CD47 protein responsible for ligand binding.

A non-human animal (e.g., a mouse) having a humanized CD47 gene at the endogenous CD47 locus can be made by any method known in the art. For example, a targeting vector can be made that introduces a human CD47 gene in whole or in part with a selectable marker gene. FIG. 2 illustrates an endogenous CD47 locus of a mouse genome comprising an insertion of exons 2-7 of a human CD47 gene. As illustrated, the targeting construct contains a 5' homology arm containing sequence upstream of exon 2 of an endogenous murine CD47 gene (~39 Kb), followed by a genomic DNA fragment containing exons 2-7 of a human CD47 gene (~23.9 Kb), a drug selection cassette (e.g., a neomycin resistance gene flanked on both sides by loxP sequences; ~5 Kb), and a 3' homology arm containing sequence downstream of exon 7 of an endogenous murine CD47 gene (~99 Kb). The targeting

construct contains a self-deleting drug selection cassette (e.g., a neomycin resistance gene flanked by loxP sequences; see U.S. Pat. Nos. 8,697,851, 8,518,392 and 8,354,389, all of which are incorporated herein by reference). Upon 5 homologous recombination, exons 2-7 of an endogenous murine CD47 gene are replaced by the sequence contained in the targeting vector (i.e., exons 2-7 of a human CD47 gene). A humanized CD47 gene is created resulting in a cell or non-human animal that expresses a humanized CD47 10 protein that contains amino acids encoded by exons 2-7 of a human CD47 gene. The drug selection cassette is removed in a development-dependent manner, i.e., progeny derived from mice whose germ line cells containing the humanized CD47 gene described above will shed the selectable marker 15 from differentiated cells during development.

The non-human animals of the present invention may be prepared as described above, or using methods known in the art, to comprise additional human or humanized genes, oftentimes depending on the intended use of the non-human animal. Genetic material of such additional human or 20 humanized genes may be introduced through the further alteration of the genome of cells (e.g., embryonic stem cells) having the genetic modifications as described above or through breeding techniques known in the art with other genetically modified strains as desired. In some embodiments, non-human animals of the present invention are prepared to further comprise one or more human or humanized genes selected from SIRP α (CD172a), IL-3, M-CSF, GM-CSF and TPO. In some embodiments, non-human 25 animals of the present invention may be prepared by introducing a targeting vector, as described herein, into a cell from a modified strain. To give but one example, a targeting vector, as described above, may be introduced into a mouse that is Rag2-deficient and IL-2R γ -deficient and include four 30 human cytokines (Rag2 $^{-/-}$; IL2R γ $^{-/-}$; M-CSF Hu ; IL-3/GM-CSF Hu , hSIRP α tg ; TPO Hu). In some embodiments, non-human animals of the present invention are prepared to further comprise a human or humanized signal-regulatory 35 protein alpha (SIRP α) gene. In some embodiments, non-human animals of the present invention comprise a humanized CD47 gene, as described herein, and genetic material from a heterologous species (e.g., humans), wherein the genetic material encodes, in whole or in part, one or more heterologous proteins selected from SIRP α (CD172a), IL-3, 40 M-CSF, GM-CSF and TPO. In some certain embodiments, non-human animals of the present invention comprise a humanized CD47 gene as described herein and genetic material from a heterologous species (e.g., humans), wherein the genetic material encodes, in whole or in part, a heterologous (e.g., human) SIRP α (CD172a) protein. In some certain embodiments, non-human animals of the present invention further comprise a SIRP α gene that comprises 45 an endogenous portion and a human portion (e.g., exons 2-4 of a human SIRP α gene), wherein the human portion encodes the extracellular domain of a SIRP α protein (e.g., amino acids corresponding to residues 28-362 of a human SIRP α protein) and the endogenous portion encodes the intracellular domain of an endogenous SIRP α protein; in some embodiments, the human portion and the endogenous 50 portion are operably linked to an endogenous SIRP α promoter.

For example, as described herein, non-human animals comprising a humanized CD47 gene may further comprise (e.g., via cross-breeding or multiple gene targeting strategies) one or more modifications as described in PCT/US2010/051339, filed Oct. 4, 2010; PCT/US2013/058448, filed Sep. 6, 2013; PCT/US2013/045788, filed Jun. 14,

2013; PCT/US2014/056910, filed Sep. 23, 2014; PCT/US2014/060568, filed Oct. 15, 2014; the PCT/US2012/025040, filed Feb. 14, 2014; PCT/US2012/062379, filed Oct. 29, 2012; PCT/US2014/064806, filed Nov. 10, 2014; and PCT/US2014/064810, filed Nov. 10, 2014; these applications are incorporated herein by reference in their entirety. In certain embodiments, a rodent comprising a humanized CD47 gene (i.e., exons 2-7 of a human CD47 gene operably linked to exon 1 and exon 8 (and hence any downstream exons) of an endogenous rodent CD47 gene so that the humanized CD47 gene encodes a CD47 polypeptide having an extracellular portion from a human CD47 protein and an intracellular portion from a rodent CD47 protein) is crossed to a rodent comprising a humanized SIRP α gene (e.g., exons 2-4 of a human SIRP α gene operably linked to exons 1 and 5-8 of an endogenous rodent SIRP α gene so that the humanized SIRP α gene encodes a SIRP α polypeptide having an extracellular portion from a human SIRP α protein (e.g., amino acids corresponding to residues 28-362) and an intracellular portion from a rodent SIRP α protein; see, e.g., PCT/US2014/056910, filed Sep. 23, 2014, incorporated herein by reference).

Although embodiments employing a humanized CD47 gene in a mouse (i.e., a mouse with a CD47 gene that encodes a CD47 protein that includes a human portion and a mouse portion) are extensively discussed herein, other non-human animals that comprise a humanized CD47 gene are also provided. In some embodiments, such non-human animals comprise a humanized CD47 gene operably linked to an endogenous CD47 promoter. In some embodiments, such non-human animals express a humanized CD47 protein from an endogenous locus, wherein the humanized CD47 protein comprises amino acid residues 16-292 (or 19-141 or 19-127) of a human CD47 protein. Such non-human animals include any of those which can be genetically modified to express a CD47 protein as disclosed herein, including, e.g., mammals, e.g., mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey), etc. For example, for those non-human animals for which suitable genetically modifiable ES cells are not readily available, other methods are employed to make a non-human animal comprising the genetic modification. Such methods include, e.g., modifying a non-ES cell genome (e.g., a fibroblast or an induced pluripotent cell) and employing somatic cell nuclear transfer (SCNT) to transfer the genetically modified genome to a suitable cell, e.g., an enucleated oocyte, and gestating the modified cell (e.g., the modified oocyte) in a non-human animal under suitable conditions to form an embryo.

Methods for modifying a non-human animal genome (e.g., a pig, cow, rodent, chicken, etc. genome) include, e.g., employing a zinc finger nuclease (ZFN) or a transcription activator-like effector nuclease (TALEN) to modify a genome to include a humanized CD47 gene.

In some embodiments, a non-human animal of the present invention is a mammal. In some embodiments, a non-human animal of the present invention is a small mammal, e.g., of the superfamily Dipodoidea or Muroidea. In some embodiments, a genetically modified animal of the present invention is a rodent. In some embodiments, a rodent of the present invention is selected from a mouse, a rat, and a hamster. In some embodiments, a rodent of the present invention is selected from the superfamily Muroidea. In some embodiments, a genetically modified animal of the present invention is from a family selected from Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamster, New World rats and mice, voles), Muridae (true mice and

rats, gerbils, spiny mice, crested rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, *Malagasy* rats and mice), Platacanthomyidae (e.g., spiny dormice), and Spalacidae (e.g., mole rats, bamboo rats, and zokors). In some 5 certain embodiments, a genetically modified rodent of the present invention is selected from a true mouse or rat (family Muridae), a gerbil, a spiny mouse, and a crested rat. In some certain embodiments, a genetically modified mouse of the present invention is from a member of the family Muridae. 10 In some embodiment, a non-human animal of the present invention is a rodent. In some certain embodiments, a rodent of the present invention is selected from a mouse and a rat. In some embodiments, a non-human animal of the present invention is a mouse.

15 In some embodiments, a non-human animal of the present invention is a rodent that is a mouse of a C57BL strain selected from C57BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6NJ, C57BL/10, C57BL/10ScSn, C57BL/10Cr, and C57BL/Ola.

20 In some certain embodiments, a mouse of the present invention is a 129 strain selected from the group consisting of a strain that is 129P1, 129P2, 129P3, 129X1, 12951 (e.g., 129S1/SV, 129S1/SvIm), 12952, 12954, 12955, 129S9/SvEvH, 129/SvJae, 12956 (129/SvEvTac), 12957, 12958, 25 129T1, 129T2 (see, e.g., Festing et al., 1999, *Mammalian Genome* 10:836; Auerbach, W. et al., 2000, *Biotechniques* 29(5):1024-1028, 1030, 1032). In some certain embodiments, a genetically modified mouse of the present invention is a mix of an aforementioned 129 strain and an aforementioned 30 C57BL/6 strain. In some certain embodiments, a mouse of the present invention is a mix of aforementioned 129 strains, or a mix of aforementioned BL/6 strains. In some certain embodiments, a 129 strain of the mix as described herein is a 12956 (129/SvEvTac) strain. In some 35 embodiments, a mouse of the present invention is a BALB strain, e.g., BALB/c strain. In some embodiments, a mouse of the present invention is a mix of a BALB strain and another aforementioned strain.

In some embodiments, a non-human animal of the present 40 invention is a rat. In some certain embodiments, a rat of the present invention is selected from a Wistar rat, an LEA strain, a Sprague Dawley strain, a Fischer strain, F344, F6, and Dark Agouti. In some certain embodiments, a rat strain as described herein is a mix of two or more strains selected 45 from the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6, and Dark Agouti.

Methods Employing Non-Human Animals Having Humanized CD47 Genes

CD47 mutant and transgenic non-human animals (e.g., 50 miniature swine) and cells have been reported (Koshimizu H. et al. (2014) *PLoS One*, 9(2):e89584; Lavender, K. J. et al. (2014) *J. Immunol. Methods*, 407:127-134; Tena, A. et al. (2014) *Am. J Transplant.* doi: 10.1111/ajt.12918; Lavender K. J. et al. (2013) *Blood*, 122(25):4013-4020; Tena, A. et al. 55 (2012) *Transplantation* 94(10S):776; Wang, C. et al. (2011) *Cell Transplant.* 20(11-12):1915-1920; Johansen, M. L. and Brown, E. J. (2007) *J. Biol. Chem.* 282:24219-24230; Wang, H. et al. (2007) *Proc. Nat. Acad. Sci. U.S.A.* 104:13744-13749; Tulasne D. et al. (2001) *Blood*, 98(12):3346-52; 60 Oldenborg, P. et al. (2000) *Science* 288:2051-2054; Verdrengh, M. et al. (1999) *Microbes Infect.* 1(10):745-751; Chang, H. P. et al. (1999) *Learn Mem.* 6(5):448-457; Wang, X. Q. et al. (1999) *J Cell Biol.* 147(2):389-400; Lindberg, F. P. et al. (1996) *Science* 274(5288):795-798). Such animals 65 have been employed in a variety of assays to determine, for example, the molecular aspects of CD47 expression, function and regulation. Considerable species differences have

been discovered. Indeed, nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice express a SIRP α protein that is capable of interacting with human CD47 and, therefore, have been used extensively for the development of mouse models with components of the human immune system (e.g., see Takenaka, K. et al. (2007) *Nat. Immunol.* 8(120):1313-1323). The SIRP α allele present in these mice is not representative of the SIRP α allele present in other mouse strains and, generally, there is little cross-reaction between CD47 and SIRP α between species. Also, CD47 on mouse cells has been reported to have a near-complete mobility, while CD47 on human cells demonstrate only about 30-40% (Bruce, L. et al. (2003) *Blood* 101:4180-4188; Mouro-Chanteloup, L. et al. (2000) *VoxSanguinis* 78:P030; Mouro-Chanteloup, L. et al. (2003) *Blood* 101:338-344). Thus, NOD/SCID mice are not without limitation. For example, although multi-lineage human hematopoietic development can be supported in some genetic backgrounds (e.g., BALB/c *Rag2*^{-/-}/*IL-2Ryc*^{-/-}), homeostasis of other cell types remains inefficient (e.g., T and NK cells; see e.g., Gimeno, R. et al. (2004) *Blood* 104:3886-3893; Traggiai, E. et al. (2004) *Science* 304:104-107; Legrand, N. et al. (2006) *Blood* 108:238-245). Further, CD47 is also known to interact with other cell surface proteins and provide bidirectional signaling. Thus, existing mice represent an inefficient *in vivo* system for elucidation of CD47-dependent functions in various biological processes such as, for example, engraftment and phagocytosis. Further, existing mice represent a suboptimal *in vivo* system for development of CD47 targeted therapies.

Non-human animals of the present invention provide an improved *in vivo* system and source of biological materials (e.g., cells) expressing human CD47 that are useful for a variety of assays. In various embodiments, non-human animals of the present invention are used to develop therapeutics that target CD47 and/or modulate CD47-SIRP α signaling. In various embodiments, non-human animals of the present invention are used to screen and develop candidate therapeutics (e.g., antibodies) that bind human CD47. In various embodiments, non-human animals of the present invention are used to screen and develop candidate therapeutics (e.g., antibodies) that block interaction of human CD47 with human SIRP α . In various embodiments, non-human animals of the present invention are used to determine the binding profile of antagonists and/or agonists of a humanized CD47 on the surface of a cell of a non-human animal as described herein. In some embodiments, non-human animals of the present invention are used to determine the epitope or epitopes of one or more candidate therapeutic antibodies that bind human CD47.

In various embodiments, non-human animals of the present invention are used to determine the pharmacokinetic profiles of anti-CD47 antibodies. In various embodiments, one or more non-human animals of the present invention and one or more control or reference non-human animals are each exposed to one or more candidate therapeutic anti-CD47 antibody at various doses (e.g., 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 40 mg/kg, or 50 mg/kg or more). Candidate therapeutic antibodies may be dosed via any desired route of administration (e.g., subcutaneously, intravenously, intramuscular, intraperitoneal, etc.). Blood is isolated from non-human animals (humanized and control) at various time points (e.g., 0 hr, 6 hr, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, or up to 30 or more days). Various assays may be

performed to determine the pharmacokinetic profiles of administered candidate therapeutic antibodies using samples obtained from non-human animals as described herein including, but not limited to, total IgG, anti-therapeutic antibody response, agglutination, etc.

In various embodiments, non-human animals of the present invention are used to measure the therapeutic effect of blocking or modulating CD47 signaling and the effect on gene expression as a result of cellular changes. In various 10 embodiments, a non-human animal of the present invention or cells isolated therefrom are exposed to a candidate therapeutic that binds to a humanized CD47 protein (or a human portion of a CD47 protein) on the surface of a cell of the non-human animal and, after a subsequent period of 15 time, analyzed for effects on CD47-dependent processes, for example, adhesion, angiogenesis, apoptosis, inflammation, migration, phagocytosis, proliferation and clearance of tumors (or tumor cells).

Non-human animals of the present invention express 20 humanized CD47 protein, thus cells, cell lines, and cell cultures can be generated to serve as a source of humanized CD47 for use in binding and functional assays, e.g., to assay for binding or function of a CD47 antagonist or agonist, particularly where the antagonist or agonist is specific for a 25 human SIRP α sequence or epitope. In various embodiments, CD47 epitopes bound by candidate therapeutic antibodies can be determined using cells isolated from non-human animals of the present invention.

Cells from non-human animals of the present invention 30 can be isolated and used on an ad hoc basis, or can be maintained in culture for many generations. In various embodiments, cells from a non-human animal of the present invention are immortalized and maintained in culture indefinitely (e.g., in serial cultures).

In various embodiments, cells and/or non-human animals 35 of the present invention are used in a survival and/or proliferation assay (e.g., employing B or T cells) to screen and develop candidate therapeutics that modulate human CD47 signaling. Activation or loss of CD47 can play an 40 important role in the regulation of cell proliferation, and induction of apoptosis by CD47 may result from the activation of specific epitopes of the extracellular domain of CD47; therefore, candidate CD47 modulators (e.g., antagonists or agonists) may be identified, characterized and developed 45 using cells of non-human animals of the present invention and/or a non-human animal as described herein. In some embodiments, cells and/or non-human animals of the present invention are used in survival or death assay(s) to determine the effect on proliferation or apoptosis of a 50 specific cell(s) (e.g., cancer cells) in the presence and absence of CD47.

In various embodiments, cells and/or non-human animals 55 of the present invention are used in xenotransplantation of heterologous (e.g., human) cells to determine the CD47-mediated functions in the physiological (e.g., immune) response to the transplanted human cells. In some embodiments, candidate therapeutics that bind, or block one or 60 more functions of, human CD47 are characterized in a non-human animal of the present invention. Suitable measurements include various cellular assays, proliferation assays, serum immunoglobulin analysis (e.g., antibody titer), cytotoxicity assays, and characterization of ligand-receptor interactions (immunoprecipitation assays). In some 65 embodiments, non-human animals of the present invention are used to characterize the CD47-mediated functions regulating an immune response to an antigen. In some embodiments, the antigen is associated with a neoplasm. In some

embodiments, the antigen is associated with an autoimmune disease or condition. In some embodiments, the antigen is a target associated with a disease or condition suffered by one or more human patients in need of treatment.

In various embodiments, non-human animals of the present invention are used in transplantation or adoptive transfer experiments to determine the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of new lymphocytes and their immune function. In various embodiments, non-human animals of the present invention are transplanted with human B cells.

In various embodiments, cells of non-human animals of the present invention are used in a cell migration or spreading assay to screen and develop candidate therapeutics that modulate human CD47. Such processes are necessary for many cellular processes including wound healing, differentiation, proliferation and survival.

In various embodiments, cells of non-human animals of the present invention are used in phagocytosis assays to determine the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of phagocytosis.

In various embodiments, cells of non-human animals of the present invention are used in tumor cell growth (or proliferation) assays to determine the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation and/or apoptosis of tumor cells.

In various embodiments, an inflammatory disease or condition is induced in one or more non-human animals of the present invention to provide an in vivo system for determining the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of one or more functions of the inflammatory disease or condition. In some embodiments, the inflammatory disease or condition is associated with a neoplasm.

In various embodiments, an anti-angiogenic condition is induced in one or more non-human animals of the present invention to provide an in vivo system for determining the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of one or more functions of the anti-angiogenic condition. Exemplary functions that can be evaluated to determine therapeutic efficacy include chemokine expression, nitric oxide (NO)-stimulated responses and blood flow recovery.

Non-human animals of the present invention provide an in vivo system for the analysis and testing of a drug or vaccine. In various embodiments, a candidate drug or vaccine may be delivered to one or more non-human animals of the present invention, followed by monitoring of the non-human animals to determine one or more of the immune response to the drug or vaccine, the safety profile of the drug or vaccine, or the effect on a disease or condition. Exemplary methods used to determine the safety profile include measurements of toxicity, optimal dose concentration, efficacy of the drug or vaccine, and possible risk factors. Such drugs or vaccines may be improved and/or developed in such non-human animals.

Non-human animals of the present invention provide an in vivo system for assessing the pharmacokinetic properties of a drug targeting CD47. In various embodiments, a drug targeting CD47 may be delivered or administered to one or more non-human animals of the present invention, followed by monitoring of, or performing one or more assays on, the non-human animals (or cells isolated therefrom) to determine the effect of the drug on the non-human animal. Pharmacokinetic properties include, but are not limited to, how an animal processes the drug into various metabolites

(or detection of the presence or absence of one or more drug metabolites, including, toxic metabolites), drug half-life, circulating levels of drug after administration (e.g., serum concentration of drug), anti-drug response (e.g., anti-drug antibodies), drug absorption and distribution, route of administration, routes of excretion and/or clearance of the drug. In some embodiments, pharmacokinetic and pharmacodynamic properties of drugs (e.g., CD47 modulators) are monitored in or through the use of non-human animals of the present invention.

Non-human animals of the present invention provide an in vivo system for assessing the on-target toxicity of a drug targeting CD47. In various embodiments, a drug targeting CD47 may be delivered or administered to one or more non-human animals of the present invention, followed by monitoring of or performing one or more assays on the non-human animals (or cells isolated therefrom) to determine the on-target toxic effect of the drug on the non-human animal. Typically, drugs are intended to modulate one or more functions of their targets. To give but one example, a CD47 modulator is intended to modulate CD47-mediated functions (e.g., CD47 induced apoptosis) through interacting in some way with the CD47 molecule on the surface of one or more cells. In some embodiments, such a modulator may have an adverse effect that is an exaggeration of the desired pharmacologic action(s) of the modulator. Such effects are termed on-target effects. Exemplary on-target effects include too high of a dose, chronic activation/inactivation, and correct action in an incorrect tissue. In some embodiments, on-target effects of a drug targeting CD47 identified in or through the use of non-human animals of the present invention are used to determine a previously unknown function(s) of CD47.

Non-human animals of the present invention provide an in vivo system for assessing the off-target toxicity of a drug targeting CD47. In various embodiments, a drug targeting CD47 may be delivered or administered to one or more non-human animals of the present invention, followed by monitoring of or performing one or more assays on the non-human animals (or cells isolated therefrom) to determine the off-target toxic effect of the drug on the non-human animal. Off-target effects can occur when a drug interacts with an unintended target (e.g., cross-reactivity to a common epitope). Such interactions can occur in an intended or unintended tissue. To give but one example, mirror image isomers (enantiomers) of a drug can lead to off-target toxic effects. Further, a drug can inappropriately interact with and unintentionally activate different receptor subtypes. Exemplary off-target effects include incorrect activation/inhibition of an incorrect target regardless of the tissue in which the incorrect target is found. In some embodiments, off-target effects of a drug targeting CD47 are determined by comparing the effects of administering the drug to non-human animals of the present invention to one or more reference non-human animals.

In some embodiments, performing an assay includes determining the effect on the phenotype (e.g., change in body weight) and/or genotype of the non-human animal to which the drug is administered. In some embodiments, performing an assay includes determining lot-to-lot variability for a CD47 modulator (e.g., an antagonist or an agonist). In some embodiments, performing an assay includes determining the differences between the effects of a drug targeting CD47 administered to a non-human animal of the present invention and a reference non-human animal. In various embodiments, reference non-human animals may have a modification as described herein, a modification that

81

is different as described herein (e.g., one that has a disruption, deletion or otherwise non-functional CD47 gene) or no modification (i.e., a wild-type non-human animal).

Exemplary parameters that may be measured in non-human animals (or in and/or using cells isolated therefrom) for assessing the pharmacokinetic properties, on-target toxicity, and/or off-target toxicity of a drug targeting CD47 include, but are not limited to, agglutination, autophagy, cell division, cell death, complement-mediated hemolysis, DNA integrity, drug-specific antibody titer, drug metabolism, gene expression arrays, hematocrit levels, hematuria, metabolic activity, mitochondrial activity, oxidative stress, phagocytosis, protein biosynthesis, protein degradation, protein secretion, stress response, target tissue drug concentration, non-target tissue drug concentration, transcriptional activity and the like. In various embodiments, non-human animals of the present invention are used to determine a pharmaceutically effective dose of a CD47 modulator.

Non-human animals of the present invention provide an improved in vivo system for the development and characterization of candidate therapeutics for use in cancer. In various embodiments, non-human animals of the present invention may be implanted with a tumor, followed by administration of one or more candidate therapeutics. In some embodiments, candidate therapeutics may include a multi-specific antibody (e.g., a bi-specific antibody) or an antibody cocktail; in some embodiments, candidate therapeutics include combination therapy such as, for example, administration of mono-specific antibodies dosed sequentially or simultaneously. The tumor may be allowed sufficient time to be established in one or more locations within the non-human animal. Tumor cell proliferation, growth, etc. may be measured both before and after administration with the candidate therapeutic(s). Cytotoxicity of candidate therapeutics may also be measured in the non-human animal as desired.

Non-human animals of the present invention provide an improved in vivo system elucidating mechanisms of human cell-to-cell interaction through adoptive transfer. In various embodiments, non-human animals of the present invention may be implanted with a tumor xenograft, followed by a second implantation of tumor infiltrating lymphocytes could be implanted in the non-human animals by adoptive transfer to determine the effectiveness in eradication of solid tumors or other malignancies. Such experiments may be done with human cells due to the exclusive presence of human CD47 without competition with endogenous CD47 of the non-human animal. Alternatively, such experiments may include the use of mouse cells from a NOD/SCID or BRG (BALB/c Rag2^{-/-}IL-2Rγc^{-/-}) background. Further, therapies and pharmaceuticals for use in xenotransplantation can be improved and/or developed in such non-human animals.

Non-human animals of the present invention provide an improved in vivo system for maintenance and development of human hematopoietic stem cells through engraftment. In various embodiments, non-human animals of the present invention provide improved development and maintenance of human stem cells within the non-human animal. In various embodiments, increased populations of differentiated human B and T cells are observed in the blood, bone marrow, spleen and thymus of the non-human animal. In various embodiments, optimal T and NK cell homeostasis is observed in cells in the blood, bone marrow, spleen and thymus of the non-human animal. In various embodiments, non-human animals of the present invention demonstrate an increase in the level or amount of red blood cells (RBCs) as compared to one or more reference non-human animals.

82

Non-human animals of the present invention can be employed to assess the efficacy of a therapeutic drug targeting human cells. In various embodiments, a non-human animal of the present invention is transplanted with human cells, and a drug candidate targeting such human cells is administered to such non-human animal. The therapeutic efficacy of the drug is then determined by monitoring the human cells in the non-human animal after the administration of the drug. Drugs that can be tested in the non-human animals include both small molecule compounds, i.e., compounds of molecular weights of less than 1500 kD, 1200 kD, 1000 kD, or 800 daltons, and large molecular compounds (such as proteins, e.g., antibodies), which have intended therapeutic effects for the treatment of human diseases and conditions by targeting (e.g., binding to and/or acting on) human cells.

In some embodiments, the drug is an anti-cancer drug, and the human cells are cancer cells, which can be cells of a primary cancer or cells of cell lines established from a primary cancer. In these embodiments, a non-human animal of the present invention is transplanted with human cancer cells, and an anti-cancer drug is given to the non-human animal. The efficacy of the drug can be determined by assessing whether growth or metastasis of the human cancer cells in the non-human animal is inhibited as a result of the administration of the drug.

In specific embodiments, the anti-cancer drug is an antibody molecule, which binds to an antigen on human cancer cells. In particular embodiments, the anti-cancer drug is a bi-specific antibody that binds to an antigen on human cancer cells, and to an antigen on other human cells, for example, cells of the human immune system (or "human immune cells") such as B cells and T cells.

In some embodiments, a non-human animal of the present invention is engrafted with human immune cells or cells that differentiate into human immune cells. Such non-human animal with engrafted human immune cells is transplanted with human cancer cells, and is administered an anti-cancer drug, such as a bi-specific antibody that binds to an antigen on human cancer cells and to an antigen on human immune cells (e.g., T cells). The therapeutic efficacy of the bi-specific antibody can be evaluated based on its ability to inhibit growth or metastasis of the human cancer cells in the non-human animal. In a specific embodiment, the non-human animal of the present invention is engrafted with human CD34⁺ hematopoietic progenitor cells which give rise to human immune cells (including T cells, B cells, NK cells, among others). Human B cell lymphoma cells (e.g., Raji cells) are transplanted into such non-human animal with engrafted human immune cells, which is then administered with a bi-specific antibody that binds to tumor antigen (e.g., an antigen on normal B cells and certain B cell malignancies such as CD20) and to the CD3 subunit of the T cell receptor, to test the ability of the bi-specific antibody to inhibit tumor growth in the non-human animal.

EXAMPLES

The following examples are provided so as to describe to those of ordinary skill in the art how to make and use methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Unless indicated otherwise, temperature is indicated in Celsius, and pressure is at or near atmospheric.

Example 1. Humanization of an Endogenous Cluster of Differentiation 47 (CD47) Gene

This example illustrates exemplary methods of humanizing an endogenous gene encoding cluster of differentiation

47 (CD47) in a non-human mammal such as a rodent (e.g., a mouse). The methods described in this example can be employed to humanize an endogenous CD47 gene of a non-human animal using any human sequence, or combination of human sequences (or sequence fragments) as desired. In this example, a human CD47 gene that appears in bacterial artificial chromosome (BAC) clone RP11-69A17 is employed for humanizing an endogenous CD47 gene of a mouse.

A targeting vector for humanization of the genetic material encoding an extracellular N-terminal IgV domain and five transmembrane domains of an endogenous CD47 gene was constructed using VELOCIGENE® technology (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, *Nature Biotech.* 21(6):652-659; incorporated herein by reference).

Briefly, mouse bacterial artification chromosome (BAC) clone RP23-230L20 (Invitrogen) was modified to delete the sequence containing exons 2-7 of an endogenous CD47 gene and insert exons 2-7 of a human CD47 gene using human BAC clone RP11-69A17 (Invitrogen), which encodes amino acids 16-292 of a human CD47 polypeptide. Endogenous DNA containing genomic DNA corresponding to exons 1, 8 and 9 of isoform 2 as well as the 5' and 3' untranslated regions (UTRs) were retained. Sequence analysis of the human CD47 sequence contained in BAC clone RP11-69A17 confirmed all CD47 exons and splicing signals. Sequence analysis revealed that the sequence matched the reference genome and CD47 transcripts NM_001777.3 and NM_198793.2. The genomic DNA corresponding to exons 2-7 of an endogenous CD47 gene (~30.8 kb) was replaced in BAC clone RP23-230L20 by homologous recombination in bacterial cells to insert a DNA fragment containing ~23.9 kb of genomic human DNA corresponding to exons 2-7 of a human CD47 gene from BAC clone RP11-69A17 and ~4995 bp corresponding to a self-deleting neomycin cassette flanked by recombinase recognition sites (loxP-hUbl-em7-Neo-pA-mPrm1-Cre1-loxP; see U.S. Pat. Nos. 8,697,851, 8,518,392 and 8,354,389, which are incorporated herein by reference). The self-deleting neomycin cassette was added to the end of the ~23.9 kb human DNA fragment containing exons 2-7 of the human CD47 gene (FIG. 2). The targeting vector contained, from 5' to 3', a 5' homology arm containing ~39 kb of mouse genomic DNA from BAC clone RP23-230L20, ~29.3 kb of human genomic DNA from BAC clone RP11-69A17 (containing exons 2-7 of a human CD47 gene), a self-deleting neomycin cassette flanked by loxP sites, and ~98.8 kb of mouse genomic DNA from BAC clone RP23-230L20. After homolgous recombination in bacterial cells with the targeting vector described above, a modified RP23-230L20 BAC clone was created that resulted in a humanized CD47 gene which contained a mouse 5' UTR, a mouse exon 1, human exons 2-7, mouse exons 8-9 and a mouse 3'UTR. Protein sequences of four projected alternatively spliced isoforms of humanized CD47 are provided in Table 3 which indicate the resulting mouse and human amino acids encoded by the mouse and human DNA, respectively.

The modified BAC clone described above was used to electroporate F1H4 (50% 129/SvEv/Tac, 50% C57BL/6NTac; Auerbach, W. et al. (2000) *Biotechniques* 29(5): 1024-8, 1030, 1032) mouse embryonic stem (ES) cells to create modified ES cells comprising an endogenous CD47 gene that is humanized from exons 2-7. Positively targeted ES cells containing a humanized CD47 gene were identified by an assay (Valenzuela et al., *supra*) that detected the presence of the human CD47 sequences (e.g., exons 2-7) and

confirmed the loss and/or retention of mouse CD47 sequences (e.g., exons 1, 8 and 9 and/or exons 2-7). Table 4 sets forth the primers and probes that were used to confirm humanization of an endogenous CD47 gene as described above (FIG. 3). The nucleotide sequence across the upstream insertion point included the following, which indicates endogenous mouse sequence upstream of the insertion point (contained within the parentheses below with an *AsiSI* restriction site italicized) linked contiguously to a human CD47 sequence present at the insertion point:

(SEQ ID NO: 33)
(GCAGACATGA TTACTTCAGA GCTTTCAAAG
CTAGATACTG TACCTTGAT ATTCCAACAC)
GCGATCGC ATTTTAAGAT TTTCCATCCT
AGTGGAAAGA TATGATTGATTCATCCTAT
TTACTTTGTA TATTAAGTA CAGTAGAAC
TGCCCACTTTT.

The nucleotide sequence across the downstream insertion point at the 5' end of the self-deleting neomycin cassette included the following, which indicates human CD47 genomic sequence contiguous with cassette sequence downstream of the insertion point (contained within the parentheses below with loxP sequence italicized):

(SEQ ID NO: 34)
GGATCCATT TAAAGTAATAG AATAGGATT
TTAATTGTTC CAGTGTTC GTGATAGAGC
TGTCCTGCAC AGACCTGTTT (CTCGAGATAA
CTTCGTATAA TGTATGCTAT ACGAAGTTAT
ATGCATGGCC TCCGCGCCGG GTTTGGCGC
CTCCCGCGGG).

The nucleotide sequence across the downstream insertion point at the 3' end of the neomycin cassette included the following, which indicates cassette sequence contiguous with mouse genomic sequence 3' of exon 7 of an endogenous CD47 gene (contained within the parentheses below with loxP sequence italicized):

(SEQ ID NO: 35)
CATGTCGGAA ATAACCTCGT ATAATGTATG
CTATACGAAG TTATGCTAGT AACTATAACG
GTCCTAAGGT AGCGACTAGC (ATTAGTATGG
AAGGTCCGTC CACTGTCCAG GTTCCTCTTG
CGGAGCTCTT TGTCTCTCTG GACTCTGTAT
ACACTGCTTG).

The nucleotide sequence across the downstream insertion point after deletion of the neomycin cassette (76 bp remaining) included the following, which indicates human and mouse genomic sequence juxtaposed with remaining cassette sequence loxP sequence (contained within the parentheses below with loxP sequence italicized):

(SEQ ID NO: 36)

```

GGATCCATT TAAGTAATAG AATAGGATT TTAATTGTTCT
CAGTGTCT GTGATAGAGC TGCCTGCAC AGACCTGTTCT
(CTCGAGATAA CTTCGTATAA TGTATGCTAT ACGAAGTTAT
GCTAGTAACT ATAACGGTCC TAAGGTAGCG ACTAGC) ATT
AGTATGGAAG GTCCGTCAC TGTCCAGGTT CCTCTTGCGG
AGCTCTTGT CTCTCTGGAC TCTGTATACA CTGCTTGCAT.

```

Positive ES cell clones were then used to implant female mice using the VELOCIMOUSE® method (see, e.g., U.S. Pat. No. 7,294,754 and Poueymirou et al., F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses, 2007, *Nature Biotech.* 25(1):91-99) to generate a litter of pups containing an insertion of exons 2-7 of a human CD47 gene into an endogenous CD47 gene of a mouse. Mice bearing the humanization of exons 2-7 of an endogenous CD47 gene were again confirmed and identified by genotyping of DNA isolated from tail snips using a modification of allele assay (Valenzuela et al., supra) that detected the presence of the human CD47 gene sequences. Pups are genotyped and cohorts of animals heterozygous for the humanized CD47 gene construct are selected for characterization.

TABLE 4

Name	Primer	Sequence (5'-3')
7190mTU	Forward	TGCAGAACGTC ACTAGGAGGAAT (SEQ ID NO: 21)
	Probe	TCACTCAACTCTTC TGGGTTGTTTCC (SEQ ID NO: 22)
	Reverse	GTGCCAGACTCA CTTTCTATCCA (SEQ ID NO: 23)
	Forward	TGCTGCCAATA TACGGCTCTG (SEQ ID NO: 24)
	Probe	CAGCTCTCATCA GCAAACATATGG TGCC (SEQ ID NO: 25)
	Reverse	TCAAGCAGAGC CTGGTTATCTG (SEQ ID NO: 26)
	Forward	GTCGTCATTCC ATGCTTGTGTTAC (SEQ ID NO: 27)
	Probe	TGGAGGCACAAA ACACTACTGAAG TATACG (SEQ ID NO: 28)
	Reverse	GGACAGTGGACT TGTTTAGAGC (SEQ ID NO: 29)

TABLE 4-continued

Name	Primer	Sequence (5'-3')
5	7190hTD	Forward (SEQ ID NO: 30)
	Probe	AGCACCCAACT GATATGCCTGTA TTTG (SEQ ID NO: 31)
	Reverse	TGGGAACGGTG TTTCAAGTCTA (SEQ ID NO: 32)
	Forward	GGCTTGGTGGCT GATTGTTCT
	Probe	(SEQ ID NO: 33)
	Reverse	TGGGAACGGTG TTTCAAGTCTA (SEQ ID NO: 34)
	Forward	(SEQ ID NO: 35)
	Probe	(SEQ ID NO: 36)
	Reverse	(SEQ ID NO: 37)

Example 2. Expression of Humanized CD47 Polypeptide by Mouse Red Blood Cells

This Example demonstrates that non-human animals (e.g., rodents) modified to contain a humanized CD47 gene according to Example 1 can be used to screen CD47 modulators (e.g., anti-CD47 antibodies) and determine various characteristics such as, for example, pharmacokinetics and safety profiles. In this Example, several anti-CD47 antibodies are screened on mouse red blood cells (RBCs) isolated from rodents made in accordance with Example 1, which rodents express a humanized CD47 polypeptide as described herein.

- 25 Briefly, 2 mL of whole blood from humanized CD47 mice (n=2) was transferred to a 15 mL tube and centrifuged at 200×g for 10 minutes at 4° C. The plasma and buffy coat were aspirated and then 15 mL of PBS was added and the cells were mixed gently. The mixture was centrifuged again at 200×g for five minutes at 4° C. The supernatant was aspirated and the cells were washed two additional times. Pelleted RBCs were resuspended to a final volume in 10 mL of PBS. The resuspended RBCs were centrifuged a final time at 200×g for 10 minutes at 4° C. The volume of packed RBCs was estimated 0.5 mL and diluted to a concentration of 0.5% with PBS (0.5 mL packed RBC/100 mL PBS). Actual RBC concentration was determined with a Cellometer Auto T4 (1.5×10⁷/mL; Nexcelom Bioscience).
- 30
- 35 Eighty (80) μL of 0.5% mouse RBCs were added to each well of a 96-well V-bottom plate. Anti-CD47 antibodies were added into each well (20 μL at 33 nM). The plate was gently tapped to mix and incubated on ice for 30 minutes. The plate was then washed twice with staining buffer (PBS with 2% FBS). Secondary antibody Fab-488 (Alexa Fluor 488-conjugated AffiniPure mouse anti-human IgG, F(ab)₂ fragment specific, Jackson Immuno Research) was added to each well at a concentration of 10 μg/mL. The plate was incubated again on ice for 30 minutes, followed by washing once with staining buffer. The cells in each well were resuspended in 200 μL of staining buffer and filtered through a 96-well filter plate. The cells in the plate were analyzed using the BD ACCURIT™ C6 system (BD Biosciences).
- 40
- 45
- 50
- 55
- 60
- 65
- Exemplary results are shown in FIG. 4. The mean fluorescence intensity (MFI) above isotype control for each tested antibody is shown in Table 5.

TABLE 5

Antibody	MFI	Fold above isotype control
Ab A, hIgG4s	28898	258
Ab B, hIgG4s	27545	246
Ab C, hIgG4s	24620	220
Ab D, hIgG1	29882	267
Ab E, hIgG4	33423	298
Control, hIgG4s	112	—
Control, hIgG4	112	—

hIgG4s: human IgG4 with modified Fc region that has reduced effector function

As shown in FIG. 4, all anti-CD47 antibodies bound to RBCs from humanized CD47 mice. Taken together, this Example demonstrates that (1) non-human animals (e.g., rodents) engineered to contain a humanized CD47 gene as described herein express a humanized CD47 polypeptide on the surface of cells (e.g., RBCs) of the non-human animal, and (2) such cells are useful for screening CD47 modulators (e.g., CD47 antibodies) and determining the pharmacokinetic profiles of such modulators.

Example 3. Hemagglutination of Mouse Red Blood Cells Expressing Humanized CD47 Polypeptide

This Example further demonstrates that non-human animals (e.g., rodents) modified to contain a humanized CD47 gene according to Example 1 can be used in various assays (e.g., hemagglutination assay) to screen CD47 modulators (e.g., anti-CD47 antibodies) and determine various characteristics such as, for example, pharmacokinetics and safety profiles. In this Example, several anti-CD47 antibodies are screened on mouse red blood cells (RBCs) that express a humanized CD47 polypeptide as described herein to determine antibody concentration that promotes hemagglutination.

Briefly, RBCs from wild-type and humanized CD47 mice (n=2) were prepared as described in Example 2. Twenty (20) μL of anti-CD47 antibody (at 5-fold serial dilution) was added into wells 1-12 across a 96-well V-bottom plate followed by the addition of 80 μL of 0.5% mouse RBCs to all wells of the plate. The plates were tapped gently to mix and incubated at room temperature (24-27° C.) for 30 minutes. Agglutination endpoint was observed visually (i.e., RBCs settle to the bottom in negative samples, while RBCs agglutinate in positive samples). Exemplary results are shown in FIG. 5, with boxes to outline the wells that show heme-agglutination.

As shown in FIG. 5, only lectin caused agglutination in wild-type mice. However, two anti-CD47 antibodies (Ab E and Ab C) in addition to lectin induced agglutination in RBCs from two humanized CD47 rodents made according

to Example 1. The concentration at which these two antibodies induced agglutination started from 11 nM. Taken together, this Example demonstrates that non-human animals (e.g., rodents) engineered to contain a humanized CD47 gene as described herein can be used to assess one or more properties (e.g., hemagglutination) of CD47 modulators (e.g., CD47 antibodies).

Example 4. Pharmacokinetic Clearance of CD47 Modulators in Humanized CD47 Rodents

This Example illustrates a method of assessing the pharmacokinetic clearance of CD47 modulators (e.g., anti-CD47 antibodies) in non-human animals (e.g., rodents) modified to contain a humanized CD47 gene according to Example 1. In this Example, wild-type and humanized CD47 rodents (e.g., mice) were administered anti-CD47 antibodies and serum levels of antibodies were determined using an ELISA assay.

Briefly, wild-type (n=5) or mice homozygous for humanized CD47 (n=5; as described above) were administered four anti-CD47 antibodies (Ab F, Ab G, Ab H and Ab I) and an IgG4s isotype control antibody (IgG4s). The genetic background of the mice were 75% CD57BL/6 and 25% 129Sv. Each antibody was tested in five humanized CD47 rodents. All antibodies were administered subcutaneously at a dose of 50 mg/kg. One pre-bleed was collected one day prior to administration of antibody (day 0). Post-injection bleeds were collected at 6 hours, 1 day, 2 days, 3 days, 4 days, 7 days, 10 days and 14 days. Serum fractions from bleeds were separated and subjected to total human antibody analysis using an ELISA immunoassay.

Briefly, a goat anti-human IgG polyclonal antibody (Jackson ImmunoResearch) was coated onto 96-well plates to capture the tested human antibodies in the sera, and then plate bound antibodies were detected using a goat anti-human IgG polyclonal antibody conjugated with horseradish peroxidase (Jackson ImmunoResearch) and TMB substrate (BD Pharmingen). The serum samples were in six-dose serial dilutions and reference standards of the respective antibodies in 12-dose serial dilutions. Drug antibody concentrations in the sera were calculated based on the reference standard curve generated using Graphpad Prism software. Exemplary results are shown in FIG. 6 and Table 6.

The data demonstrated that the antibodies administered to wild-type and humanized mice as described herein were well tolerated. Taken together, this Example demonstrates that non-human animals of the present invention can be used to assess one or more pharmacokinetic properties of a drug targeting CD47 (e.g., an anti-CD47 antibody) such as, for example, circulating drug levels. Moreover, non-human animals described herein can be used to assess the toxicity of a drug targeting CD47 by determining adverse effects after administration.

TABLE 6

Antibody	Serum antibody concentrations ($\mu\text{g/mL} \pm \text{SEM}$)							
	6 hour	Day 1	Day 2	Day 3	Day 4	Day 7	Day 10	
Ab F	116.7 \pm 14.0	196.4 \pm 10.6	96.0 \pm 13.3	24.7 \pm 7.0	3.7 \pm 0.42	<0.35	<0.35	
Ab G	115.0 \pm 22.1	198.8 \pm 23.4	118.4 \pm 20.9	48.3 \pm 16.0	2.9 \pm 1.97	<0.35	<0.35	
Ab H	64.5 \pm 3.85	108.0 \pm 5.13	32.0 \pm 6.08	1.0 \pm 0.2	0.4 \pm 0.03	0.06 \pm 0.03	0.05 \pm 0.02	
Ab I	51.1 \pm 16.6	115.2 \pm 14.8	63.8 \pm 8.3	11.1 \pm 4.2	0.5 \pm 0.1	0.1 \pm 0.02	<0.35	
IgG4s isotype control	458.2 \pm 34.4	702.5 \pm 32.3	616.6 \pm 27.0	567.1 \pm 39.5	488.9 \pm 45.0	357.0 \pm 51.1	307.6 \pm 61.1	

Example 5. Pharmacokinetic Profiles of CD47 Modulators in Humanized CD47/SIRP α Rodents

This Example illustrates a method of assessing the pharmacokinetic clearance of CD47 modulators (e.g., anti-CD47 antibodies) in non-human animals (e.g., rodents) modified to contain humanized CD47 (according to Example 1) and SIRP α genes. In particular, humanized CD47 rodents described herein were modified to further contain a humanized SIRP α gene that contains an endogenous portion and a human portion, which human portion encodes the extracellular domain of a human SIRP α protein (e.g., amino acids 28-362 of a human SIRP α protein) and which endogenous portion encodes an intracellular domain of an endogenous SIRP α protein (e.g., amino acids encoding transmembrane and intracellular portions of a murine SIRP α protein) as described in PCT/US14/56910, filed Sep. 23, 2014, which is incorporated herein by reference. Double humanized CD47/SIRP α mice were made by breeding humanized SIRP α mice to humanized CD47 mice. In this Example, double humanized CD47/SIRP α rodents (e.g., mice) were administered various anti-CD47 antibodies and their corresponding pharmacokinetic profiles were determined.

Briefly, groups of wild type (n=5) and mice homozygous for humanized CD47 and SIRP α genes (CD47^{hu/hu} SIRP α ^{hu/hu}, n=5 per group) were administered selected anti-CD47 antibodies and an IgG4 isotype control antibody (IgG4s). The genetic background of the mice were 75% CD57BL/6 and 25% 129Sv. All antibodies were administered in a single subcutaneous dose of 50 mg/kg. One pre-bleed was collected one day prior to administration of antibody (day 0). Post-injection bleeds were collected at 6 hours, 1 day, 2 days, 3 days, 4 days, 7 days and 10 days. Serum fractions from bleeds were separated and subjected to total human antibody analysis using an ELISA immunoassay (described above). Additionally, hematocrit levels were measured at 6 hours, 1 day, 2 days, 3 days, 4 days, 7 days and 10 days and a urine test was performed as needed (at 6 hours and when urine color deviated from yellow color) to determine red blood cell counts. Exemplary results are shown in FIGS. 7-9.

As shown in FIGS. 7 and 8, all anti-CD47 antibodies demonstrated target-mediated clearance in CD47^{hu/hu}SIRP α ^{hu/hu} mice and, in particular, many demonstrated similar pharmacokinetic profiles. Further, a monovalent version of one anti-CD47 antibody (Ab F) demonstrated greater bioavailability than its bivalent equivalent (FIG. 8). The inventors observed similar pharmacokinetic profiles for the antibodies among multiple experiments with humanized CD47 and double humanized animals (i.e., CD47^{hu/hu}SIRP α ^{hu/hu} mice).

Ab J had less of an effect on hematocrit levels than other anti-CD47 antibodies tested (Ab F, Ab G, Ab I, etc.) and comparable changes in hematocrit levels to control (IgG4s) in CD47^{hu/hu}SIRP α ^{hu/hu} mice. Measurements of hematocrit on days 2-4 showed the largest drop from normal range (~38.5-45.1%), which included groups administered Abs F, G and I. In particular, a monovalent form of Ab F demonstrated a delayed lowering effect on hematocrit as compared to other antibodies tested. The inventors reasoned that differences in hematocrit levels among the various treatment groups could be attributed to a difference in epitope recognized by the various antibodies. Also, mice dosed with selected anti-CD47 antibodies demonstrated positive urine dipstick tests for heme at 6 hours. For example, Ab J and Ab F treatment groups each had one mouse positive for heme on day 1, while all other timepoints were negative. No significant weight loss (>20%) was observed in any treatment group.

Taken together, this Example demonstrates that non-human animals of the present invention provide an in vivo

system for assessing the pharmacokinetic properties and/or profiles of one or more drugs targeting CD47 (e.g., one or more anti-CD47 antibodies) such as, for example, circulating drug levels. Moreover, non-human animals as described herein engineered to further contain other humanized genes (e.g., humanized SIRP α) can be used to assess the target-mediated clearance of one or more drugs targeting CD47.

EQUIVALENTS

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated by those skilled in the art that various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawing are by way of example only and the invention is described in detail by the claims that follow.

Use of ordinal terms such as "first," "second," "third," etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.

The articles "a" and "an" as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to include the plural referents. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or the entire group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim (or, as relevant, any other claim) unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. Where elements are presented as lists, (e.g., in Markush group or similar format) it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, etc. For purposes of simplicity those embodiments have not in every case been specifically set forth in so many words herein. It should also be understood that any embodiment or aspect of the invention can be explicitly excluded from the claims, regardless of whether the specific exclusion is recited in the specification.

Those skilled in the art will appreciate typical standards of deviation or error attributable to values obtained in assays or other processes described herein.

The publications, websites and other reference materials referenced herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference.

SEQUENCE LISTING

Sequence total quantity: 36

SEQ ID NO: 1 moltype = DNA length = 5591
 FEATURE Location/Qualifiers
 source 1..5591
 mol_type = other DNA
 organism = Mus musculus

SEQUENCE: 1
 gcctacaccg ggagacgagg gaggaggagt tggactgagg ttggggggct ccgagggtcca 60
 gggcgagctt ggccagaggg agtagagago ageggggctcg cgcaggacg cgtgcgtga 120
 gtcccggtga cgctgtgtc cccatgtccc cgtcttcag cggggccag gacacgaac 180
 cggaaagagag ctggctggg ggacgggggg cgtagcaga gagtgcaccc cgccgacggcc 240
 cggggacagg ctgattcttgc ggcgtctccg cccgggtcg ggttgaggc 300
 tggcgtcacc tcaacgagca gaggggcca ggccgggggg agtgcgcgtg cgccggggcg 360
 cggacgcgcg cgcgcgcgc cccccggca gcctggcgcc cgctccgtgc ctgtcactgc 420
 tgccgcgcgcgt ctggctgggt gtggcccttg aaggcagcggc eggaggccggc ggctgtccca 480
 gacacccgtgc gggggccacc cccggccgcg cggggatgtg gcctttggcg gggggcgtgt 540
 tgctgggtc ctgtcgtgc gggtcagctc aactactgtt tagtaactgc aactccatag 600
 agttcaacttc atgcaatgaa actgtggta tccttgcatt cgtccgtat gtggaggcgc 660
 aaagccgcg agaaaatgtt gtgtaacaatc atcgatattt ttcatctatg 720
 atggaaataa aatagcact acatcagatc aaaacttac cgtgcacaaa atctcgtct 780
 caagacttaat caatggcatt gccttttga aaatggataa ggcgcgttgc atggggaa 840
 actacacttg cgaagtgcaca gagttatcca gagaaggca aacaggtaa gagtcgaaaa 900
 accgcacggc ttcaacact cacaaggat cagcctgttc ttacggggg gagaaaggaa 960
 gtggcaatt agttctgtgg ttttttccca atgaaaatgtt ctcattgtt atttttccca 1020
 ttttggctat atccctgttc tggggaaatg ttgttatgtt aacactcaaataataatcca 1080
 gcccatacgaa taagagaatc attttgtcgc tcgttgcgcg gctgggtctc acagtcatcg 1140
 tggttgttgg acccatccctt ctcatcccaag gagaaaaaggcg cgtgaaagat gcttttgttgc 1200
 ttggcctcat tgaatcttcc acggggatataactact tcgatcataat gtgtttatga 1260
 cagctttttgg aatgcactt tcacatttg ccattttgtt cactcaatgt ctgggcgtacg 1320
 tccttgcgtt ggtcggtcg tgcgtctgc tcattgtccgat tgagccgtg cacggcccc 1380
 ttttgcatttgc aggttgtggg atcatagtc tagcagaatc acttggatgtt gtttatatg 1440
 agtttgcgtatc ataggtaag ggaagtgcacg gactgttacta tggaaagtgc aatatggaa 1500
 atacagttgtt ctaagccatc ggttttcgcg actcacaatg ggaaggaaaca gacaacagta 1560
 actgaacttcc atccaggaaaa acatgtcaca taaatgatta ctaagtttatttattca 1620
 gctgtacttcc acataataaa aaaaatgttgc tggtgtgtt aaccaatggg aatcccattt 1680
 ttcttatttttgc tctacttcac tagggggaaa cggtttttgcg gcaacttccca agaatgtg 1740
 ttgttagatc ctagacttc tgaacactga gtttttttttgcatttttgcgg 1800
 agcactaacc ttggggttag ttaccatgg atacatcataa aaaacagtttgc tatccagca 1860
 gcttagtaa actcagtttc ccacgggttgc tgccacttcc gctgtcgatgc gaaataacaag 1920
 actgcacccatc ctgggtctata tgatagaga ctgaaggatggg aaccaatggg aatcccatt 1980
 aatcccgatgtt ggccctctgg tttgtgttgc tggtatgttgc acttgggttgc ttctcttg 2040
 ggggtgcatttccatca cacccttgc acataatggg gaccccgatgtt gcggccatcataat 2100
 ttttttgcgttccttgc tttctgtcaacttgc ttgttttttgc ttatgtatataatatata 2160
 tataatccatc ttctcttccttgc ttaaacttgcgatc ttctgttgc tttatgtatataatata 2200
 gaggccagact ttttttttgc ttaaacttgcgatc ttctgttgc gttatgtatataatataatata 2220
 aaaaagctata ttggtaacat atgttgc ttttttttttttttgc ttttttttgc ttttttttttgc 2280
 atctacatgtt ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2340
 tgaactgtgtt ctcctgcgtatc gcaacacgttgc ttcctgcgcgatc ttttttttttttttgc 2400
 ggggggttccatccatca ccccttcgttgc ttttttttttttttgc ttttttttttttttgc 2460
 atctctgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2520
 atccctgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2580
 ctttccatccatca ccccttcgttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2640
 agaaagaaaaac caccgtcg ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2700
 ctgttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2760
 accttctgtatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2820
 tagtgcataatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2880
 caaatatgttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 2940
 tcaccatgttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3000
 ttgttatttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3060
 tgccctctgttgc atgcataatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3120
 gggggatgttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3180
 agtacttgcg ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3240
 gtatatttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3300
 tgaaaatattt tacacttcgg ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3360
 gggggatgttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3420
 gtttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3480
 ctttgcggatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3540
 ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3600
 ctttgcggatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3660
 gggggatgttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3720
 ctttgcggatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3780
 cccgcaggatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3840
 ctttgcggatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3900
 attttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 3960
 attttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 4020
 ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 4080
 attttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 4140
 ctttgcggatc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 4200
 ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc ttttttttttttttgc 4260

-continued

cctgtgacac aatagtca gtgcagaaagg agccagactt attcgcaag cactgtgctc 2220
 aaactcttca gaaaaaaaaagg aaaaaaaaaa aaagctatacg ttgtacaatac tgtaattccag 2280
 acctctgggt taaaggcaaa agaaaaaaaaa tctacagtgt ttcttctcat gtttctgat 2340
 cggaggcatg acaaaggcaag actgaaatct gaactgtgtc tcctgeatgg caacacgtgt 2400
 ctccgtcagg ccctcgcaag gccccggggag ggggttctac gccttggc tctttgtgc 2460
 atgctgaaca ctcatcgct tctactgtta tcttgcctc tgcagectcc ctcttcetcc 2520
 tccctcttctc ttccctctc ttccctcttctc tccccaaggta tgaaaggta 2580
 aacaaaacta ccacattccc tacccagtttta gaagaaaacc accgttctgtc cagttgttat 2640
 cgcgttggact acttttagat tattagcaco tggttttac tcgttggc tgctgtttgt 2700
 atgtgcacat gtatggact ggcacatcg ctttctgtat gggcagaggc gtggcata 2760
 cagaagagca gatgcacact ttgtgtttt agtatacata tttaaaaaaa aaaaccaacg 2820
 gtccttattt agtggaaattt tatttgatgc aaatatttta gcttttaag actttaaaac 2880
 tagataatgt gcaagcttt taggactgtt caccatgtc ctctgaaaggaa acaccatgt 2940
 ttttcttcttgg tttgttataa aaggcttgc tggttttgc ttgcataatc taatggttat 3000
 ttcttcttag tccactgtt gtttcatgt gctctcgta tgccaaactt ttgtcatct 3060
 ttcatgtggg gaccaaatgg tttgtctgt gcaaacatca acctatgacc tgctgaggcc 3120
 tccagaaaaa ctgaccacag taccatggaa gtacttcgca aagaaaaatgaa gtttccctcc 3180
 ctgggttggt agctgtcgcc aatatttgcg taatccaaagg gatgtgaacg cttttatata 3240
 aatctgtatgg caccatgtt ttttgttgcgtaa gaaaatatttta acactcgat catgttgg 3300
 atgacttaaa caaagtttgc atgagagag caaaaaaaaaa gcaagggttat ttggaacagt 3360
 ttcaagggtt tttttttttt ttgtttttttt tttttttttt tttttttttt 3420
 tctgttcttgc tttagaaaaag tcagggttgc tctgtcaggc tatcttata gtcaattttt 3480
 tttagcaact aaatgtatc ttttatatttta gtagtcaacg cccctctgtc cgggttcc 3540
 ttttgggtt ttaaccatgtc tcatgttctc tatgtgcctt gcaacttgag gcaacttgat 3600
 cccttagacac tcccatcggt ggttagccgg gaaacgaaagg acgaactcaa ctcttgc 3660
 taataatcaa ctctctgtat gaaggatggc agcattaaga gtccttcgtc ctggcattta 3720
 ttggcccaatg tccatccatc tttatcaaccc cccgactggc tcccatgtt cgtcccatca 3780
 gatttaaattt gtaacatgtt tggggggcactt caccatgttgc ttgttgcocca caatgcgtt 3840
 ttctctccca aatcccgatt tctgtgtca tagcctctat tcaatttta ttattgtct 3900
 gccccttcaatcataatcg tagagacaa tgocattttgc cacttttgc aacagtttt 3960
 tgagcccttta tggctgaatc ccatttttttcttccatccatcactgttgc ccatttgc 4020
 tcccgccacgg ctgtccgtac agtcatccca tccatctggg ggccttttc atctctcacc 4080
 ctccctgggtt ctccgtggat ctctgttttccatccatcactgttgc ttttttttt 4140
 tatttttttttgcgactt aagatatttttttgcgactt ccacagggaa agtgcgtcctt cccttttttgc 4200
 cccgcgttgc tttgtgtact ttagatatac tctgttgc tctgttgc acatgttgc gcaaaatgtt 4260
 cctgcacttta aatttttctt ttaatagggt tgaacttagat ttggagttt tttctcttt 4320
 ttctcttttc tctctctctc tctctctctc tctctctctc tccctccctc 4380
 cttccctccccc tccatccatcactgttgc ttcttttttccatccatcactgttgc tttttttttgc 4440
 tctttcttttc tcttttttttgcgactt ttttttttttgcgactt ccacagggat ttgagaattt 4500
 taaaagggtga cagttcacatc gaaaatcaca ggttgcgtt gtttaatgtt ttgagaattt 4560
 tccgattttt aagtcttgcgat tctgttgcata ataggcttgc ttccaggacg ttgttagtca 4620
 tagagtggctt gacccatact ttagtttgcgat aagctcaaaa actgtatgcac ccactctgt 4680
 attatcgatgt tagtaatggat ttagatgtat atctttgtat agttttatct tgcgttccatc 4740
 tgggtatttca aatatggccca ccagggatata tggatgttgc ttttttttttgc 4800
 ttgttgcgat tggggggaa aacaaaaat gtcgttgcac cttttgcctt ttttttttgc 4860
 attatgtatc agtttttttgcgat ttttttttttgcgactt ccacatccatcactgttgc gccacaaccc 4920
 acagagggttgc ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 4980
 agagatggc agtaccatgg aatatttttgcgactt ccacatccatcactgttgc ttttttttttgc 5040
 ctgtttaatgcgat ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5100
 aataatgtatc ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5160
 gaggggaaaca ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5220
 aattatgtatc cccatccatcactgttgc ttttttttttgcgactt ccacatccatcactgttgc 5280
 ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5340
 ctatccatcactgttgc ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5400
 ttatccatcactgttgc ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5460
 atacatccatcactgttgc ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5520
 cctgtatataatgcgat ttttttttttgcgactt ccacatccatcactgttgc gtttttttttgc 5580

SEQ ID NO: 4 moltype = AA length = 303
 FEATURE Location/Qualifiers
 source 1..303
 mol_type = protein
 organism = Mus musculus

SEQUENCE: 4
 MWPLAAALL GSCCCCGSAQL LFSNVNSIEF TSCNETVVIP CIVRNVEAQS TEEMFVKWKL 60
 NKSYIFYIDG NKNSTTTDQN FTSAKISVSD LINGIASLKM DKRDAMVGNY TCEVTELSRE 120
 GKTVIELKNR TVSWFSPNEK ILIVIFPILA ILLFWGKPGI LTLKYKSSHT NKRIILLLVA 180
 GLVLTVIVVV GAILLIPGEK PVKNASGLGL IVISTGILIL LQYNVFMTAF GMTSFTIAIL 240
 ITQVLGYVLA LVGLCLCIMA CEPVHGPLLII SGLGIIALAE LLGLVYMKFV ASNQRTIQPP 300
 RNR 303

SEQ ID NO: 5 moltype = DNA length = 5648
 FEATURE Location/Qualifiers
 source 1..5648
 mol_type = other DNA
 organism = Mus musculus

SEQUENCE: 5
 gcctacaccg ggagagcagg gaggaggat tggactgagg ttggggggctt ccgagggttcca 60
 gggcgagctt ggccagaggc agtagagacg agcggggctt cgcaggacg cgttccatcactgttgc 120

-continued

gttccgggtga	gcgtgtgtgt	cccatgtcctcg	cggttttcag	gcccggcccg	gacaagaagg	180
cggaaagagag	ctggctggag	ggacgggggc	cgtgagcaga	gagtgcaccc	cgcgcagccc	240
cggggacagg	ctgattcttg	gwgctctcg	ccggagctcg	cccaggctcg	ggtgtgaggc	300
tggcgtacg	tcaacgagca	gaggggcga	ggcgccccgg	agtgcgcgtg	cgcggggcgg	360
cggcgcacgg	cgcgcgcga	ccccggggca	gcttggggcg	cgcgcctcg	ctgtcactcg	420
tggggcgtg	ctggctggtc	gttcccttg	aaggcagcga	cgaggggcgg	ggctgtccca	480
gacacctcg	goggcgacc	ccccggggcg	cgaggatgtg	gcccttggcg	gcccggctgt	540
tgctgggtc	ctgtgtctgc	ggttcagtc	aactactgtt	tagtaacgtc	aactccatag	600
agtgcacttc	atgcaatgg	actgtggtc	tcccttgc	cgtccgtaat	gtggaggcgc	660
aaagcaccga	aaaaatgttt	gtgaagttgg	agtgtaccaa	atcgatattt	ttcatctatg	720
atggaaataa	aaatagcact	actacagato	aaaactttac	cagtcaaaa	atctcagtt	780
cagacttaat	caatggcatt	gcctcttgc	aatggataaa	gcccgtatgc	atgggtggaa	840
actacacttg	cgaatgtaca	gaggatattca	gagaaggcca	aacagtataa	gagctgaaaa	900
accgcacggc	cttcaacact	gaccaaggat	cagccgttgc	ttacaggag	gagaaggagg	960
gttgcattaa	atgttcgtgg	tttttccaa	atgaaaaatg	ccttcatttt	attttccaa	1020
ttttggat	actctgttc	tgggggaaatg	ttgttatttt	aacactcaaa	tataaatcca	1080
gcctatggaa	taagagaatc	attctgtgc	tcgttgcgg	gcttgggtc	acagtcatcg	1140
ttgttgggg	aggccatctt	ctcatcccg	gagaaagggc	cgtgagaat	gcttctggac	1200
ttggcctcat	tgtatctt	acggggat	taatactact	tcgtacaat	gtgttatgt	1260
cagctttgg	aatgacctt	ttcaccattt	ccatattgt	cactcaagtg	ctgggctacg	1320
tccttgc	gttgcggcgt	tggttctgc	tcatggcat	tgagccatg	cacggcccc	1380
ttttgat	agggttgggg	atcatgtc	tagcagaat	actttggat	gtttatatg	1440
agtttgc	tcccaacc	aggacttcc	aacctccat	gaaagctgt	gaggaacccc	1500
ttaacgaata	ggtgaagggg	agtgcacgg	tgtacttgc	aaagtcaaaa	tggagaataa	1560
cagttgttca	agcacccat	tttacacgt	cacagcttgc	aggaacagac	aacagtaact	1620
gacttccat	caggaaacaa	tgtatcata	atgattacta	agtttatatt	caaagcagct	1680
gtactttata	taaaaaaaa	atatatgt	gtgtgttac	caatttgc	tttttttt	1740
tatttttct	actcaactag	gggcaaaatg	ttcagggggc	acttccaa	atgtatgtt	1800
tttagatctt	gagttcttgc	acatgtgtt	taatttgc	ccgagtgaga	ctcgccaagc	1860
actaacatgt	gggttagtta	cccaagat	cctatggaa	acagtggat	ccagcaagcc	1920
tttagaaatc	cagggttcc	cgacgttgc	cacttccgc	gctactgt	taacaagact	1980
cccaactctg	ggtcatatgt	atagagactg	aaatggaaaa	acgaatgtgg	ttgggcaat	2040
cccggtgtgc	ccctctgtgt	gctatgtat	tgatggact	ggtgttca	ttcttgggg	2100
tttgcacat	tcacatccat	cccttgc	taactgtc	cccagggtt	aatacattt	2160
tttgcaccc	tttccgttc	tgtacttttgc	atttgcgtt	tgtatatata	atataatata	2220
aataacctt	ttcccttta	aaatggcc	tgtgacacaa	tagtcaat	cagaaaggag	2280
ccagacttat	tcgcaaaagc	ctgtgtca	actttcaga	aaaaaaaggaa	aaaaaaaaaa	2340
agotatagt	gtacatattt	tatttgc	ctctgggtt	aaggcaaa	aaaaaaaaatc	2400
taacatgtt	tttctcatgt	tttctgc	atgtgttgc	gaggcat	aaagcaagac	2460
actctgttcc	ctgcatggc	acacgtgtt	ccgtcaggcc	ctcgcaaggc	ccggggagg	2520
ggttctacgc	ctttgttcc	tttgcgtat	gctgaacact	catcgcc	ctactgtatc	2580
ctgccttc	caggccctt	cttcccttc	cttcccttc	cttcccttc	cttcccttc	2640
ctcctcttcc	tccaaatgtt	aaaggccat	aaaactacc	acatccca	cccaggtag	2700
agaaaaaccac	ctgtctgaca	gttgcgtat	catgggtat	tttttagat	tttagactgt	2760
tttttacctt	gtttgtggc	gtgttgc	gtgcacatgt	atgaagt	cgacatgcacc	2820
ttctgtatgg	cgagaggcg	ggcacttaca	gaagaggcga	tgccaaat	gtgttttag	2880
tgaatacatt	aaaaaaaaaa	accaacatgt	ccttatttgc	tggatttca	tttgatgc	2940
atatttgc	ttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3000
ccagtcct	ctgaaagaaac	accgtactt	tttctgttt	gtgtatataa	ggcatattt	3060
tattttgtt	tgcataacta	atgtgtt	tttctgttgc	cactgtatgt	ttccatgttgc	3120
ctctgtatgt	ccaaatttt	tgtattttgc	catgtgggg	ccaaatgttt	tgctgtggc	3180
aaaccttac	ctatgtatgt	ctgaggcc	tcagaaaact	gaccacatg	ccaaatgt	3240
acttcgaa	aaaaatgtt	tttcccttc	ggttttgtat	ctgtcgcc	tattagcgt	3300
attccaaag	gtgtacggc	tttataataa	tctgtatgc	ctgtatgtt	tttagtcttgc	3360
aaatatttttac	actcgatca	ttgtgttgc	gacttaaaca	aaatgttgc	gaagagagca	3420
aaaaaaaaaa	aggtgtat	ggacagttt	cagggtttt	tttgcgtt	tttttttt	3480
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3540
tgtcaggat	tctttatgt	caatattttt	tacgtacta	agtagtaccc	ttttatatgt	3600
agtcaacggc	cctctgtcg	gggttcgtt	tttgcgttca	accagctgtc	atgttcttca	3660
tgtgtctgc	cacttgcgg	actgtgtcc	ctagacatgt	ccatcggtt	tagccagg	3720
aacgaaagac	gaactcaact	tttgcgttca	ataatcaact	ctctgtat	aggatggcag	3780
catataatgt	cctctgtcc	gggttattt	ggccaggat	acccttca	aatcaacccc	3840
gcgtggc	ccaggatcg	tccatcaga	ttttaatttgc	taacatgt	ggggccacca	3900
cgcatcttt	tttgcgttca	atcgcttt	cttcccttca	cccccattt	tgctgtatca	3960
gcctcttcc	aatttttt	tatttgc	cttccactt	tacaatgt	gagagcaat	4020
ccattttgtca	tttctgtcc	cagtttttgc	agcgtttat	gtgtatccc	attttcttcc	4080
tctttcaac	ttttttgtcc	atttgc	ccggcgtat	tcatccat	4140	
catcttgggg	ttttttttat	ttttttttat	ttttttttat	ttttttttat	ttttttttat	4200
ctgttgggtt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	4260
acagcgaag	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	4320
cagtgtat	ttttgtat	aaaatgttgc	tttttttttt	tttttttttt	tttttttttt	4380
aactatgtt	ggatgtttt	tctttttttt	tttttttttt	tttttttttt	tttttttttt	4440
tctctcttcc	tctctcttcc	tcttccat	tttttttttt	tttttttttt	tttttttttt	4500
ttttttttcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	4560
tgacaaatct	cacaggctt	gagaattata	aaaggtgaca	gttcacatgc	aaatcacagg	4620
tctggcgtt	ttaaatttgc	gagaatatac	cgataaa	tcttgcgtt	gtgtccta	4680
aggctctt	tcaggacgtt	gtgtcaata	gagtggtgt	accatactg	agtttataaa	4740
gtcaaaaac	tgatgcaccc	actctgtat	tatgtgttgc	gtaaaggttgc	agctgtat	4800
cattgtatgt	gtttatcttgc	tcctacatgt	ggtattcaaa	tatggccacc	agaggatatg	4860

-continued

tgtaaatata agcacctgtat	tttgctgtt gttgagaact ggaggggaaa caaaaatgt	4920
ctggcaacc tttgccttta taaccgtat	taatttgacag ttatttaga gataagagtt	4980
tccaaatcc tcttaactgc	cacaacccac agagggctt gtttgocat cttcagtggc	5040
tcacagat gatccaagtt	aacttggaaag agatgagcaag taccaggaa attgtctgc	5100
ctttaactt ggctgtccct	aatttgcatt gtttaatgcg gaatttcca tcgcgtctgt	5160
gtttgagggt aaagaaaagc	cttttttaaa taatgttttgc tgtaaaacgg catcggtggg	5220
atttctgtt ttgcattac	gggtgaaaaga gggaaacatt ttttattttt attaagcaga	5280
gcattatttta cagaaagcca	ttgttgagaa ttgttcccata catcatataa atatcatta	5340
accattctaa atgttaagag	aacttgcggc ttgcattatgc caaggaactc tcctggggc	5400
cttttttgc atagcaatta	aaaggatgttgc atttgtcatttgc agccccttt tgcgttgc	5460
taaaagaccaa aatttgcatttca	cagctgttttgc accctttaaaat gtttttttttatgttat	5520
atcaatttat cacttgcatttca	agcttgcataat acctgcaatc ttgcagaaata tacttttttgc	5580
ttttaaaaaa taacttgcatttca	aatatttaccctgtatattata tataacttttatataaaacatt	5640
ttaagcttgcatttca		5648

SEQ ID NO: 6 moltype = AA length = 331
FEATURE Location/Qualifiers
source 1..331
 mol_type = protein
 organism = Mus musculus

SEQUENCE: 6

MWPPLAALLL GSCCCGSAQL LFSNVNSIEF TSCNETVVIP CIVRNVEAQS TEEMFWKWL 60
NKSYIIFYIDG NKNSTTDDQF FTSAKISVSD LINGIASLKM DKRDAMVGNY TCEVTELSRE 120
GKTVIELKNR TAFNTDQGSA CSYEEEKGGC KLVSWFSPNE KILIVIFPIL AILFWGKFG 180
ILTLKYKSSH TNKRIILLLV AGLVLTIVIV VGAIIIPGE KPVKNASGLG LIVISTGILI 240
LLQYNVFMIA FGMTSFTIAI LITQVLGYVL ALVGLCLCIM ACEPVHGPLL ISGLGIIALA 300
ELLGLVYMKF VASNQRTIQP PRKAVEEPLN E 331

SEQ ID NO: 7 moltype = DNA length = 5618
FEATURE Location/Qualifiers
source 1..5618
 mol_type = other DNA
 organism = Mus musculus

SEQUENCE: 7

gcctacacccg ggagagcagg gaggaggagt tggactgagg ttggggcgct ccgagggtcca 60
gggcgagctt gcccaagagg agtagagago aggccccctg cgccaggaaacg cgtgcgtgt 120
gttccgggtga gggtgtgtt cccatgtctcc cgtctttcag gccggccccag gacacgaac 180
cggaagagag ctggcgccgg ggacggggggc cgtgaggcaga gtagtcaacc ccgcgcggcc 240
cggggacagg ctggatttttgc ggcgtctccg ccggagccctg cccaggctg ggtgtgagggc 300
tggcgctacgg tcaacgagca gaggccggca ggccggggcgg agtgcgcgtg ccgcggggcg 360
cgagcacgcg cgccgcgcgc cccccgggca gcctggggcg ccgtctctgc ctgtcaactgc 420
tgcggcgctc ctggcgccgtt gtttttcggta aagggcagcagg cggaggccggc ggctgctcc 480
gacactcttgc ctggcgccggc cccggggcgg cggagatgttgc gccccttggcg ccggcgctgt 540
tgctgggctgc ctggcgccgtt gggttgcattc aactactgtt tagtaactgtc aactccatag 600
agttcacttc atgcaatgaa actgttgcattc tcccttgcat cgtccgtat gtggaggcgc 660
aaaggccggc aaaaaatgtt gcgtttgaaatc aactccatggc aatccatgt 720
atggaaataa aataatgcatt aactacatgtt aactacatgtt aactacatgtt aatccatgt 780
cagacttaaaat ctggcgccgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 840
actacacttgc ctggcgccgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 900
accgcacccggt ttcgttgcatttgc tcccttgcatttgc aacttcatttgc aatccatgtt 960
tggctataacttgcgttgg tggaaatgtt aactccatgtt aatccatgtt aatccatgtt 1020
atacgaatataa aataatgtt aactacatgtt aatccatgtt aatccatgtt aatccatgtt 1080
ttgttggggc catcatttc aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1140
gcctcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1200
ctttggatatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1260
ttgttggggc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1320
tgatttcagg ttgggggatc atagcttcgc ctttttttttgc aactccatgtt aatccatgtt 1380
ttgtcgcttc aacccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1440
acgcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1500
tgtaacttttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1560
cacagcttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1620
atgatttgcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1680
gtcgatgttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1740
ttccatgttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1800
taaattttttttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1860
cctatgcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1920
cacttccgcgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 1980
aagttagggc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2040
tgcgttgcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2100
tacacttgcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2160
atttgcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2220
tgcgttgcatttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2280
acttccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2340
ctcttttttc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2400
gaggcatgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2460
ccgttcaggcc ctcgcaggc aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2520
gtcgatgttgc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2580
ctcttttttc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2640
aaaaactacc aatccatgtt aatccatgtt aatccatgtt aatccatgtt aatccatgtt 2700

-continued

catggaggatc ttttagatta ttagcacctg tttttacctc gtttgggc gtgttttat 2760
 gtgcacatgt atgaagtcgg cacatgcacc ttctgtatgg gcagaggcgt ggcacatcaca 2820
 gaagagcaga tgccaaactt gtgttttag tgaatacatt aaaaaaaaaa aaccaacggc 2880
 ccttatttag gttttatcta tttatgtgaa atatttgacg tctttaagac tttaaaacta 2940
 gataatgtgc caagcttta ggactgtcta ccagtgcctt ctgaagaac accagtactt 3000
 ttccctgttt gtgtataaaa ggcataattt gttttgttgc tgcataacta atggtttattt 3060
 ctctttagtc cactgaatgt ttccatgtgc ctctcgatc ccaaacttt tgcatacttt 3120
 catgtgggaa ccaaattgtt tgcataatggc aaaccaacaa cttatgcacgc ctgaggcctc 3180
 tcagaaaaactt gaccacatg ccaatgttactt acattcgacaa gaaaatggg ttccctccct 3240
 gggttttagt ctgtcgccaa tattagcgta attccaaggaa gtcgacgc tttatataaa 3300
 ctctgtatggc ctgtatgtt tgcataatggc aatatttac actcgatca tgcataatgg 3360
 gacttaaaca aagtttgcgtt gaagagagca aaaaaaaaaa aggtggattt ggaacagttt 3420
 cagggtttttt ttgtttttt gttttttt tttttttt tttttttt 3480
 tttttttttt tagaaaaatgc aggtttttt tgcataatggc tttttttt tttttttt 3540
 taacgaactaa agtagtaccc tttatataatgtt agtcaacgc cttctgtcgg ggggttcgtt 3600
 ttgggttta accagctgtc atgttctta tgcataatggc aacttgcactt ctgtctca 3660
 cttagacatgc ccatecggtt tagccaggaa aacggaaatgc aacttgcactt ctgtctca 3720
 ataatcaactt ctctgtatggc aggtttttt tttttttt tttttttt 3780
 gggccatgtc acccttttaa atcaaaaccc qcaatggcctc ccaatggc tcccatcaga 3840
 ttttaattgc taacagtatg gggggcccca cgcattctgtt ttgtcccaaca atgcgttttt 3900
 ctctccaaa tcccgattt tgcataatggc tttttttt tttttttt 3960
 cttccactta tacaatgtt gagacatgtt cttttttt tttttttt 4020
 agcctttatgtt gttttttt tttttttt tttttttt 4080
 ccgcacggcgtt gttttttt tttttttt tttttttt 4140
 tttttttttt tttttttt tttttttt tttttttt 4200
 ttcttttco tttttttt tttttttt tttttttt 4260
 cgcaatgttcc tttttttt tttttttt tttttttt 4320
 tgcacttaaa tttttttt tttttttt tttttttt 4380
 ctttttttt tttttttt tttttttt tttttttt 4440
 tttttttttt tttttttt tttttttt tttttttt 4500
 ttttttttt tttttttt tttttttt tttttttt 4560
 aaaggtaaca gttttttt tttttttt tttttttt 4620
 cgatggggatggc tttttttt tttttttt tttttttt 4680
 gagttttttt tttttttt tttttttt tttttttt 4740
 tttttttttt tttttttt tttttttt tttttttt 4800
 gttttttttt tttttttt tttttttt tttttttt 4860
 gttttttttt tttttttt tttttttt tttttttt 4920
 taattttttt tttttttt tttttttt tttttttt 4980
 agggggatggc tttttttt tttttttt tttttttt 5040
 agatggatggc tttttttt tttttttt tttttttt 5100
 gttttttttt tttttttt tttttttt tttttttt 5160
 taattttttt tttttttt tttttttt tttttttt 5220
 gggggggggg tttttttt tttttttt tttttttt 5280
 ttttttttt tttttttt tttttttt tttttttt 5340
 ttttttttt tttttttt tttttttt tttttttt 5400
 attttttttt tttttttt tttttttt tttttttt 5460
 accctttttt tttttttt tttttttt tttttttt 5520
 acctttttt tttttttt tttttttt tttttttt 5580
 tgtaatatta tataatataatggc tttttttt tttttttt 5618

SEQ ID NO: 8 moltype = AA length = 321
 FEATURE Location/Qualifiers
 source 1..321
 mol_type = protein
 organism = Mus musculus
 SEQUENCE: 8
 MWPLAALLL GSCCCCGSAQL LFSNVNSIEF TSCNETVVIP CIVRNVEAQ S TEEMFVKWKL 60
 NKSYIFIFYIDG NKNSTTDDQ FTSKASISLKM DKRDAVMGNY TCEVTELSSRE 120
 GKTVIELKNR TVSWFSPNEK ILIVIFPILA ILLFWGKFGL I LTLKYKSSHT NKRIIPLLVA 180
 GLVLTVIVVV GAILLIPGEK PVKNASGLGL IVISTGILIL QYQNVFMATAF GMTSFTIAI 240
 ITQVLGYVLA LVGLCLCIMA CEPVHGPLL SGLGIIALAE LLGLVYMKFV ASNQRQTIQPP 300
 RKAVEREPLNA FKESKGMMND E 321

SEQ ID NO: 9 moltype = DNA length = 5021
 FEATURE Location/Qualifiers
 source 1..5021
 mol_type = other DNA
 organism = Homo sapiens
 SEQUENCE: 9
 agtggggagcg cggcgtgcgcg cggccgtgc gcctgggcg tgggtctgc ctgtgacgc 60
 cggccggcgtt cggctctgcgc tgtaacggcg gcccggcgtt ctgcctggca cacctgcggc 120
 gggccggcgc accccggcgc gggccggcgc atgtggccccc tgggtcgccgc gctgtgtgt 180
 ggctcgccgtt ctgtcgccgtt agtctcgatca tttttttt aatattttttt tttttttt 240
 acgtttttttt atgacactgt cgttcatcata tttttttt tttttttt 300
 actactgaag tataactgtttaa ttgtttttt aatattttttt tttttttt 360
 gctctaaaca agtccactgtt cccactgc tttttttt tttttttt 420
 ttactaaaag gagatgcctc ttgtttttt tttttttt 480
 aactacactt gtgtttttt tttttttt 540
 tttttttt tttttttt tttttttt 600

-continued

tttgctatac tcctgttctg gggacagttt ggtattaaaa cacttaaata tagatcccg 660
 ggatggat agaaaacaat tgcttactt gttgctggac tagtgatcac tgtcattgtc 720
 attgttggag cattttttt cgccccaggtaaatggatcat taaagaatgc tactggcctt 780
 ggtttaattt gtaacttctac agggatatta atattacttc actactatgt gtttagtaca 840
 gcaatggat taacccttctt cgtcattggatattggatcttgcgtgtat agccatatc 900
 ctgcgtgtt ttggactgag tctgtatggatccatgcataccatgc ttggccttctt 960
 ctgatccatg gttagtat cttagcttca gcacaattac ttggactgtttatgaaa 1020
 tttgttggat aactgaatgt aagtgtatggatcccgatttggaggtatgatgaaa 1080
 ggaatacttctg tttgttttaa cccatggcc ttgtatgttactgtttgggg agaagaacaa 1140
 agaaaatgtt ccgggttgcctt ctttgcgtgtatggatcttgcgtgttatt 1200
 caaaagcgtt gtaattttat taaataataattatgtatc tttgtgttgccttgcgtgt 1260
 atccagttttt ttgttgcattttttaatcaa tttagggcaatgtttatgatggata 1320
 aaaaatgtatc ctttgcgttgcgtgtatggatccatgc tttagggatgttgcgtgt 1380
 tcagggtgtat aactttagt cactgttgcgtgtatggatccatgc tttagggatgttgcgtgt 1440
 gtggccttca tttttttttt cccatggcc ttgtatgttactgtttgggg agaagaacaa 1500
 tatggcattt gctgagatgtt gtctgttactt ttttttttttgcgtgttgcgtgt 1560
 aggccaggat ttgggttggatccatgc ttttttttttgcgtgttgcgtgttgcgtgt 1620
 atatgttgccttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 1680
 acaggcttcccccgttgcgtgtatggatccatgc tttagggatgttgcgtgt 1740
 taacccttgc ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 1800
 acotttttttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 1860
 cagactgtt ccgggttgcgtgtatggatccatgc tttagggatgttgcgtgt 1920
 atatgttgccttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 1980
 ctgtatctggg gcatgaaaaaa agcaagatttgcgtgtatggatccatgc tttagggatgttgcgtgt 2040
 acaaaaatgtt ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2100
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2160
 cccatggatccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 2220
 attaatgttgc ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2280
 tacctgttgtt ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2340
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2400
 aaacatggatccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 2460
 actttaaaactt ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2520
 ctgtaaaatgtt ccgggttgcgtgtatggatccatgc tttagggatgttgcgtgt 2580
 taataatgttgc ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2640
 attgtcatat ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2700
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2760
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2820
 tttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 2880
 ttatacaatgtt ccgggttgcgtgtatggatccatgc tttagggatgttgcgtgt 2940
 aaccttagttt gtttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3000
 gaaaaagatc ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3060
 aaactaaatgtt ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3120
 gatctcatttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 3180
 cttagacaatgtt ccgggttgcgtgtatggatccatgc tttagggatgttgcgtgt 3240
 cttaggttgc ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3300
 catgggocatgttgc ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3360
 cacatggatccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 3420
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3480
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3540
 aatttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3600
 ctgtcttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3660
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3720
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3780
 agttaatgtt ccgggttgcgtgtatggatccatgc tttagggatgttgcgtgt 3840
 agatggatccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 3900
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 3960
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4020
 gtaatggatccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 4080
 ttgttatggatccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 4140
 aaaaatgttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 4200
 ggggatgttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 4260
 ggagaaatgtt ccgggttgcgtgtatggatccatgc tttagggatgttgcgtgt 4320
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4380
 ggggttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4440
 atgagcgttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 4500
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4560
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4620
 gaagaaaaatgtt ccgggttgcgtgtatggatccatgc tttagggatgttgcgtgt 4680
 ttatggatccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 4740
 gtttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4800
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4860
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4920
 ttttttttttgcgtgtatggatccatgc tttagggatgttgcgtgt 4980
 ccctgtatataatgttccatgttgcgtgtatggatccatgc tttagggatgttgcgtgt 5021

SEQ ID NO: 10 moltype = AA length = 293
 FEATURE Location/Qualifiers
 source 1..293
 mol_type = protein

-continued

```

tgagagttt ctttctttct gttttttttt ttttgggtttt tttttttttt 3960
ttttttact aatttcacat gctctaaaaa ctttcaagg tgatttttt tctctgaa 4020
actccaggc cattctgttt aaatccctaa gaatgtcaga attaaaaata cagggctatc 4080
ccgtaattgg aaatattttct ttttcagga tgctatagtc aatttagtaa gtgaccacca 4140
aatttgtttt tgcactaaca aagctcaaaa caccataagt ttactccccc atctcagtaa 4200
taaaaaattaa gctgtatca accttctagg tttctcttgc cttaaaatgg gtattcaaaa 4260
atggggatct gtgggtgtatg tatggaaaca catactcctt aatttaccc ttgttggaaa 4320
ctggagaaat gattgtcggt caaccgttta ttttttattt tatttttattt gggttgggg 4380
ttttttata aacagtttta ctgtgtcat atttttaaaat tactaactgc catcacctgc 4440
tggggcttctt tggtaggtca ttttctgtga ctaataggaa taatccaggta aactttgaag 4500
agatgacgac tgtagtgacca ggcgtttt ctgcctttag ctgtgacagt tcttaattaa 4560
gatcattgaa gaccagctt ctcataaatt tctctttttt aaaaaaaagaa agcatttgta 4620
ctaagctctt ctgtaaagaca acatctttaaattttaaatttgc ttgttataca tgactggta 4680
gagaagaaaaa cattttttt tttttttttt gggcattttt tttttttttt tttttttttt 4740
aatttagatcc cacatcgat aatatctat taaccattctt aataaaaaagaa aactccagtg 4800
ttgtctatgtc caagatctc ttttggagct tttttgcata gcaattaaag gtgtgctatt 4860
tgtagtgc tttttttttt cttttttttt tttttttttt tttttttttt tttttttttt 4920
cgttttttttt atatgttata aatcaattttttaaatttgc ttactgttta aagctttgaa 4980
tatctgcaat ctttgccaaat gttttttttt tttttttttt tttttttttt tttttttttt 5040
taccctgttaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5100
tatttgcgtc acagcagacc acaaggccat tttttttttt tttttttttt tttttttttt 5160
ttaagtttgc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5220
tttttgcgtttaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5280
aatcagtc

```

SEQ ID NO: 12 moltype = AA length = 305
 FEATURE Location/Qualifiers
 source 1..305
 mol_type = protein
 organism = Homo sapiens

SEQUENCE: 12
 MWPLVAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWF 60
 KGKDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDAISLKM DKSDAVSHG NYTCETVTEL 120
 REGETTIEELK YRVVSWFSPN ENILIVIPPI FAILLFWGQF GIKTLKYRSG GMDEKTIAL 180
 VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA 240
 ILVIQVIAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQKTIQ 300
 PPRNN 305

SEQ ID NO: 13 moltype = DNA length = 5078
 FEATURE Location/Qualifiers
 source 1..5078
 mol_type = other DNA
 organism = Homo sapiens

SEQUENCE: 13
 agtggggagcg cgccgtgcgcg cggccgtgcga gcctgggcaag tgggtcctgc ctgtgacgcg 60
 cggccggcggtt cgggtcctgcg tggtaacggcg ggcgcggctg ctgcctccggc caccctgcggc 120
 gggggcgccgcg accccggcgcg gggggcgccgcg atgtggccccc tggttagggc gctgttgcgt 180
 gggtcggcggtt gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 240
 acgtttttgtt atgacactgt cgtcatattca tgctttgtta ctaatatggaa ggcacaaaac 300
 actactgttgcg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360
 gctcttaaacaaat gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 420
 ttactaaatggat gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 480
 aactacactt gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660
 ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720
 attttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 840
 gtcgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 900
 ctccgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 960
 ctgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1020
 ttgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1080
 aatgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1140
 atacactttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1200
 aaagttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1260
 agcagttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1320
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1380
 aatgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1440
 ggggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1500
 gctttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1560
 ggcattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1620
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1680
 gtgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1740
 ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1800
 cccctttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1860
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1920
 actttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1980
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2040
 atctttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2100

-continued

```

aatgtgtgt caccatcagg ccaacaggcc agcccttcaa tggggattta ttactgtgt 2160
atctatgtt catgataaac attcatcacc ttccctctgt agtcctgc ctgtactcccc 2220
ttccccatgtt atgaaaagt aaacaaaacc cacatttccc atccgggtt gaagaaaatt 2280
aatgttgcg cagttgtgtat cgcctggagt acttttagac ttttagcatt cggtttttac 2340
ctgtttgtgg atgtgtgtt gtatgtgtat acgtatgaga taggcacatg catcttcgt 2400
atggacaagat gttgggttacc tacaggagag caaagggttta tttgtgtt tttagaaaaaa 2460
catttaataa caaagtctt tattgggtgg aatttattt gatgcaataa tttgtactt 2520
taaaaactttt aaaacttcta ggtaatttgc cacgtttttt gactgtcac caataccctg 2580
taaaaatatacg taattttcc tgggtgttataa ataaatgtt catatgtt gttgatcaa 2640
taatagtttt ttcttagtcc atcagatgtt cccgtgtgc tcttttatgc caaattgatt 2700
gtcatatttc atgttgggac caagtatgtt gccccatggca aacctaattt tatgacccgt 2760
tgaggccctc cagaaaaactg agcataactag caagacagctt ctcttggaaa aaaaaaaat 2820
gtatcacaaa atatatactgtt atatcttat atacgtatgtt atatacacac atgttatattt 2880
ttccctgtt gttgtgtgtt cccaaataat aacatataat gaggggatgtt tattctttt 2940
tacaaaatctt atggctctg cagactttt tccttctgaa aatatttaca ttttgatcaa 3000
ctagttgtt actttaaaaa tcagtttgaa tgaaaggagg gaaaaggcaga tggacttgaa 3060
aaagatccaa gtccttataa gaaaatggat gaaaatctt atagtaaaaat tttttataaa 3120
cttaaagtgtt accttttaat atgttagttaa ctctcatttta ttgggggttcc gcttttgat 3180
ctcatccattt cattgtgttc tctttatgc tgctgtttt ttggcattt cactggccct 3240
gacaatgcga ccagagatag tggggaaaat gcccggatggaa accaaactttt gcttcacta 3300
gttgtccagct tcttgcgtt agtggccaccataa gaagcggggat ttccctcgat tgggcattcat 3360
tggggccatgtt cttttttttt aatcggatgtt tgtaatggcctt cccaaatccc atccatccat 3420
atttaaattt cagacatgtt ttgcacatc atgtatctgtt ttgtccatc aatatgtttt 3480
ttactccctt atcccgatgg tgggtgttgc ctcttcattt cagtttttattt tattgtgtgt 3540
ttccacatgtt acaccatttgc tcccttttgc caacaacccctt tccagctact ttggccaaat 3600
tctattttgc ttcttcatttca aaacatcatttgc ctgttcatttgc ctgttgcatttgc ttgttagctg 3660
ctttttttgc tttaaacttca cccatcatttgc atgtactttat gcatttcgttgc ttgttcttat 3720
tagtttttgc ggcttgcatttgc tcttgcatttgc tttaaaatttgc ctttgcatttgc tagagctttt 3780
ctttcttca ttcttcatttgc ctgcatttgc ttgcatttgcatc cagaacgttgc ttgatataatgt 3840
taaatgttgcg agagtttttttgc ttatgttagt ttaatagggatgtt gagtttgaaa 3900
gtttttttttc ttctgtttt tttttttttt tttttttttt tttttttttt 3960
tgactaattt cacaatgttctt aaaaacccctt aaggtgtttt atttttcttcc tggaaactcc 4020
agggccatc tttttttttttgc ctttttttttttgc tcaaaatggat ttttttttttttgc 4080
attggaaatatac tttttttttttgc ctttttttttttgc ttttttttttttgc ttttttttttttgc 4140
ttatgttgc ttaaaaaatgttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4200
attaagtgtt aatcaacccctt ctgggttttttgc ttttttttttttgc aatgggttttgc ttttttttttttgc 4260
gatctgtgtt gtatgtatgg aaacacatac ttcccttgc ttttttttttttgc ttttttttttttgc 4320
gaaatgttgc ttggggcaacc tttttttttttgc ttttttttttttgc ttttttttttttgc 4380
ttataaacatc tttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4440
ttccctgttgc ggttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4500
agcgtgttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4560
ttgaagacca gtttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4620
ctccctgttgc agacaaatccatc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4680
gaaaacatc tttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4740
gatcccccacatc ttttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4800
atgtgttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4860
gttttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4920
aagggttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 4980
gcaatcttgc ccaaggatgttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 5040
ttaatatttataatataatatttgc ttttttttttttgc ttttttttttttgc ttttttttttttgc 5078

```

SEQ ID NO: 14 moltype = AA length = 312
 FEATURE Location/Qualifiers
 source 1..312
 mol_type = protein
 organism = Homo sapiens

SEQUENCE: 14
 MWPLVAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWKF 60
 KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDAISLK DKSDAVSHTG NYTCEVTELT 120
 REGETIIELK YRVVSWFSPN ENILIVIFPI FAIILFWQOF GIKTLKYRSG GMDEKTIALL 180
 VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYVFST AIGLTSFVIA 240
 ILVIQVITAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQKTIQ 300
 PPRKAVEEPL NE 312

SEQ ID NO: 15 moltype = DNA length = 5346
 FEATURE Location/Qualifiers
 source 1..5346
 mol_type = other DNA
 organism = Homo sapiens

SEQUENCE: 15
 gggggaggagg cggggggaggcg ggcggggaggcg agtggggaggcg cgcgtgcgcg cggccgtgc 60
 gccgtggggaggcg tgggttctgc ctgttgcgcgcg cggccggccgc ttgttaacggcg 120
 gggggggggcgcg ctgttcctgc caccgtggcg gggggggggcg accccccggcggc gggccggcg 180
 atgtggcccccc tggtagcggc gctgttgcgtt ggttgcggcgctt gtttgcggatc agtctaggctt 240
 ctatataataa aacaaatc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 300
 ttttttttttttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 360
 aaaaaaaaaaaaaatgttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 420
 ttttttttttttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 480
 gataaaggatgttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 540

-continued

agagaagggtg	aaacgatcat	cgagctaaa	tatcgtgtt	tttcatgggt	ttctccaaat	600
aaaaatattc	ttattgttat	tttccaatt	tttgctatac	tcctgtctg	gggacagtt	660
ggtttaaaa	cacttaata	tagatccgt	ggtatggat	agaaaacaat	tgcttactt	720
gttgcgtgac	tagtgcac	tgtcattgtc	attgttggag	ccatttttt	cgtcccagg	780
gaatattat	taaagaatgc	tactggcct	ggtttaattt	tgacttctac	aggatatta	840
atattactt	actactatgt	gtttagtaca	gcgattggat	taaccctctt	cgtcattgccc	900
atattggta	ttcagggtat	agccatatac	ctcgctgtt	ttggactgag	tctctgttt	960
gccccgtgt	taccaatgca	tgcccttctt	ctgatttcag	gtttgagtat	cttagctcta	1020
gcacaattac	ttggactgt	ttatgtatgg	tttggggctt	ccaatcaga	gactatacaa	1080
cctccttag	aactgtaga	ggaacccctt	aatgcattca	aagaatcaa	aggaatgtat	1140
aatgtat	aactgtaga	aatgtatgg	ctccgatttgc	gagagtagt	agacgtgaaa	1200
ggaatacact	tgtgtttaag	caccatggcc	ttgatgatcc	actgttgggg	agaagaaaca	1260
agaaaqgtt	ctgggtgtca	cctatggat	ccttacgtgt	ttgttagtta	agttttttt	1320
caaaggcgt	gtatattgt	taataaaata	attatgtatc	atgttggtt	cccaatttgag	1380
atccagttt	tttgtttat	ttttaatcaa	tttagggca	tagtagaaatg	gacaatttcc	1440
aagaatgtat	ccttcagg	cctaggccct	ctggctctt	ggttaccaat	ttaaatttgg	1500
tcagggtat	aactacttag	cactgccc	gtgatttaccc	agagatattt	atgaaaacc	1560
gtggcttcca	tcaaacctt	gccaactcg	gttcacacg	gtttggggca	gttatggcag	1620
atggcatta	gttgcaggat	gttgcctact	tctgggtca	tggataataa	attaatgtac	1680
aggcaggaa	ttgggtggg	gcatttgc	tgtctccgt	atgtatgtat	attgtatggag	1740
atagtgtcc	tcatttctgg	gggttgcatt	tcacacattt	cccccttca	aaacagtgt	1800
acagggtctt	cccaatgg	gggttactttt	attgtatgtat	atgtttctt	tttatttcata	1860
taacccttgc	aaaccctgt	ttgtctctt	gttacttgc	tctgtgtac	aagatgtac	1920
accttttctc	ctcttgcac	atggtctatg	gacacggtag	caccatgtc	aggaaggagg	1980
caagacttgc	ttcagagcac	tgtgttcaca	cttttcagca	aaaatagct	tgggtgtac	2040
atatgtatc	ccttcctctg	atttgttgc	aaaatctac	atgttctt	cactttttt	2100
ctgatctgg	gcatggaaaa	accaatgg	ttttttttt	atgtatgtc	ctgcattggca	2160
acaaaatgt	tgtcaccatc	aggecaacag	gccagccctt	gaatggggat	ttattactgt	2220
tgtatctatg	ttgcgtatg	aacatccatc	accttcctcc	tgtatgtctg	cctcgtaact	2280
cccttcctt	atgttgcata	aaaatccat	cttacatcgg	tttgcattttt	tttagaagaaaa	2340
attaatgtt	tcagatgt	gttcgcctgg	agttttttt	gacttttgc	attcgtttt	2400
tacctgttt	ttggatgtgt	ttttgtatgt	catacgat	agataggcac	atgcatttcc	2460
tgtatggaca	aagggtgggt	acccatcgat	gagcaaaatgt	taattttgt	cttttttagaa	2520
aaacattat	atacaaaatgt	cttttttttt	ttggattata	tttgcatttt	atatttgcac	2580
actttaaaat	ttttaatgtt	tttgcatttt	tttgcacgtt	tttgcatttt	caccaatacc	2640
ctgttaaaat	acgttaattt	tcctgtttt	gttataatgt	attcatattt	gtatgtcat	2700
taataatagt	tattttttt	tccatcgat	ttttttttt	ttttttttt	ttttttttt	2760
attgtat	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	2820
tggttgcatt	tcttcagat	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	2880
tatgtatata	caaataatata	cgatataatc	tatataatgt	tgtatataca	cacatgtata	2940
tttttcctt	atgtgttag	tgtccaaat	aataacatata	atagagggg	ctgttatttct	3000
ttatataat	ttgtgcgtc	ctgcagact	tttttcctt	gaaaatattt	acattttgc	3060
acacatgtt	tttactttt	aaatgtatc	tttgcatttt	tttgcatttt	tttgcatttt	3120
gaaaaagatc	caagcttca	tttagaaaa	tttgcatttt	tttgcatttt	tttgcatttt	3180
aaactaaatgt	tgtatctttt	aatatgtat	aaactctcat	ttttttttt	tttgcatttt	3240
gtatctatcc	atccatgtt	ttttttttt	tttgcatttt	tttgcatttt	tttgcatttt	3300
ctagacaat	ccaccagaga	ttttttttt	tttgcatttt	tttgcatttt	tttgcatttt	3360
ctagtgtca	gtttctctgg	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3420
cattggccca	gttcccttc	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3480
cacat	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3540
tttttacttcc	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3600
tgttctcaca	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3660
aattctattt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3720
ctgtctttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3780
tattatgtt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3840
tttctttttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3900
agttatgt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	3960
agatgtttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4020
tttttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4080
tccagggtca	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4140
gtaatttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4200
tttttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4260
aaaatataatgt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4320
ggggatctgt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4380
ggagaaaatgt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4440
tttttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4500
gggttccctt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4560
atgagatgt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4620
tcattgtat	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4680
aagcttctt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4740
gaagaaaatgt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4800
tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4860
gtatgttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4920
tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	4980
ttaaagggtt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	5040
tctgcattt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	5100
ccctgtat	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	5160
tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	5220
aagtgttca	tatttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	tttgcatttt	5280

-continued

tttggatata atacccaata agctttaat tagagcagag ttttaattaa aagtttaaa	5340
tcagtc	5346
SEQ ID NO: 16	moltype = AA length = 323
FEATURE	Location/Qualifiers
source	1..323
	mol_type = protein
	organism = Homo sapiens
SEQUENCE: 16	
MWPLVAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWF	60
KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDAASLMK DKSDAVSHTG NYTCEVTELT	120
REGETIIELK YRVVSWFSPN ENILIVIFPI FAILLFWGQF GIKTLKYRSG GMDEKTIALL	180
VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA	240
ILVIQVIAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQRTIQ	300
PPRKAVEEPL NAFKESKGMM NDE	323
SEQ ID NO: 17	moltype = AA length = 293
FEATURE	Location/Qualifiers
REGION	1..293
source	note = Synthetic polypeptide
	1..293
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 17	
MWPLAAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWF	60
KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDAASLMK DKSDAVSHTG NYTCEVTELT	120
REGETIIELK YRVVSWFSPN ENILIVIFPI FAILLFWGQF GIKTLKYRSG GMDEKTIALL	180
VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA	240
ILVIQVIAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVE	293
SEQ ID NO: 18	moltype = AA length = 305
FEATURE	Location/Qualifiers
REGION	1..305
source	note = Synthetic polypeptide
	1..305
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 18	
MWPLAAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWF	60
KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDAASLMK DKSDAVSHTG NYTCEVTELT	120
REGETIIELK YRVVSWFSPN ENILIVIFPI FAILLFWGQF GIKTLKYRSG GMDEKTIALL	180
VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA	240
ILVIQVIAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQRTIQ	300
PPRNR	305
SEQ ID NO: 19	moltype = AA length = 312
FEATURE	Location/Qualifiers
REGION	1..312
source	note = Synthetic polypeptide
	1..312
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 19	
MWPLAAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWF	60
KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDAASLMK DKSDAVSHTG NYTCEVTELT	120
REGETIIELK YRVVSWFSPN ENILIVIFPI FAILLFWGQF GIKTLKYRSG GMDEKTIALL	180
VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA	240
ILVIQVIAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQRTIQ	300
PPRKAVEEPL NE	312
SEQ ID NO: 20	moltype = AA length = 323
FEATURE	Location/Qualifiers
REGION	1..323
source	note = Synthetic polypeptide
	1..323
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 20	
MWPLAAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWF	60
KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDAASLMK DKSDAVSHTG NYTCEVTELT	120
REGETIIELK YRVVSWFSPN ENILIVIFPI FAILLFWGQF GIKTLKYRSG GMDEKTIALL	180
VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA	240
ILVIQVIAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQRTIQ	300
PPRKAVEEPL NAFKESKGMM NDE	323
SEQ ID NO: 21	moltype = DNA length = 22
FEATURE	Location/Qualifiers
misc_feature	1..22
	note = Synthetic primer

-continued

```

source          1..22
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 21
tgcagaagtc actaggagga at                                22

SEQ ID NO: 22      moltype = DNA  length = 27
FEATURE          Location/Qualifiers
misc_feature     1..27
note = Synthetic probe
source           1..27
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 22
tcagtcaact tcttctgggt tgttcc                                27

SEQ ID NO: 23      moltype = DNA  length = 23
FEATURE          Location/Qualifiers
misc_feature     1..23
note = Synthetic primer
source           1..23
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 23
gtgccagact cactttctat cca                                23

SEQ ID NO: 24      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
misc_feature     1..22
note = Synthetic primer
source           1..22
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 24
tgttgccaaat atacggcttc tg                                 22

SEQ ID NO: 25      moltype = DNA  length = 26
FEATURE          Location/Qualifiers
misc_feature     1..26
note = Synthetic probe
source           1..26
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 25
cagctctcat agccaaactat ggtgcc                                26

SEQ ID NO: 26      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
misc_feature     1..22
note = Synthetic primer
source           1..22
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 26
tcaaggcagag cctggttatc tg                                22

SEQ ID NO: 27      moltype = DNA  length = 23
FEATURE          Location/Qualifiers
misc_feature     1..23
note = Synthetic primer
source           1..23
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 27
gtcggtcattc catgctttgt tac                                23

SEQ ID NO: 28      moltype = DNA  length = 30
FEATURE          Location/Qualifiers
misc_feature     1..30
note = Synthetic probe
source           1..30
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 28
tggaggcaca aaacactact gaagtatacg                                30

SEQ ID NO: 29      moltype = DNA  length = 22
FEATURE          Location/Qualifiers
misc_feature     1..22

```

-continued

```

source          note = Synthetic primer
1..22
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 29
ggacagtgga cttgtttaga gc                                22

SEQ ID NO: 30      moltype = DNA length = 21
FEATURE           Location/Qualifiers
misc_feature      1..21
note = Synthetic primer
source            1..21
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 30
ggcttggtgg ctgattgttc t                                         21

SEQ ID NO: 31      moltype = DNA length = 28
FEATURE           Location/Qualifiers
misc_feature      1..28
note = Synthetic probe
source            1..28
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 31
agoacccaaa ctgatatgcc tgtatttg                                28

SEQ ID NO: 32      moltype = DNA length = 23
FEATURE           Location/Qualifiers
misc_feature      1..23
note = Synthetic primer
source            1..23
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 32
tgggaactgg tgtttcaagt cta                                23

SEQ ID NO: 33      moltype = DNA length = 158
FEATURE           Location/Qualifiers
misc_feature      1..158
note = Synthetic polynucleotide
source            1..158
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 33
gcagacatgta tacttcaga gctttcaaag ctgataactg taccttgcat attccaaacac 60
gcgatcgcattttaagatgg tccatccatg tggaaagatg tgatttgatt catcctattt 120
actttgtatacataaaggta cttttttttt ccactttt                                158

SEQ ID NO: 34      moltype = DNA length = 160
FEATURE           Location/Qualifiers
misc_feature      1..160
note = Synthetic polynucleotide
source            1..160
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 34
ggatccattt taagtaatag aataggattt ttaattgttc cagttttct gtgtatagac 60
tgtcctgcac agacctgttt ctcgagatataa cttcgatataa tttttttttt acgaaatgtt 120
atgcattggcc tccgcgcgg gttttggcgc cttccgcggg                                160

SEQ ID NO: 35      moltype = DNA length = 160
FEATURE           Location/Qualifiers
misc_feature      1..160
note = Synthetic polynucleotide
source            1..160
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 35
catgtctgga ataacttcgt ataatgtatg ctatacgaag ttatgtatgt aactataacg 60
gtccttaaggatgcgacttagc attagttatgg aagggtccgtc cactgtccag gttcctttt 120
cgaggacttctt tttttttttt gttttttttt acactgttat                                160

SEQ ID NO: 36      moltype = DNA length = 239
FEATURE           Location/Qualifiers
misc_feature      1..239
note = Synthetic polynucleotide
source            1..239
mol_type = other DNA

```

-continued

organism = synthetic construct

SEQUENCE: 36

```

ggatccattt taagtaatag aataggattt ttaattgttc cagtgtttct gtgatagac 60
tgtcctgcac agacctgttt ctgcgataaa cttcgtataaa tgtatgttat acgaagtat 120
gtctgtact ataacggtcc taaggtagcg actagcattaa gtatggagg tccgtccact 180
gtccagggttc ctcttgccga gtcctttgtc tctctggact ctgtatacac tgcttgcac 239

```

We claim:

1. A targeting nucleic acid vector, comprising
a 5' homology arm comprising a genomic sequence
upstream of exon 2 of a mouse CD47 gene,
a genomic DNA fragment comprising exons 2-7 of a
human CD47 gene,
a drug selection cassette, and
a 3' homology arm comprising a genomic sequence down-
stream of exon 7 of the mouse CD47 gene,
wherein the genomic fragment comprising exons 2-7 of
the human CD47 gene encodes a polypeptide compris-
ing an amino acid sequence having at least 98% identi-
ty with the amino acid sequence as set forth in amino
acids 16-292 of SEQ ID NO: 10,
wherein the genomic sequence upstream of exon 2 of the
mouse CD47 gene comprises exon 1 of the mouse
CD47 gene,
wherein the genomic sequence downstream of exon 7 of
the mouse CD47 gene comprises the exons downstream
of exon 7 of the mouse CD47 gene, and
wherein the 5' and 3' homology arms mediate integration
of the genomic fragment comprising exons 2-7 of the
human CD47 gene into a mouse CD47 locus to form a
humanized CD47 gene.
2. The targeting nucleic acid vector of claim 1, wherein
the genomic fragment comprising exons 2-7 of the human
CD47 gene encodes a polypeptide comprising the amino
acid sequence as set forth in amino acids 16-292 of SEQ ID
NO: 10.
3. The targeting nucleic acid vector of claim 1, wherein
the drug selection cassette is a self-deleting drug selection
cassette.
4. A method of making a genetically modified mouse
embryonic stem (ES) cell, comprising:
introducing the targeting nucleic acid vector of claim 1
into mouse ES cells, and
selecting a mouse ES cell in which the genomic fragment
comprising exons 2-7 of the human CD47 gene has
integrated into the mouse CD47 locus and replaced
exons 2-7 of the endogenous mouse CD47 gene,
thereby obtaining the genetically modified mouse ES cell
in which the genomic fragment comprising exons 2-7

- 10 of the human CD47 gene has integrated into the mouse
CD47 locus and replaced exons 2-7 of the endogenous
mouse CD47 gene.
- 15 5. The method of claim 4, wherein the genomic fragment
comprising exons 2-7 of the human CD47 gene encodes a
polypeptide comprising the amino acid sequence as set forth
in amino acids 16-292 of SEQ ID NO: 10.
- 20 6. The method of claim 4, wherein the drug selection
cassette is a self-deleting drug selection cassette.
- 25 7. A method of making a genetically modified mouse,
comprising:
introducing the targeting nucleic acid vector of claim 1
into mouse ES cells,
selecting a genetically modified mouse ES cell in which
the genomic fragment comprising exons 2-7 of the
human CD47 gene has integrated into the mouse CD47
locus and replaced exons 2-7 of the endogenous mouse
CD47 gene; and
producing the genetically modified mouse from the
selected genetically modified mouse ES cell, wherein
the genome of the genetically modified mouse com-
prises a replacement of a genomic fragment comprising
exons 2-7 of a mouse CD47 gene at an endogenous
mouse CD47 locus with the human genomic fragment
comprising exons 2-7 of the human CD47 gene to form
the humanized CD47 gene, wherein the exons of the
humanized CD47 gene consist of exon 1 of the mouse
CD47 gene, exons 2-7 of the human CD47 gene, and
the remaining exons downstream of exon 7 of the
mouse CD47 gene, wherein the humanized CD47 gene
is under control of the endogenous mouse CD47 pro-
moter at the endogenous mouse CD47 locus, and
wherein the mouse expresses a humanized CD47 pro-
tein encoded by the humanized CD47 gene.
- 30 8. The method of claim 7, wherein the genomic fragment
comprising exons 2-7 of the human CD47 gene encodes a
polypeptide comprising the amino acid sequence as set forth
in amino acids 16-292 of SEQ ID NO: 10.
- 35 9. The method of claim 7, wherein the drug selection
cassette is a self-deleting drug selection cassette.

* * * * *